{"da2601c9e2cb56774e310323edff62eafa52a601": [["nasopharyngeal swab confirmed the diagnosis of Covid-19, two times.", [["nasopharyngeal swab", "ANATOMY", 0, 19], ["nasopharyngeal swab", "CANCER", 0, 19], ["nasopharyngeal swab", "TEST", 0, 19], ["Covid", "TEST", 47, 52]]], ["Chest X-rays and computed tomography scanning of the chest were normal.", [["chest", "ANATOMY", 53, 58], ["chest", "ORGAN", 53, 58], ["Chest X-rays", "TEST", 0, 12], ["computed tomography scanning of the chest", "TEST", 17, 58], ["chest", "ANATOMY", 53, 58], ["normal", "OBSERVATION", 64, 70]]], ["Thyroid ultrasound examination showed a relative diffuse decrease of vascularity and parenchyma was heterogeneous.", [["Thyroid", "ANATOMY", 0, 7], ["parenchyma", "ANATOMY", 85, 95], ["Thyroid", "ORGAN", 0, 7], ["parenchyma", "TISSUE", 85, 95], ["Thyroid ultrasound examination", "TEST", 0, 30], ["a relative diffuse decrease of vascularity", "PROBLEM", 38, 80], ["diffuse", "OBSERVATION_MODIFIER", 49, 56], ["decrease", "OBSERVATION_MODIFIER", 57, 65], ["vascularity", "OBSERVATION", 69, 80], ["parenchyma", "ANATOMY_MODIFIER", 85, 95], ["heterogeneous", "OBSERVATION_MODIFIER", 100, 113]]], ["Patient received hydroxychloroquine tablet 200 mg bid for 5 days.", [["hydroxychloroquine", "CHEMICAL", 17, 35], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["Patient", "ORGANISM", 0, 7], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 17, 35], ["Patient", "SPECIES", 0, 7], ["hydroxychloroquine tablet", "TREATMENT", 17, 42]]], ["Prednisolone 16 mg daily was given and she showed significant improvement of clinical condition.", [["Prednisolone", "CHEMICAL", 0, 12], ["Prednisolone", "CHEMICAL", 0, 12], ["Prednisolone", "SIMPLE_CHEMICAL", 0, 12], ["Prednisolone", "TREATMENT", 0, 12], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["improvement", "OBSERVATION_MODIFIER", 62, 73]]], ["She was discharged on prednisolone tapering dose for 4 weeks with outpatient follow-up.", [["prednisolone", "CHEMICAL", 22, 34], ["prednisolone", "CHEMICAL", 22, 34], ["prednisolone", "SIMPLE_CHEMICAL", 22, 34], ["prednisolone tapering dose", "TREATMENT", 22, 48]]]], "fd8e3a2a233995dd3e6ba043ff8dc19cee5614f3": [["IntroductionThe durability of textiles can be endangered in different ways.", [["The durability of textiles", "TREATMENT", 12, 38]]], ["Abrasion or scratching, attack by bacteria or fungi, and the influence of UV or temperature impair the preservation of properties induced during the processing of textiles.", [["Abrasion", "DISEASE", 0, 8], ["UV", "CHEMICAL", 74, 76], ["Abrasion", "PROBLEM", 0, 8], ["scratching", "PROBLEM", 12, 22], ["attack", "PROBLEM", 24, 30], ["bacteria", "PROBLEM", 34, 42], ["fungi", "PROBLEM", 46, 51], ["UV", "TREATMENT", 74, 76], ["temperature", "TREATMENT", 80, 91], ["scratching", "OBSERVATION_MODIFIER", 12, 22], ["bacteria", "OBSERVATION_MODIFIER", 34, 42], ["fungi", "OBSERVATION", 46, 51]]], ["Various textile treatments are used to protect against degradation or damage or even to restore or repair the initial properties.", [["Various textile treatments", "TREATMENT", 0, 26], ["damage", "PROBLEM", 70, 76], ["repair", "TREATMENT", 99, 105], ["textile treatments", "OBSERVATION", 8, 26]]], ["Besides conventional coating methodologies, increasing focus is put on smart coatings to comply with these demands.IntroductionIn the following paragraphs an overview of some work done at Centexbel in the area of smart durable coatings is presented: Self-healing coatings active at room temperature were developed as a way to protect against scratches, coatings protect textiles against attack by bacteria or fungi, and UV and infrared (IR)-responsive coatings were developed enabling the detection of harmful chemicals in the environment, undesirable temperature changes and excessive UV levels.Types and classifications of smart coatings forimproving textile durability 4.2.1 Self-healing textile coatingsTypes and classifications of smart coatings forThe lifetime of a coated textile can be prolonged if it can be healed at an early stage of damage formation (stage of microcracks).", [["conventional coating methodologies", "TREATMENT", 8, 42], ["smart coatings", "TREATMENT", 71, 85], ["scratches", "PROBLEM", 342, 351], ["bacteria", "PROBLEM", 397, 405], ["fungi", "PROBLEM", 409, 414], ["UV", "TREATMENT", 420, 422], ["infrared (IR)-responsive coatings", "TREATMENT", 427, 460], ["undesirable temperature changes", "PROBLEM", 540, 571], ["excessive UV levels", "PROBLEM", 576, 595], ["smart coatings forimproving textile durability", "TREATMENT", 625, 671], ["Self-healing textile coatings", "TREATMENT", 678, 707], ["smart coatings", "TREATMENT", 736, 750], ["a coated textile", "TREATMENT", 770, 786], ["damage formation", "PROBLEM", 845, 861], ["durable coatings", "OBSERVATION", 219, 235], ["healing", "OBSERVATION_MODIFIER", 255, 262], ["coatings", "OBSERVATION_MODIFIER", 263, 271], ["active", "OBSERVATION_MODIFIER", 272, 278], ["excessive", "OBSERVATION_MODIFIER", 576, 585], ["UV levels", "OBSERVATION", 586, 595], ["textile coatings", "OBSERVATION", 691, 707], ["early stage", "OBSERVATION_MODIFIER", 830, 841], ["damage", "OBSERVATION", 845, 851]]], ["If the coating is able to self-heal and therefore able to repair deterioration of its functionality, the durability of the coated products can be extended.", [["the coated products", "TREATMENT", 119, 138]]], ["This self-healing process can occur autonomously or can be triggered by an external stimulus (eg, heat, radiation).", [["This self-healing process", "PROBLEM", 0, 25], ["an external stimulus", "TEST", 72, 92], ["radiation", "TREATMENT", 104, 113]]], ["A lot of emphasis is put on the use of self-healing concrete, composites and coatings for corrosion prevention.", [["self-healing concrete", "TREATMENT", 39, 60], ["composites and coatings", "TREATMENT", 62, 85], ["corrosion prevention", "TREATMENT", 90, 110]]], ["The use of self-healing coatings on textiles has been less investigated to date.Types and classifications of smart coatings forBoth extrinsic and intrinsic systems have been developed.", [["self-healing coatings on textiles", "TREATMENT", 11, 44], ["smart coatings forBoth extrinsic and intrinsic systems", "PROBLEM", 109, 163], ["smart coatings", "OBSERVATION", 109, 123]]], ["Extrinsic approaches make use of a container which is filled with the healing agent.", [["a container", "TREATMENT", 33, 44], ["the healing agent", "TREATMENT", 66, 83], ["healing", "OBSERVATION_MODIFIER", 70, 77]]], ["When damage occurs, the container breaks and the healing agent is released in the crack and reacts with the catalyst or curing agent present.", [["damage", "PROBLEM", 5, 11], ["the container breaks", "PROBLEM", 20, 40], ["the healing agent", "TREATMENT", 45, 62], ["the catalyst", "TREATMENT", 104, 116], ["healing", "OBSERVATION_MODIFIER", 49, 56]]], ["These containers can be spherical microcapsules (Fig. 4.1; White et al., 2001) , hollow (Fig. 4.2; Mauldin and Kessler, 2010) , or compartmented fibres (Mookhoek et al., 2012) , or a vascular system can be created (Toohey et al., 2007) .Types and classifications of smart coatings forIn a textile coating the use of microcapsules is the most feasible extrinsic approach.", [["vascular system", "ANATOMY", 183, 198], ["vascular", "MULTI-TISSUE_STRUCTURE", 183, 191], ["smart coatings", "TREATMENT", 266, 280], ["a textile coating", "TREATMENT", 287, 304], ["microcapsules", "TREATMENT", 316, 329], ["vascular system", "ANATOMY", 183, 198], ["smart coatings", "OBSERVATION", 266, 280]]], ["Microcapsules containing a healing agent can be added to an existing coating paste and are easily applicable.", [["Microcapsules", "TREATMENT", 0, 13], ["a healing agent", "TREATMENT", 25, 40], ["an existing coating paste", "TREATMENT", 57, 82], ["healing", "OBSERVATION_MODIFIER", 27, 34]]], ["A drawback of this method is the nonrecurring healing action, as damage at this particular area will be repaired only once.", [["this method", "TREATMENT", 14, 25], ["damage", "PROBLEM", 65, 71], ["healing", "OBSERVATION_MODIFIER", 46, 53], ["repaired", "OBSERVATION", 104, 112]]], ["Also, the amount of available healing agent is limited owing to the size of the capsules.Types and classifications of smart coatings forWhen multiple repair actions are desired, one can use an intrinsic system based on reversible covalent chemistry, physical or supramolecular interactions (Garcia and Fischer, 2014) .", [["available healing agent", "TREATMENT", 20, 43], ["smart coatings", "TREATMENT", 118, 132], ["multiple repair actions", "TREATMENT", 141, 164], ["reversible covalent chemistry", "PROBLEM", 219, 248], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["healing", "OBSERVATION", 30, 37], ["size", "OBSERVATION_MODIFIER", 68, 72], ["capsules", "ANATOMY", 80, 88], ["repair", "OBSERVATION", 150, 156]]], ["In this case the damaged coating is able to repair itself by means of an increase in mobility.", [["the damaged coating", "TREATMENT", 13, 32], ["repair", "TREATMENT", 44, 50], ["an increase in mobility", "PROBLEM", 70, 93], ["increase", "OBSERVATION_MODIFIER", 73, 81], ["mobility", "OBSERVATION_MODIFIER", 85, 93]]], ["The coating has an enhanced flow (mostly at elevated temperatures) which enables a refill of the scratch.", [["an enhanced flow", "PROBLEM", 16, 32], ["elevated temperatures", "PROBLEM", 44, 65], ["coating", "OBSERVATION_MODIFIER", 4, 11], ["enhanced", "OBSERVATION_MODIFIER", 19, 27], ["flow", "OBSERVATION", 28, 32], ["refill", "OBSERVATION_MODIFIER", 83, 89], ["scratch", "OBSERVATION", 97, 104]]], ["The restored scratch gains strength because of restored bonds (chemically/physically) (Garc\u00eda et al., 2011; Ghosh, 2009 This technology is already in use in the aerospace and automotive industry.", [["scratch", "OBSERVATION", 13, 20]]], ["Self-repairing car paints have been developed in which heat triggers the repair action.", [["the repair action", "TREATMENT", 69, 86], ["repair", "OBSERVATION", 73, 79]]], ["Several companies have developed self-healing systems which possibly could be implemented on textiles.", [["self-healing systems", "PROBLEM", 33, 53], ["healing", "OBSERVATION", 38, 45], ["possibly could be", "UNCERTAINTY", 60, 77]]], ["An overview is given in Table 4 .1.Types and classifications of smart coatings forOther companies such as BASF, AkzoNobel, Dow and DSM are also investigating the possibilities.Antimicrobial and antifouling coatingsBecause of the high surface area, roughness, and ability to absorb moisture, textiles are prone to be rapidly colonised by microorganisms.", [["surface area", "ANATOMY", 234, 246], ["Antimicrobial and antifouling coatings", "TREATMENT", 176, 214], ["the high surface area", "PROBLEM", 225, 246], ["textiles", "TREATMENT", 291, 299], ["antifouling coatings", "OBSERVATION", 194, 214], ["high", "OBSERVATION_MODIFIER", 229, 233], ["surface", "OBSERVATION_MODIFIER", 234, 241], ["area", "OBSERVATION_MODIFIER", 242, 246], ["roughness", "OBSERVATION_MODIFIER", 248, 257]]], ["These organisms affect the textile's lifetime by destroying the fibres and discolouring the fabric and they may spread unpleasant odours (Boryo, 2013; Burgess, 1954) .", [["fibres", "ANATOMY", 64, 70]]], ["The latter has been an important incentive to develop antimicrobial textile treatments for garments, bedding and sportswear.", [["antimicrobial textile treatments", "TREATMENT", 54, 86]]], ["In addition, textiles may act as vectors for infectious diseases or spread nosocomial bacteria throughout hospital facilities (Leung and Chan, 2006; Treakle et al., 2009; Curtis White et al., 2010) .", [["infectious diseases", "DISEASE", 45, 64], ["infectious diseases", "PROBLEM", 45, 64], ["spread nosocomial bacteria", "PROBLEM", 68, 94]]], ["Several methods have been devised to hamper bacterial growth (bacteriostatic) or even kill bacteria (bactericide) on textiles.", [["bactericide", "CHEMICAL", 101, 112], ["bactericide", "SIMPLE_CHEMICAL", 101, 112], ["Several methods", "TREATMENT", 0, 15], ["bacterial growth (bacteriostatic)", "PROBLEM", 44, 77], ["kill bacteria", "PROBLEM", 86, 99]]], ["The treatments include releasing toxic compounds from fabric or attack microorganisms when they approach the fibre surface.", [["fibre surface", "ANATOMY", 109, 122], ["fibre surface", "CELLULAR_COMPONENT", 109, 122], ["The treatments", "TREATMENT", 0, 14], ["releasing toxic compounds", "PROBLEM", 23, 48], ["fabric or attack microorganisms", "PROBLEM", 54, 85]]], ["Some treatments offer broad-spectrum protection whereas others are predominantly useful against bacteria or fungi.", [["Some treatments", "TREATMENT", 0, 15], ["broad-spectrum protection", "TREATMENT", 22, 47], ["bacteria", "PROBLEM", 96, 104], ["fungi", "PROBLEM", 108, 113], ["fungi", "OBSERVATION", 108, 113]]], ["Antimicrobial compounds include metals, organometal derivatives, phenolic compounds, nitrogen and halogen compounds and nanoparticles (Coleman, 2005; Dastjerdi and Montazer, 2010; Gouveia, 2010; Shahidi and Wiener, 2012; Varesano et al., 2011; Vaun Mcarthur et al., 2012; Lacasse and Baumann, 2004; Simoncic and Tomsic, 2010) .", [["metals", "CHEMICAL", 32, 38], ["organometal", "CHEMICAL", 40, 51], ["nitrogen", "CHEMICAL", 85, 93], ["organometal", "CHEMICAL", 40, 51], ["nitrogen", "CHEMICAL", 85, 93], ["halogen", "CHEMICAL", 98, 105], ["metals", "SIMPLE_CHEMICAL", 32, 38], ["organometal derivatives", "SIMPLE_CHEMICAL", 40, 63], ["phenolic compounds", "SIMPLE_CHEMICAL", 65, 83], ["nitrogen", "SIMPLE_CHEMICAL", 85, 93], ["halogen compounds", "SIMPLE_CHEMICAL", 98, 115], ["nanoparticles", "SIMPLE_CHEMICAL", 120, 133], ["Antimicrobial compounds", "TREATMENT", 0, 23], ["organometal derivatives", "TREATMENT", 40, 63], ["phenolic compounds", "TREATMENT", 65, 83], ["nitrogen and halogen compounds", "TREATMENT", 85, 115], ["phenolic compounds", "OBSERVATION", 65, 83]]], ["Bio-based products have gained increasing attention (Joshi et al., 2009; Simoncic and Tomsic, 2010; Yuan and Cranston, 2008) .Metal-based antimicrobialsMetals such as silver, titanium, zinc and copper are used in finishes and coatings and during fibre extrusion.", [["Metal", "CHEMICAL", 126, 131], ["Metals", "CHEMICAL", 152, 158], ["silver", "CHEMICAL", 167, 173], ["titanium", "CHEMICAL", 175, 183], ["zinc", "CHEMICAL", 185, 189], ["copper", "CHEMICAL", 194, 200], ["silver", "CHEMICAL", 167, 173], ["titanium", "CHEMICAL", 175, 183], ["zinc", "CHEMICAL", 185, 189], ["copper", "CHEMICAL", 194, 200], ["silver", "SIMPLE_CHEMICAL", 167, 173], ["titanium", "SIMPLE_CHEMICAL", 175, 183], ["zinc", "SIMPLE_CHEMICAL", 185, 189], ["copper", "SIMPLE_CHEMICAL", 194, 200], ["Metal-based antimicrobials", "TREATMENT", 126, 152], ["Metals", "TREATMENT", 152, 158], ["silver, titanium, zinc and copper", "TREATMENT", 167, 200], ["fibre extrusion", "PROBLEM", 246, 261], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["antimicrobials", "OBSERVATION", 138, 152], ["fibre extrusion", "OBSERVATION", 246, 261]]], ["Although silver is relatively more effective against bacteria compared with copper, which is more effective towards fungi, in both cases the metal ion needs to be released from the metal core to exert its activity.", [["silver", "CHEMICAL", 9, 15], ["copper", "CHEMICAL", 76, 82], ["silver", "CHEMICAL", 9, 15], ["copper", "CHEMICAL", 76, 82], ["silver", "SIMPLE_CHEMICAL", 9, 15], ["copper", "SIMPLE_CHEMICAL", 76, 82], ["metal ion", "SIMPLE_CHEMICAL", 141, 150], ["bacteria", "PROBLEM", 53, 61], ["fungi", "PROBLEM", 116, 121], ["silver", "OBSERVATION_MODIFIER", 9, 15], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["more effective", "OBSERVATION_MODIFIER", 30, 44], ["more effective", "OBSERVATION_MODIFIER", 93, 107]]], ["The metal ion will form complexes with vital compounds of the microorganism such as the cell membrane, enzymes and DNA.", [["cell membrane", "ANATOMY", 88, 101], ["metal ion", "SIMPLE_CHEMICAL", 4, 13], ["cell membrane", "CELLULAR_COMPONENT", 88, 101], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["enzymes", "PROTEIN", 103, 110], ["vital compounds", "TEST", 39, 54], ["the microorganism", "PROBLEM", 58, 75], ["the cell membrane", "TEST", 84, 101], ["enzymes", "TEST", 103, 110], ["DNA", "PROBLEM", 115, 118]]], ["As a result, the microorganism's metabolism fails in several crucial areas (Lemire et al., 2013) .", [["the microorganism's metabolism", "PROBLEM", 13, 43], ["several", "OBSERVATION_MODIFIER", 53, 60], ["crucial", "OBSERVATION_MODIFIER", 61, 68]]], ["Therefore, resistance against these ions is unlikely to develop because the microorganism is under attack at several targets at the same time.", [["these ions", "PROBLEM", 30, 40], ["the microorganism", "PROBLEM", 72, 89]]], ["However, as to all antimicrobial products, also for silver and copper, resistive strains have been identified but only in very specific environments such as wastewater treatment plants and mining (Silver, 2003) .", [["silver", "CHEMICAL", 52, 58], ["copper", "CHEMICAL", 63, 69], ["silver", "CHEMICAL", 52, 58], ["copper", "CHEMICAL", 63, 69], ["silver", "SIMPLE_CHEMICAL", 52, 58], ["copper", "SIMPLE_CHEMICAL", 63, 69], ["all antimicrobial products", "TREATMENT", 15, 41], ["silver and copper, resistive strains", "PROBLEM", 52, 88], ["wastewater treatment plants", "TREATMENT", 157, 184]]], ["The active metal ions can be released by dissolving directly from the metal, or by ion exchange.", [["metal ions", "SIMPLE_CHEMICAL", 11, 21], ["ion", "SIMPLE_CHEMICAL", 83, 86], ["The active metal ions", "TREATMENT", 0, 21], ["active", "OBSERVATION_MODIFIER", 4, 10], ["metal ions", "OBSERVATION", 11, 21]]], ["The latter is often used in silver-based products in which silver ions are bound to a ceramic matrix (Lorenz et al., 2012) .", [["silver", "CHEMICAL", 28, 34], ["silver ions", "CHEMICAL", 59, 70], ["silver", "CHEMICAL", 28, 34], ["silver", "CHEMICAL", 59, 65], ["silver", "SIMPLE_CHEMICAL", 28, 34], ["silver ions", "SIMPLE_CHEMICAL", 59, 70], ["silver-based products", "TREATMENT", 28, 49]]], ["Although the mobile metal ion is the active compound, metal-based antimicrobials are often not considered to be leaching out.", [["metal ion", "SIMPLE_CHEMICAL", 20, 29], ["metal-based antimicrobials", "SIMPLE_CHEMICAL", 54, 80], ["the active compound", "PROBLEM", 33, 52], ["metal-based antimicrobials", "TREATMENT", 54, 80], ["active", "OBSERVATION_MODIFIER", 37, 43], ["compound", "OBSERVATION_MODIFIER", 44, 52], ["leaching", "OBSERVATION", 112, 120]]], ["In contrast to toxic chemical compounds, silver and copper ions easily form metal complexes with any organic substance in the vicinity.", [["silver", "CHEMICAL", 41, 47], ["copper", "CHEMICAL", 52, 58], ["silver", "CHEMICAL", 41, 47], ["copper", "CHEMICAL", 52, 58], ["silver", "SIMPLE_CHEMICAL", 41, 47], ["copper ions", "SIMPLE_CHEMICAL", 52, 63], ["metal complexes", "SIMPLE_CHEMICAL", 76, 91], ["toxic chemical compounds", "PROBLEM", 15, 39], ["silver and copper ions", "TREATMENT", 41, 63], ["toxic", "OBSERVATION_MODIFIER", 15, 20], ["chemical compounds", "OBSERVATION", 21, 39], ["organic substance", "OBSERVATION", 101, 118]]], ["Leaching test methods such as agar diffusion tests (EN 20645 and AATCC 147) will therefore show no or only limited leaching from silver-treated fabrics.Halogen compoundsHalogen-based antimicrobials from highly reactive oxides are known for strong disinfecting properties.", [["EN 20645", "CHEMICAL", 52, 60], ["silver", "CHEMICAL", 129, 135], ["Halogen compounds", "CHEMICAL", 152, 169], ["Halogen", "CHEMICAL", 169, 176], ["silver", "CHEMICAL", 129, 135], ["Halogen", "CHEMICAL", 152, 159], ["Halogen", "CHEMICAL", 169, 176], ["oxides", "CHEMICAL", 219, 225], ["silver", "SIMPLE_CHEMICAL", 129, 135], ["Halogen", "SIMPLE_CHEMICAL", 152, 159], ["Halogen", "SIMPLE_CHEMICAL", 169, 176], ["reactive oxides", "SIMPLE_CHEMICAL", 210, 225], ["Leaching test methods", "TEST", 0, 21], ["agar diffusion tests", "TEST", 30, 50], ["AATCC", "TEST", 65, 70], ["silver-treated fabrics", "TREATMENT", 129, 151], ["Halogen compounds", "TREATMENT", 152, 169], ["Halogen", "TREATMENT", 169, 176], ["antimicrobials", "TREATMENT", 183, 197], ["highly reactive oxides", "TREATMENT", 203, 225], ["reactive oxides", "OBSERVATION", 210, 225]]], ["Chlorine-and iodine-based products are well-known cleaning and disinfectants (bleach, chlorhexidine and Betadine).", [["Chlorine", "CHEMICAL", 0, 8], ["iodine", "CHEMICAL", 13, 19], ["chlorhexidine", "CHEMICAL", 86, 99], ["Betadine", "CHEMICAL", 104, 112], ["Chlorine", "CHEMICAL", 0, 8], ["iodine", "CHEMICAL", 13, 19], ["chlorhexidine", "CHEMICAL", 86, 99], ["Betadine", "CHEMICAL", 104, 112], ["Chlorine", "SIMPLE_CHEMICAL", 0, 8], ["iodine", "SIMPLE_CHEMICAL", 13, 19], ["bleach", "SIMPLE_CHEMICAL", 78, 84], ["chlorhexidine", "SIMPLE_CHEMICAL", 86, 99], ["Betadine", "SIMPLE_CHEMICAL", 104, 112], ["Chlorine", "TREATMENT", 0, 8], ["iodine-based products", "TREATMENT", 13, 34], ["disinfectants (bleach", "TREATMENT", 63, 84], ["chlorhexidine", "TREATMENT", 86, 99], ["Betadine", "TREATMENT", 104, 112]]], ["Such derivatives are also used in textiles (Coleman, 2005) .", [["Such derivatives", "TREATMENT", 0, 16]]], ["However, the persistence of halogens in the environment, the aggressive nature of these products (also to textile fibres) and their relation to cancer by disinfectant by-products (in particular for chlorine) limit their use in textiles.", [["cancer", "ANATOMY", 144, 150], ["halogens", "CHEMICAL", 28, 36], ["cancer", "DISEASE", 144, 150], ["chlorine", "CHEMICAL", 198, 206], ["halogens", "CHEMICAL", 28, 36], ["chlorine", "CHEMICAL", 198, 206], ["halogens", "SIMPLE_CHEMICAL", 28, 36], ["cancer", "CANCER", 144, 150], ["chlorine", "SIMPLE_CHEMICAL", 198, 206], ["cancer", "PROBLEM", 144, 150], ["persistence", "OBSERVATION_MODIFIER", 13, 24], ["halogens", "OBSERVATION", 28, 36], ["cancer", "OBSERVATION", 144, 150]]], ["Common products are pentachlorophenol, dichlorodiphenyl methane, iodine and iodophors (Lacasse and Baumann, 2004) .Nitrogen compoundsNitrogen compounds such as urea, amine and guanidine are used to denature proteins, hence their antimicrobial properties.", [["pentachlorophenol", "CHEMICAL", 20, 37], ["dichlorodiphenyl methane, iodine", "CHEMICAL", 39, 71], ["Nitrogen compounds", "CHEMICAL", 115, 133], ["urea", "CHEMICAL", 160, 164], ["amine", "CHEMICAL", 166, 171], ["guanidine", "CHEMICAL", 176, 185], ["pentachlorophenol", "CHEMICAL", 20, 37], ["dichlorodiphenyl methane", "CHEMICAL", 39, 63], ["iodine", "CHEMICAL", 65, 71], ["iodophors", "CHEMICAL", 76, 85], ["Nitrogen", "CHEMICAL", 115, 123], ["Nitrogen", "CHEMICAL", 133, 141], ["urea", "CHEMICAL", 160, 164], ["amine", "CHEMICAL", 166, 171], ["guanidine", "CHEMICAL", 176, 185], ["pentachlorophenol", "SIMPLE_CHEMICAL", 20, 37], ["dichlorodiphenyl methane", "SIMPLE_CHEMICAL", 39, 63], ["iodine", "SIMPLE_CHEMICAL", 65, 71], ["iodophors", "SIMPLE_CHEMICAL", 76, 85], ["Nitrogen compounds", "SIMPLE_CHEMICAL", 133, 151], ["urea", "SIMPLE_CHEMICAL", 160, 164], ["amine", "SIMPLE_CHEMICAL", 166, 171], ["guanidine", "SIMPLE_CHEMICAL", 176, 185], ["Common products", "TREATMENT", 0, 15], ["pentachlorophenol", "TREATMENT", 20, 37], ["dichlorodiphenyl methane", "TREATMENT", 39, 63], ["iodine", "TREATMENT", 65, 71], ["iodophors (Lacasse", "TREATMENT", 76, 94], ["Baumann", "TREATMENT", 99, 106], ["Nitrogen compounds", "TREATMENT", 115, 133], ["Nitrogen compounds", "TREATMENT", 133, 151], ["urea, amine", "TREATMENT", 160, 171], ["guanidine", "TREATMENT", 176, 185], ["denature proteins", "PROBLEM", 198, 215], ["their antimicrobial properties", "TREATMENT", 223, 253]]], ["One special form of nitrogen compounds for antimicrobial treatment is the so-called quats or quaternary ammonium salts (Coleman, 2005; Shahidi and Wiener, 2012; Windler et al., 2013) .", [["nitrogen compounds", "CHEMICAL", 20, 38], ["quaternary ammonium salts", "CHEMICAL", 93, 118], ["nitrogen", "CHEMICAL", 20, 28], ["quaternary ammonium salts", "CHEMICAL", 93, 118], ["nitrogen compounds", "SIMPLE_CHEMICAL", 20, 38], ["quats", "SIMPLE_CHEMICAL", 84, 89], ["quaternary ammonium salts", "SIMPLE_CHEMICAL", 93, 118], ["nitrogen compounds", "TREATMENT", 20, 38], ["antimicrobial treatment", "TREATMENT", 43, 66]]], ["These molecules have a positive charge, attracting the negatively charged cell membrane of microorganisms.", [["cell membrane", "ANATOMY", 74, 87], ["cell membrane", "CELLULAR_COMPONENT", 74, 87], ["a positive charge", "PROBLEM", 21, 38], ["positive charge", "OBSERVATION_MODIFIER", 23, 38], ["cell membrane", "OBSERVATION", 74, 87]]], ["Mostly, the positively charged nitrogen head is followed by a long organic chain.", [["nitrogen", "CHEMICAL", 31, 39], ["nitrogen", "CHEMICAL", 31, 39], ["long organic chain", "PROTEIN", 62, 80]]], ["This combination allows the molecule to puncture the cell membrane, consequently destroying the microorganisms (Curtis White et al., 2010) .", [["cell membrane", "ANATOMY", 53, 66], ["cell membrane", "CELLULAR_COMPONENT", 53, 66], ["cell membrane", "OBSERVATION", 53, 66]]], ["The advantage of the quats' molecules is their odour-free nature and the ability to add functional groups to the organic chain, which allows them to form a chemical bond to the textile fibres.", [["textile fibres", "ANATOMY", 177, 191], ["textile fibres", "OBSERVATION", 177, 191]]], ["In this way, leaching is limited and durability increases compared with the smaller nitrogen compounds mentioned previously.Phenolic compoundsPhenolic compounds have a long history as disinfectants.", [["nitrogen", "CHEMICAL", 84, 92], ["Phenolic", "CHEMICAL", 142, 150], ["the smaller nitrogen compounds", "PROBLEM", 72, 102], ["Phenolic compounds", "PROBLEM", 124, 142], ["leaching", "OBSERVATION", 13, 21], ["durability", "OBSERVATION_MODIFIER", 37, 47], ["increases", "OBSERVATION_MODIFIER", 48, 57], ["compounds", "OBSERVATION", 133, 142]]], ["However, the carcinogenic nature of phenols has led to the development of derivatives that are less toxic to humans.", [["phenols", "CHEMICAL", 36, 43], ["phenols", "CHEMICAL", 36, 43], ["phenols", "SIMPLE_CHEMICAL", 36, 43], ["humans", "ORGANISM", 109, 115], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 109, 115], ["derivatives", "TREATMENT", 74, 85]]], ["The best known is triclosan.", [["triclosan", "CHEMICAL", 18, 27], ["triclosan", "CHEMICAL", 18, 27], ["triclosan", "SIMPLE_CHEMICAL", 18, 27], ["triclosan", "OBSERVATION", 18, 27]]], ["Its relatively low toxicity to humans, effective disinfection properties and cheap production has led triclosan to become one of the highest selling disinfectants worldwide.", [["toxicity", "DISEASE", 19, 27], ["triclosan", "CHEMICAL", 102, 111], ["triclosan", "CHEMICAL", 102, 111], ["humans", "ORGANISM", 31, 37], ["triclosan", "SIMPLE_CHEMICAL", 102, 111], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37], ["Its relatively low toxicity", "PROBLEM", 0, 27], ["effective disinfection properties", "TREATMENT", 39, 72], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["low toxicity", "OBSERVATION_MODIFIER", 15, 27]]], ["However, its use in a wide variety of customer care products has induced the development of resistive bacteria strains (Windler et al., 2013; Lacasse and Baumann, 2004) .Aldehyde compoundsAldehyde compounds such as formaldehyde and glutaraldehyde are commonly used for cross-linking purposes in chemistry.", [["Aldehyde", "CHEMICAL", 170, 178], ["Aldehyde", "CHEMICAL", 188, 196], ["formaldehyde", "CHEMICAL", 215, 227], ["glutaraldehyde", "CHEMICAL", 232, 246], ["Aldehyde", "CHEMICAL", 170, 178], ["Aldehyde", "CHEMICAL", 188, 196], ["formaldehyde", "CHEMICAL", 215, 227], ["glutaraldehyde", "CHEMICAL", 232, 246], ["Aldehyde", "SIMPLE_CHEMICAL", 170, 178], ["Aldehyde", "SIMPLE_CHEMICAL", 188, 196], ["formaldehyde", "SIMPLE_CHEMICAL", 215, 227], ["glutaraldehyde", "SIMPLE_CHEMICAL", 232, 246], ["customer care products", "TREATMENT", 38, 60], ["resistive bacteria strains", "PROBLEM", 92, 118], ["Aldehyde compounds", "TREATMENT", 170, 188], ["Aldehyde compounds", "TREATMENT", 188, 206], ["formaldehyde and glutaraldehyde", "TREATMENT", 215, 246], ["resistive", "OBSERVATION_MODIFIER", 92, 101], ["bacteria strains", "OBSERVATION", 102, 118], ["compounds", "OBSERVATION", 179, 188]]], ["However, they also cross-link proteins and enzymes, rendering them useless for microorganisms (Windler et al., 2013; Lacasse and Baumann, 2004) .", [["enzymes", "PROTEIN", 43, 50], ["enzymes", "TEST", 43, 50], ["microorganisms", "PROBLEM", 79, 93]]], ["The carcinogenic nature of these compounds has put a strict regulation on these products in textiles.Bio-based productsOne of the best known bio-based antimicrobial products is chitosan.", [["chitosan", "CHEMICAL", 177, 185], ["chitosan", "SIMPLE_CHEMICAL", 177, 185], ["Bio-based products", "PROTEIN", 101, 119], ["bio-based antimicrobial products", "TREATMENT", 141, 173], ["carcinogenic", "OBSERVATION_MODIFIER", 4, 16], ["antimicrobial products", "OBSERVATION", 151, 173]]], ["It is a polysaccharide derived from chitin, an abundantly available waste product in shrimp farms.", [["chitin", "CHEMICAL", 36, 42], ["chitin", "SIMPLE_CHEMICAL", 36, 42], ["shrimp", "ORGANISM", 85, 91], ["farms", "ORGANISM_SUBDIVISION", 92, 97], ["chitin", "TREATMENT", 36, 42], ["shrimp farms", "OBSERVATION", 85, 97]]], ["Although the deacetylation process to form chitosan from chitin is far from ecofriendly, it still is a renewable resource of antimicrobial products.", [["chitosan", "CHEMICAL", 43, 51], ["chitin", "CHEMICAL", 57, 63], ["chitosan", "SIMPLE_CHEMICAL", 43, 51], ["chitin", "SIMPLE_CHEMICAL", 57, 63], ["the deacetylation process", "TREATMENT", 9, 34], ["antimicrobial products", "TREATMENT", 125, 147], ["antimicrobial products", "OBSERVATION", 125, 147]]], ["The active groups consist of an array of amine functionalities organised on the polysaccharide chain.", [["amine", "CHEMICAL", 41, 46], ["amine", "CHEMICAL", 41, 46], ["amine", "SIMPLE_CHEMICAL", 41, 46], ["polysaccharide chain", "PROTEIN", 80, 100], ["active", "OBSERVATION_MODIFIER", 4, 10], ["polysaccharide chain", "OBSERVATION_MODIFIER", 80, 100]]], ["Its activity is therefore similar as to the nitrogen compounds described previously.Bio-based productsThe renewed interest in bio-based products has led to the development of new antimicrobial products in textiles (De Smet et al., 2015a) .", [["nitrogen", "CHEMICAL", 44, 52], ["Bio-based products", "PROTEIN", 84, 102], ["the nitrogen compounds", "PROBLEM", 40, 62], ["bio-based products", "TREATMENT", 126, 144], ["new antimicrobial products", "TREATMENT", 175, 201], ["activity", "OBSERVATION_MODIFIER", 4, 12], ["nitrogen compounds", "OBSERVATION", 44, 62], ["new", "OBSERVATION_MODIFIER", 175, 178], ["antimicrobial products", "OBSERVATION", 179, 201]]], ["Bio-based products are mostly plant extracts such as menthol, carvacrol (Oregano sp.), thymol (Thymus sp.), eucalyptol (Eucalyptus sp.), neem extract (Azadirachta indica), aloe vera (Aloe barbadensis), prickly chaff flower (Achysanthus aspera), eugenol (Syzygium aromaticum), turmeric and cumin, to name a few (Joshi et al., 2010; De Smet et al., 2015b) .", [["extracts", "ANATOMY", 36, 44], ["menthol", "CHEMICAL", 53, 60], ["carvacrol", "CHEMICAL", 62, 71], ["thymol", "CHEMICAL", 87, 93], ["eucalyptol", "CHEMICAL", 108, 118], ["Eucalyptus sp.), neem extract", "CHEMICAL", 120, 149], ["Azadirachta indica", "CHEMICAL", 151, 169], ["aloe vera", "DISEASE", 172, 181], ["eugenol", "CHEMICAL", 245, 252], ["cumin", "CHEMICAL", 289, 294], ["menthol", "CHEMICAL", 53, 60], ["carvacrol", "CHEMICAL", 62, 71], ["thymol", "CHEMICAL", 87, 93], ["eucalyptol", "CHEMICAL", 108, 118], ["eugenol", "CHEMICAL", 245, 252], ["cumin", "CHEMICAL", 289, 294], ["extracts", "ORGANISM_SUBSTANCE", 36, 44], ["menthol", "SIMPLE_CHEMICAL", 53, 60], ["carvacrol", "SIMPLE_CHEMICAL", 62, 71], ["Oregano sp.", "ORGANISM", 73, 84], ["thymol", "SIMPLE_CHEMICAL", 87, 93], ["Thymus sp.", "ORGANISM", 95, 105], ["eucalyptol", "SIMPLE_CHEMICAL", 108, 118], ["Eucalyptus sp.", "ORGANISM", 120, 134], ["neem", "ORGANISM", 137, 141], ["Azadirachta indica", "ORGANISM", 151, 169], ["aloe vera", "ORGANISM", 172, 181], ["Aloe barbadensis", "ORGANISM", 183, 199], ["flower", "ORGANISM_SUBDIVISION", 216, 222], ["Achysanthus aspera", "ORGANISM", 224, 242], ["eugenol", "SIMPLE_CHEMICAL", 245, 252], ["Syzygium aromaticum", "ORGANISM", 254, 273], ["turmeric", "SIMPLE_CHEMICAL", 276, 284], ["cumin", "SIMPLE_CHEMICAL", 289, 294], ["Eucalyptus sp.", "SPECIES", 120, 134], ["neem", "SPECIES", 137, 141], ["Azadirachta indica", "SPECIES", 151, 169], ["aloe vera", "SPECIES", 172, 181], ["Aloe barbadensis", "SPECIES", 183, 199], ["chaff", "SPECIES", 210, 215], ["Achysanthus aspera", "SPECIES", 224, 242], ["Syzygium aromaticum", "SPECIES", 254, 273], ["Thymus sp.)", "SPECIES", 95, 106], ["Azadirachta indica", "SPECIES", 151, 169], ["aloe vera (Aloe barbadensis", "SPECIES", 172, 199], ["Achysanthus aspera", "SPECIES", 224, 242], ["Syzygium aromaticum", "SPECIES", 254, 273], ["Bio-based products", "TREATMENT", 0, 18], ["menthol", "TREATMENT", 53, 60], ["carvacrol (Oregano sp", "TREATMENT", 62, 83], ["thymol (Thymus sp", "TREATMENT", 87, 104], ["eucalyptol (Eucalyptus sp.", "TREATMENT", 108, 134], ["neem extract (Azadirachta indica", "TREATMENT", 137, 169], ["aloe vera (Aloe barbadensis", "TREATMENT", 172, 199], ["eugenol (Syzygium aromaticum", "TREATMENT", 245, 273], ["Thymus", "ANATOMY", 95, 101]]], ["The antimicrobial activity of plant extracts such as peppermint, primrose and perilla oil has been explored as well.", [["extracts", "ANATOMY", 36, 44], ["perilla oil", "ANATOMY", 78, 89], ["primrose", "CHEMICAL", 65, 73], ["extracts", "ORGANISM_SUBSTANCE", 36, 44], ["peppermint", "SIMPLE_CHEMICAL", 53, 63], ["primrose", "SIMPLE_CHEMICAL", 65, 73], ["perilla oil", "SIMPLE_CHEMICAL", 78, 89], ["peppermint", "SPECIES", 53, 63], ["The antimicrobial activity of plant extracts", "TREATMENT", 0, 44], ["peppermint", "TREATMENT", 53, 63], ["primrose and perilla oil", "TREATMENT", 65, 89], ["antimicrobial activity", "OBSERVATION", 4, 26]]], ["In addition, animal extracts also has potential as antimicrobial additives, such as sericin, a macromolecular protein derived from the silkworm Bombyx mori (Joshi et al., 2009; Shahidi and Wiener, 2012) .Bio-based productsAlthough a vast number of bio-based alternatives show clear potential as antimicrobial textile treatment, the durability, applicability, availability and sometimes discolouring or unpleasant smell limit their use at an industrial level in textiles.Bio-based productsAlternatively, and by the grace of improved biotechnology tools for peptide production, short-chain amino acids have been reported to be useful as a bio-based antimicrobial finish for textiles (Gouveia, 2010) .AntifoulingFouling is the result of the continuous accumulation of debris at the surface of films, rigid plates, and filters.", [["extracts", "ANATOMY", 20, 28], ["surface", "ANATOMY", 779, 786], ["sericin", "CHEMICAL", 84, 91], ["amino acids", "CHEMICAL", 588, 599], ["sericin", "CHEMICAL", 84, 91], ["short-chain amino acids", "CHEMICAL", 576, 599], ["extracts", "ORGANISM_SUBSTANCE", 20, 28], ["sericin", "SIMPLE_CHEMICAL", 84, 91], ["silkworm", "ORGANISM", 135, 143], ["Bombyx mori", "ORGANISM", 144, 155], ["amino acids", "AMINO_ACID", 588, 599], ["macromolecular protein", "PROTEIN", 95, 117], ["Bio-based products", "PROTEIN", 204, 222], ["Bio-based products", "PROTEIN", 470, 488], ["silkworm", "SPECIES", 135, 143], ["Bombyx mori", "SPECIES", 144, 155], ["silkworm", "SPECIES", 135, 143], ["Bombyx mori", "SPECIES", 144, 155], ["antimicrobial additives", "TREATMENT", 51, 74], ["sericin", "TREATMENT", 84, 91], ["a macromolecular protein", "TEST", 93, 117], ["bio-based alternatives", "TREATMENT", 248, 270], ["antimicrobial textile treatment", "TREATMENT", 295, 326], ["unpleasant smell", "PROBLEM", 402, 418], ["peptide production", "PROBLEM", 556, 574], ["short-chain amino acids", "PROBLEM", 576, 599], ["AntifoulingFouling", "TREATMENT", 698, 716], ["the continuous accumulation of debris", "PROBLEM", 734, 771], ["rigid plates", "TREATMENT", 797, 809], ["filters", "TREATMENT", 815, 822], ["antimicrobial textile", "OBSERVATION", 295, 316], ["Fouling", "OBSERVATION", 709, 716], ["continuous", "OBSERVATION_MODIFIER", 738, 748], ["accumulation", "OBSERVATION_MODIFIER", 749, 761], ["debris", "OBSERVATION", 765, 771], ["surface", "OBSERVATION_MODIFIER", 779, 786], ["rigid plates", "OBSERVATION", 797, 809], ["filters", "OBSERVATION", 815, 822]]], ["Clearly textiles are also prone to fouling, and this chapter will focus on biofouling or biofilm formation and how it can be tackled.", [["biofilm", "ANATOMY", 89, 96], ["fouling", "DISEASE", 35, 42], ["biofouling or biofilm formation", "TREATMENT", 75, 106]]], ["Fouling is a result of the stagnating flow of fluids at the surface from which debris will deposit, attracted by van der Waals forces.", [["surface", "ANATOMY", 60, 67], ["Fouling", "DISEASE", 0, 7], ["surface", "CELLULAR_COMPONENT", 60, 67], ["the stagnating flow of fluids", "TREATMENT", 23, 52], ["fluids", "OBSERVATION", 46, 52], ["debris", "OBSERVATION", 79, 85]]], ["In case of biofilm formation, the first molecules depositing on the surface are proteins and polysaccharides.", [["biofilm", "ANATOMY", 11, 18], ["surface", "ANATOMY", 68, 75], ["surface", "CELLULAR_COMPONENT", 68, 75], ["biofilm formation", "PROBLEM", 11, 28], ["polysaccharides", "PROBLEM", 93, 108], ["biofilm formation", "OBSERVATION", 11, 28], ["polysaccharides", "OBSERVATION_MODIFIER", 93, 108]]], ["On the one hand, these molecules cover up any surface functionality and provide a suitable ground for bacteria to attach and develop on this new extracellular matrix (ECM).", [["surface", "ANATOMY", 46, 53], ["extracellular matrix", "ANATOMY", 145, 165], ["ECM", "ANATOMY", 167, 170], ["extracellular matrix", "CELLULAR_COMPONENT", 145, 165], ["ECM", "CELLULAR_COMPONENT", 167, 170], ["bacteria", "PROBLEM", 102, 110]]], ["Bacteria possess surface-bound adhesion proteins designed to bind to such ECM, thus mediating colonisation of the surface.", [["surface", "ANATOMY", 17, 24], ["ECM", "ANATOMY", 74, 77], ["surface", "ANATOMY", 114, 121], ["Bacteria", "CELL", 0, 8], ["ECM", "CELLULAR_COMPONENT", 74, 77], ["surface", "CELLULAR_COMPONENT", 114, 121], ["adhesion proteins", "PROTEIN", 31, 48], ["Bacteria possess surface", "PROBLEM", 0, 24], ["bound adhesion proteins", "PROBLEM", 25, 48], ["surface", "OBSERVATION_MODIFIER", 17, 24], ["bound adhesion", "OBSERVATION", 25, 39], ["colonisation", "OBSERVATION", 94, 106], ["surface", "OBSERVATION_MODIFIER", 114, 121]]], ["Once the bacteria and other microorganisms have gathered, exertion of more and more proteins and polysaccharides form the so-called external polysaccharide matrix in which the microorganisms thrive and form a complex ecosystem (Bixler and Bhushan, 2012; Harder and Yee, 2009) .", [["matrix", "CELLULAR_COMPONENT", 156, 162], ["the bacteria", "PROBLEM", 5, 17], ["other microorganisms", "PROBLEM", 22, 42], ["polysaccharides", "TREATMENT", 97, 112], ["external polysaccharide matrix", "TREATMENT", 132, 162], ["bacteria", "OBSERVATION", 9, 17], ["polysaccharide matrix", "OBSERVATION", 141, 162]]], ["Some microorganisms and even macroorganisms are expert in colonising virgin surfaces by excreting specially designed attachment proteins such as adhesins (well known in various infectious bacteria) and mussel adhesion proteins (Mytilus edulis) (Klemm and Schembri, 2000; Qin and Buehler, 2014) .AntifoulingTo overcome fouling (and biofouling in particular), surface modifications aim to (Lejars et al., 2012) :Antifouling\u2022 increase shear and reduce surface energy \u2022 limit anchoring points \u2022 kill attaching organisms \u2022 periodically or gradually remove the top layer of the surface Both biofilm formation and possible antifouling strategies are illustrated in Fig. 4 .3.", [["surface", "ANATOMY", 358, 365], ["surface", "ANATOMY", 449, 456], ["surface", "ANATOMY", 572, 579], ["biofilm", "ANATOMY", 585, 592], ["fouling", "DISEASE", 318, 325], ["mussel adhesion proteins", "GENE_OR_GENE_PRODUCT", 202, 226], ["Mytilus edulis", "ORGANISM", 228, 242], ["surface", "CELLULAR_COMPONENT", 572, 579], ["attachment proteins", "PROTEIN", 117, 136], ["adhesins", "PROTEIN", 145, 153], ["mussel adhesion proteins", "PROTEIN", 202, 226], ["Mytilus edulis", "SPECIES", 228, 242], ["Mytilus edulis", "SPECIES", 228, 242], ["Some microorganisms", "PROBLEM", 0, 19], ["even macroorganisms", "PROBLEM", 24, 43], ["attachment proteins", "PROBLEM", 117, 136], ["adhesins", "PROBLEM", 145, 153], ["various infectious bacteria", "PROBLEM", 169, 196], ["mussel adhesion proteins", "PROBLEM", 202, 226], ["Antifouling", "TREATMENT", 295, 306], ["fouling (and biofouling", "TREATMENT", 318, 341], ["Antifouling\u2022 increase shear", "TREATMENT", 410, 437], ["surface energy", "TREATMENT", 449, 463], ["antifouling strategies", "TREATMENT", 616, 638], ["microorganisms", "OBSERVATION", 5, 19], ["infectious", "OBSERVATION_MODIFIER", 177, 187], ["mussel adhesion", "OBSERVATION", 202, 217], ["top", "OBSERVATION_MODIFIER", 555, 558], ["layer", "OBSERVATION_MODIFIER", 559, 564], ["biofilm", "OBSERVATION", 585, 592]]], ["Increasing the shear at the surface and limiting surface energy can be achieved by creating very sleek omniphobic surfaces (Genzer and Efimenko, 2006) .", [["surface", "ANATOMY", 28, 35], ["surface", "ANATOMY", 49, 56], ["surface", "CELLULAR_COMPONENT", 28, 35], ["shear", "OBSERVATION_MODIFIER", 15, 20], ["surface", "OBSERVATION_MODIFIER", 28, 35]]], ["Usually, water-and oil-repellent fluorine-based coatings are used to reduce surface free energy as much as possible.", [["surface", "ANATOMY", 76, 83], ["fluorine", "CHEMICAL", 33, 41], ["fluorine", "CHEMICAL", 33, 41], ["water", "SIMPLE_CHEMICAL", 9, 14], ["fluorine", "SIMPLE_CHEMICAL", 33, 41], ["repellent fluorine-based coatings", "TREATMENT", 23, 56]]], ["As a result, both the static layer of fluids near the surface and the van der Waals forces are reduced (Van Zoelen et al., 2014) .", [["surface", "ANATOMY", 54, 61], ["surface", "CELLULAR_COMPONENT", 54, 61], ["the static layer of fluids", "TREATMENT", 18, 44], ["the van der Waals forces", "TREATMENT", 66, 90], ["layer", "OBSERVATION_MODIFIER", 29, 34], ["fluids", "OBSERVATION", 38, 44]]], ["However, microorganisms still manage to colonise these surfaces by secreting viscous, slime-like substances that cover the entire surface and thus cover the underneath functionalities.", [["surface", "ANATOMY", 130, 137], ["surface", "CELLULAR_COMPONENT", 130, 137], ["microorganisms", "PROBLEM", 9, 23], ["secreting viscous, slime-like substances", "PROBLEM", 67, 107], ["secreting viscous", "OBSERVATION", 67, 84], ["entire", "OBSERVATION_MODIFIER", 123, 129], ["surface", "OBSERVATION_MODIFIER", 130, 137], ["underneath functionalities", "OBSERVATION", 157, 183]]], ["In contrast to creating hydrophobic and oleophobic surfaces, positive results have been obtained by creating extremely hydrophilic surfaces.", [["creating hydrophobic and oleophobic surfaces", "PROBLEM", 15, 59], ["hydrophobic", "OBSERVATION_MODIFIER", 24, 35]]], ["The reasoning behind this is that fouling (organic) molecules are partially composed of long-chain hydrocarbon segments that are strongly repelled by the superhydrophilic surface properties (Patel et al., 2010) .AntifoulingProtein and polysaccharide attachment can be limited by creating a dense brush-like layer at the surface.", [["surface", "ANATOMY", 171, 178], ["brush", "ANATOMY", 296, 301], ["surface", "ANATOMY", 320, 327], ["hydrocarbon", "CHEMICAL", 99, 110], ["polysaccharide", "SIMPLE_CHEMICAL", 235, 249], ["surface", "CELLULAR_COMPONENT", 320, 327], ["long-chain hydrocarbon segments", "PROTEIN", 88, 119], ["fouling (organic) molecules", "PROBLEM", 34, 61], ["long-chain hydrocarbon segments", "PROBLEM", 88, 119], ["AntifoulingProtein and polysaccharide attachment", "TREATMENT", 212, 260], ["a dense brush-like layer at the surface", "PROBLEM", 288, 327], ["fouling", "OBSERVATION", 34, 41], ["long", "OBSERVATION_MODIFIER", 88, 92], ["chain", "ANATOMY_MODIFIER", 93, 98], ["hydrocarbon segments", "ANATOMY_MODIFIER", 99, 119], ["superhydrophilic", "OBSERVATION_MODIFIER", 154, 170], ["surface", "OBSERVATION_MODIFIER", 171, 178], ["polysaccharide attachment", "OBSERVATION", 235, 260], ["dense", "OBSERVATION_MODIFIER", 290, 295], ["brush", "OBSERVATION_MODIFIER", 296, 301], ["layer", "OBSERVATION_MODIFIER", 307, 312], ["surface", "OBSERVATION_MODIFIER", 320, 327]]], ["As a result, all possible anchoring points are occupied and no new (bio)polymers can attach.", [["new (bio)polymers", "TREATMENT", 63, 80], ["no", "UNCERTAINTY", 60, 62], ["new", "OBSERVATION_MODIFIER", 63, 66]]], ["It has been demonstrated that polyethylene glycol (PEG) is effective in creating such surfaces (Ding et al., 2012) .", [["polyethylene glycol", "CHEMICAL", 30, 49], ["PEG", "CHEMICAL", 51, 54], ["polyethylene glycol", "CHEMICAL", 30, 49], ["PEG", "CHEMICAL", 51, 54], ["polyethylene glycol", "SIMPLE_CHEMICAL", 30, 49], ["PEG", "SIMPLE_CHEMICAL", 51, 54], ["polyethylene glycol (PEG)", "TREATMENT", 30, 55], ["polyethylene glycol", "OBSERVATION", 30, 49]]], ["Unfortunately, the rigidity of such a PEG brush is low and the layer is easily damaged.", [["rigidity", "DISEASE", 19, 27], ["PEG", "CHEMICAL", 38, 41], ["PEG", "CHEMICAL", 38, 41], ["the rigidity", "PROBLEM", 15, 27], ["a PEG brush", "TREATMENT", 36, 47], ["rigidity", "OBSERVATION_MODIFIER", 19, 27], ["PEG", "OBSERVATION", 38, 41], ["low", "OBSERVATION_MODIFIER", 51, 54], ["layer", "OBSERVATION_MODIFIER", 63, 68], ["easily", "OBSERVATION_MODIFIER", 72, 78], ["damaged", "OBSERVATION", 79, 86]]], ["Another option is not to prevent initial protein and polysaccharide attachment but to destroy any microorganism in the vicinity of the surface.", [["surface", "ANATOMY", 135, 142], ["polysaccharide", "SIMPLE_CHEMICAL", 53, 67], ["surface", "CELLULAR_COMPONENT", 135, 142], ["initial protein and polysaccharide attachment", "PROBLEM", 33, 78], ["polysaccharide attachment", "OBSERVATION", 53, 78], ["microorganism", "OBSERVATION", 98, 111], ["surface", "ANATOMY_MODIFIER", 135, 142]]], ["This way, only a thin fouling film is developed but biofilm formation and growth of the film is significantly hampered or blocked.AntifoulingCopper and heavy metal (such as mercury and tin) based products are available in coating formulations.", [["biofilm", "ANATOMY", 52, 59], ["Copper", "CHEMICAL", 141, 147], ["mercury", "CHEMICAL", 173, 180], ["tin", "CHEMICAL", 185, 188], ["Copper", "CHEMICAL", 141, 147], ["mercury", "CHEMICAL", 173, 180], ["tin", "CHEMICAL", 185, 188], ["Copper", "SIMPLE_CHEMICAL", 141, 147], ["heavy metal", "SIMPLE_CHEMICAL", 152, 163], ["mercury", "SIMPLE_CHEMICAL", 173, 180], ["tin", "SIMPLE_CHEMICAL", 185, 188], ["a thin fouling film", "TEST", 15, 34], ["biofilm formation", "PROBLEM", 52, 69], ["the film", "TEST", 84, 92], ["AntifoulingCopper and heavy metal (such as mercury and tin) based products", "TREATMENT", 130, 204], ["biofilm", "OBSERVATION", 52, 59], ["growth", "OBSERVATION_MODIFIER", 74, 80], ["heavy metal", "OBSERVATION_MODIFIER", 152, 163]]], ["To be effective, however, they need to leach out toxic compounds, and thus environmental concerns rise regarding the use of such coatings (Dafforn et al., 2011) .AntifoulingA final option is to release a small part of the coating on the surface periodically or gradually.", [["surface", "ANATOMY", 237, 244], ["surface", "CELLULAR_COMPONENT", 237, 244], ["toxic compounds", "PROBLEM", 49, 64], ["effective", "OBSERVATION", 6, 15], ["small", "OBSERVATION_MODIFIER", 204, 209], ["coating", "OBSERVATION", 222, 229]]], ["Any biofilm developed will be removed and a new clean surface is obtained.UltravioletFabrics exposed to UV irradiation fade in colour, strength and durability.", [["biofilm", "ANATOMY", 4, 11], ["surface", "ANATOMY", 54, 61], ["UltravioletFabrics", "CHEMICAL", 74, 92], ["Any biofilm", "PROBLEM", 0, 11], ["a new clean surface", "TREATMENT", 42, 61], ["UltravioletFabrics", "TREATMENT", 74, 92], ["UV irradiation", "TREATMENT", 104, 118], ["biofilm", "OBSERVATION", 4, 11], ["new", "OBSERVATION_MODIFIER", 44, 47], ["clean", "OBSERVATION", 48, 53], ["UV irradiation", "OBSERVATION", 104, 118]]], ["This so-called ageing is caused by short-wavelength light that interacts with electron-rich molecules.", [["electron", "SIMPLE_CHEMICAL", 78, 86], ["electron-rich molecules", "PROTEIN", 78, 101]]], ["UV rays are predominantly found in sunlight but artificial lights such as discharge lamps (tube lights, halogen bulbs) also emit UV.", [["halogen", "CHEMICAL", 104, 111], ["UV rays", "TREATMENT", 0, 7], ["artificial lights", "TREATMENT", 48, 65], ["discharge lamps", "TREATMENT", 74, 89], ["tube lights, halogen bulbs", "TREATMENT", 91, 117], ["predominantly", "OBSERVATION_MODIFIER", 12, 25]]], ["The problem of UV ageing is mostly recognised for outdoor textiles, leisurewear and car interiors but also indoor textiles close to windows such as upholstery, curtains and sun blinds.", [["UV ageing", "TREATMENT", 15, 24]]], ["UV-protective additives in finishing, dyeing, coating and extrusion focus on blocking the highly reactive UV rays from reaching sensitive pigments, binders or fibres.", [["fibres", "ANATOMY", 159, 165], ["fibres", "CELLULAR_COMPONENT", 159, 165], ["UV-protective additives", "TREATMENT", 0, 23], ["dyeing", "TREATMENT", 38, 44], ["extrusion focus", "PROBLEM", 58, 73], ["blocking the highly reactive UV rays", "PROBLEM", 77, 113], ["protective additives", "OBSERVATION_MODIFIER", 3, 23], ["extrusion", "OBSERVATION_MODIFIER", 58, 67], ["focus", "OBSERVATION_MODIFIER", 68, 73], ["reactive", "OBSERVATION_MODIFIER", 97, 105], ["UV rays", "OBSERVATION", 106, 113]]], ["Some products have a high affinity for the UV waves and are preferably attacked by UV, transforming it into harmless heat (UV absorbers).", [["UV absorbers", "TREATMENT", 123, 135], ["high affinity", "OBSERVATION_MODIFIER", 21, 34]]], ["Others block the propagation of free radicals initiated by UV irradiation (radical scavengers).", [["UV", "CHEMICAL", 59, 61], ["free radicals", "TREATMENT", 32, 45], ["UV irradiation (radical scavengers", "TREATMENT", 59, 93], ["free radicals", "OBSERVATION", 32, 45]]], ["A third mode of action is to decompose peroxides formed by UV irradiation in combination with oxygen.", [["UV", "CHEMICAL", 59, 61], ["oxygen", "CHEMICAL", 94, 100], ["peroxides", "CHEMICAL", 39, 48], ["oxygen", "CHEMICAL", 94, 100], ["peroxides", "SIMPLE_CHEMICAL", 39, 48], ["oxygen", "SIMPLE_CHEMICAL", 94, 100], ["peroxides", "TREATMENT", 39, 48], ["UV irradiation", "TREATMENT", 59, 73], ["oxygen", "TREATMENT", 94, 100], ["UV irradiation", "OBSERVATION", 59, 73]]], ["These products act as antioxidants but can also improve UV durability (peroxide decomposer).", [["peroxide", "CHEMICAL", 71, 79], ["peroxide", "CHEMICAL", 71, 79], ["peroxide", "SIMPLE_CHEMICAL", 71, 79], ["antioxidants", "TREATMENT", 22, 34], ["UV durability (peroxide decomposer", "TREATMENT", 56, 90]]], ["A final mode of action is to quench excited states and divert the energy into lower-wavelength light (fluorescence or phosphorescence) or heat (quenchers) (Patra and Gouda, 2013; Kasza, 2013; Lacasse and Baumann, 2004) .", [["heat (quenchers", "TREATMENT", 138, 153], ["Baumann", "TREATMENT", 204, 211]]], ["The different modes of action of UV-stabilising additives are presented in Fig. 4 .4 whereas Table 4 .2 summarises typical light-stabilising compounds.UltravioletAlthough these UV stabilisers are used in numerous applications, their small molecular nature allows for easy migration throughout the polymer.", [["UV", "CHEMICAL", 33, 35], ["UV-stabilising additives", "TREATMENT", 33, 57], ["UltravioletAlthough these UV stabilisers", "TREATMENT", 151, 191], ["easy migration throughout the polymer", "TREATMENT", 267, 304], ["UV stabilisers", "OBSERVATION", 177, 191], ["small", "OBSERVATION_MODIFIER", 233, 238]]], ["Small molecule stabilisers may leach out into the environment and no longer protect the material (Scott, 1999) .", [["Small molecule stabilisers", "PROBLEM", 0, 26], ["molecule stabilisers", "OBSERVATION", 6, 26], ["no longer", "UNCERTAINTY", 66, 75]]], ["The current trend is to develop macromolecular UV, heat or hydrolysis stabilisers (Raching GmbH, Chemtura, Ciba and Vanderbilt).", [["macromolecular UV", "PROBLEM", 32, 49], ["hydrolysis stabilisers", "TREATMENT", 59, 81], ["macromolecular UV", "OBSERVATION", 32, 49]]], ["However, macromolecular UV stabilisers require more synthesis, which results in more expensive additives (Kasza, 2013) .InfraredThe heat stability of coated textiles differs depending on the coating composition.", [["macromolecular UV stabilisers", "TREATMENT", 9, 38], ["The heat stability of coated textiles", "TREATMENT", 128, 165], ["UV stabilisers", "OBSERVATION", 24, 38], ["heat", "OBSERVATION_MODIFIER", 132, 136], ["stability", "OBSERVATION_MODIFIER", 137, 146], ["coated textiles", "OBSERVATION", 150, 165]]], ["Exposure of a coated textile to sunlight can have a deteriorating effect.", [["a coated textile", "TREATMENT", 12, 28], ["deteriorating", "OBSERVATION_MODIFIER", 52, 65], ["effect", "OBSERVATION_MODIFIER", 66, 72]]], ["Sunlight consists of visible light, accompanied by about 53% IR light.", [["visible light", "OBSERVATION_MODIFIER", 21, 34]]], ["IR radiation with wavelengths in the range of 780 nm up to 1 mm ( Fig. 4.3) is responsible for heating phenomena.", [["IR radiation", "TREATMENT", 0, 12], ["Fig.", "TEST", 66, 70], ["heating phenomena", "PROBLEM", 95, 112], ["responsible for", "UNCERTAINTY", 79, 94], ["heating phenomena", "OBSERVATION", 95, 112]]], ["Thus, coated textiles exposed to sunlight will heat up when absorbing these wavelengths.", [["coated textiles", "TREATMENT", 6, 21]]], ["It is claimed that a lower-temperature increase in the coating will result in enhanced durability because of less polymer degradation and thermal expansion Pasternack, 2013) .", [["a lower-temperature increase", "PROBLEM", 19, 47], ["less polymer degradation", "PROBLEM", 109, 133], ["lower", "OBSERVATION_MODIFIER", 21, 26]]], ["Only limited research has been performed on the effect of reflective pigments, the related temperature rise of the coating and the durability of the coatings (Salminen, 2014) .", [["reflective pigments", "TREATMENT", 58, 77], ["the coating", "TREATMENT", 111, 122], ["temperature", "OBSERVATION_MODIFIER", 91, 102], ["rise", "OBSERVATION_MODIFIER", 103, 107]]], ["The reflection of this IR radiation on a coated textile can be augmented by the incorporation of IR-reflective pigments.", [["this IR radiation", "TREATMENT", 18, 35], ["a coated textile", "TREATMENT", 39, 55]]], ["This results in a lower absorption and transmission of IR, and therefore less heating.", [["a lower absorption", "PROBLEM", 16, 34], ["lower absorption", "OBSERVATION_MODIFIER", 18, 34]]], ["These coatings are denominated as low-E coatings (low emissivity).InfraredThese low-E coatings are predominantly used in architectural textiles for their thermal properties (Cremers, 2010) .", [["These low-E coatings", "TREATMENT", 74, 94], ["coatings", "OBSERVATION_MODIFIER", 6, 14], ["low-E coatings", "OBSERVATION_MODIFIER", 34, 48], ["low emissivity", "OBSERVATION_MODIFIER", 50, 64], ["low", "OBSERVATION_MODIFIER", 80, 83], ["-E coatings", "OBSERVATION_MODIFIER", 83, 94], ["predominantly", "OBSERVATION_MODIFIER", 99, 112], ["architectural textiles", "OBSERVATION", 121, 143]]], ["For example, the inside temperature of a building will be lowered when such a coating is implemented on the fa\u00e7ade of the building.", [["a coating", "TREATMENT", 76, 85]]], ["This results in lower energy consumption because of reduced air conditioning.", [["reduced air conditioning", "PROBLEM", 52, 76], ["lower", "OBSERVATION_MODIFIER", 16, 21], ["energy consumption", "OBSERVATION", 22, 40], ["reduced", "OBSERVATION_MODIFIER", 52, 59], ["air conditioning", "OBSERVATION", 60, 76]]], ["Examples of IR-reflective coatings can also be found in the ceiling of ice tracks and on roofs and window blinds.InfraredSeveral types of IR-reflecting additives have been designed based on:Infrared\u2022 Pure metals (such as Al, Ag and Cu) with a specific size \u2022 Metals with surface coatings (AlO [OH] or SiO 2 on Al and AgS on Ag)Infrared\u2022 Metal oxides such as titanium dioxide and zinc oxide \u2022 Multiple-layered structures: TiO 2 /Au/TiO 2 , silicon powder and metal-coated cenosphere particles \u2022 Minerals such as mica 4.3 Properties of textiles with durability-enhancing coatingsScratch resistanceResearch in the field of self-healing coatings focusses on corrosion protective coatings and concrete; not much research has been performed on coated textiles.", [["surface", "ANATOMY", 271, 278], ["Al", "CHEMICAL", 221, 223], ["Ag", "CHEMICAL", 225, 227], ["Cu", "CHEMICAL", 232, 234], ["AlO [OH", "CHEMICAL", 289, 296], ["SiO 2 on Al", "CHEMICAL", 301, 312], ["Metal oxides", "CHEMICAL", 337, 349], ["titanium dioxide", "CHEMICAL", 358, 374], ["zinc oxide", "CHEMICAL", 379, 389], ["TiO 2 /Au", "CHEMICAL", 421, 430], ["TiO 2", "CHEMICAL", 431, 436], ["silicon", "CHEMICAL", 439, 446], ["Al", "CHEMICAL", 221, 223], ["Ag", "CHEMICAL", 225, 227], ["Cu", "CHEMICAL", 232, 234], ["AlO [OH]", "CHEMICAL", 289, 297], ["SiO 2", "CHEMICAL", 301, 306], ["Al", "CHEMICAL", 310, 312], ["AgS", "CHEMICAL", 317, 320], ["Ag", "CHEMICAL", 324, 326], ["Metal oxides", "CHEMICAL", 337, 349], ["titanium dioxide", "CHEMICAL", 358, 374], ["zinc oxide", "CHEMICAL", 379, 389], ["TiO 2", "CHEMICAL", 421, 426], ["Au", "CHEMICAL", 428, 430], ["TiO 2", "CHEMICAL", 431, 436], ["silicon", "CHEMICAL", 439, 446], ["Al", "SIMPLE_CHEMICAL", 221, 223], ["Ag", "SIMPLE_CHEMICAL", 225, 227], ["Cu", "SIMPLE_CHEMICAL", 232, 234], ["AlO [OH]", "SIMPLE_CHEMICAL", 289, 297], ["SiO 2", "SIMPLE_CHEMICAL", 301, 306], ["Al", "SIMPLE_CHEMICAL", 310, 312], ["AgS", "SIMPLE_CHEMICAL", 317, 320], ["Metal oxides", "SIMPLE_CHEMICAL", 337, 349], ["titanium dioxide", "SIMPLE_CHEMICAL", 358, 374], ["zinc oxide", "SIMPLE_CHEMICAL", 379, 389], ["TiO 2 /Au/TiO 2", "SIMPLE_CHEMICAL", 421, 436], ["silicon powder", "SIMPLE_CHEMICAL", 439, 453], ["metal-coated cenosphere particles", "SIMPLE_CHEMICAL", 458, 491], ["Al, Ag and Cu)", "TREATMENT", 221, 235], ["a specific size \u2022 Metals with surface coatings (AlO [OH] or SiO", "TREATMENT", 241, 304], ["Metal oxides", "TREATMENT", 337, 349], ["titanium dioxide", "TREATMENT", 358, 374], ["zinc oxide", "TREATMENT", 379, 389], ["Multiple-layered structures", "TREATMENT", 392, 419], ["TiO 2 /Au/TiO", "TREATMENT", 421, 434], ["silicon powder and metal-coated cenosphere particles \u2022 Minerals", "TREATMENT", 439, 502], ["durability-enhancing coatings", "TREATMENT", 548, 577], ["Scratch resistance", "PROBLEM", 577, 595], ["healing coatings", "TREATMENT", 625, 641], ["corrosion protective coatings", "TREATMENT", 654, 683], ["metals", "OBSERVATION", 205, 211], ["enhancing coatings", "OBSERVATION", 559, 577], ["resistance", "OBSERVATION", 585, 595]]], ["The first self-healing experiments with polyurethane-coated fabric, in which the embedded microcapsules were filled with a PU binder, show great potential but still need to be optimised.", [["polyurethane", "CHEMICAL", 40, 52], ["polyurethane", "CHEMICAL", 40, 52], ["polyurethane-coated fabric", "TREATMENT", 40, 66], ["the embedded microcapsules", "TREATMENT", 77, 103], ["a PU binder", "TREATMENT", 121, 132], ["healing", "OBSERVATION_MODIFIER", 15, 22], ["coated fabric", "OBSERVATION_MODIFIER", 53, 66], ["PU binder", "OBSERVATION_MODIFIER", 123, 132], ["great potential", "OBSERVATION_MODIFIER", 139, 154]]], ["The research was executed in the framework of the FP7 Safe@ Sea project, in which improved garments for fishermen were developed (Anon, 2016a) .Scratch resistanceIn experiments in which heat-triggered, self-healing polymers were evaluated on textiles, the typical open textile structure proved worrisome because the elevated temperature (up to 140 C) enhanced the flow of the polymer needed to close the crack.", [["Scratch resistanceIn experiments", "PROBLEM", 144, 176], ["self-healing polymers", "PROBLEM", 202, 223], ["the typical open textile structure", "PROBLEM", 252, 286], ["the elevated temperature", "PROBLEM", 312, 336], ["textile structure", "OBSERVATION", 269, 286], ["elevated", "OBSERVATION_MODIFIER", 316, 324], ["temperature", "OBSERVATION_MODIFIER", 325, 336], ["crack", "OBSERVATION_MODIFIER", 404, 409]]], ["Owing to this enhanced flowing behaviour, the coating starts to penetrate into the textile substrate, which is not advantageous for the flexibility of the coated textile (De Vilder and Vanneste, 2013) .", [["the coating", "TREATMENT", 42, 53]]], ["Also, introducing these elevated temperatures to the coated textiles during the lifetime of the protective garment, technical textile, and so on is not self-evident because this can alter properties such as dimensional stability.Scratch resistanceAt Centexbel, a self-healing coating was developed which acts at room temperature.", [["Centexbel", "CHEMICAL", 250, 259], ["these elevated temperatures", "PROBLEM", 18, 45], ["the protective garment", "TREATMENT", 92, 114], ["a self-healing coating", "PROBLEM", 261, 283], ["elevated", "OBSERVATION_MODIFIER", 24, 32], ["temperatures", "OBSERVATION_MODIFIER", 33, 45], ["healing", "OBSERVATION_MODIFIER", 268, 275], ["coating", "OBSERVATION", 276, 283]]], ["An acrylate textile coating was selected which shows the desired flowing behaviour.", [["acrylate", "CHEMICAL", 3, 11], ["acrylate", "CHEMICAL", 3, 11], ["acrylate", "SIMPLE_CHEMICAL", 3, 11], ["An acrylate textile coating", "TREATMENT", 0, 27], ["acrylate", "OBSERVATION", 3, 11], ["textile coating", "OBSERVATION", 12, 27], ["desired", "OBSERVATION_MODIFIER", 57, 64], ["flowing", "OBSERVATION_MODIFIER", 65, 72], ["behaviour", "OBSERVATION_MODIFIER", 73, 82]]], ["A supramolecular additive with a self-healing property based on hydrogen bond formation was added to the coating.", [["hydrogen", "CHEMICAL", 64, 72], ["hydrogen bond", "SIMPLE_CHEMICAL", 64, 77], ["A supramolecular additive", "TREATMENT", 0, 25], ["a self-healing property", "TREATMENT", 31, 54], ["hydrogen bond formation", "TREATMENT", 64, 87], ["the coating", "TREATMENT", 101, 112], ["hydrogen bond", "OBSERVATION", 64, 77]]], ["This additive improves the mechanical strength of the filled crack.", [["mechanical strength", "OBSERVATION", 27, 46], ["filled crack", "OBSERVATION", 54, 66]]], ["The coating was applied on a polyester substrate via knife-over-roll (200 mm).", [["polyester", "CHEMICAL", 29, 38], ["The coating", "TREATMENT", 0, 11], ["a polyester substrate via knife", "TREATMENT", 27, 58], ["coating", "OBSERVATION_MODIFIER", 4, 11]]], ["The coating was abraded with F2 sandpaper (Martindale, EN 510, five cycles).", [["coating", "OBSERVATION_MODIFIER", 4, 11]]], ["At the stage of microcracks, full recovery was observed (Fig. 4 .5).", [["microcracks", "OBSERVATION_MODIFIER", 16, 27]]], ["When too much coating material is removed, the system is unable to refill the crack completely.Scratch resistanceTo evaluate the effect of different formulations, a homogeneous and uniform scratch was made with a modified motorised pencil hardness tester (De Vilder and Vanneste, 2013; Fig. 4.6) .", [["Scratch resistanceTo", "TEST", 95, 115], ["different formulations", "TREATMENT", 139, 161], ["a homogeneous and uniform scratch", "PROBLEM", 163, 196], ["crack", "OBSERVATION_MODIFIER", 78, 83], ["homogeneous", "OBSERVATION_MODIFIER", 165, 176], ["uniform", "OBSERVATION_MODIFIER", 181, 188], ["scratch", "OBSERVATION", 189, 196]]], ["This allowed the efficacy of the self-healing properties to be compared for different formulations.Scratch resistanceSelf-healing coatings can be implemented when the textile is prone to wear and tear, cuts, abrasion and so forth.", [["abrasion", "DISEASE", 208, 216], ["the self-healing properties", "TREATMENT", 29, 56], ["different formulations", "TREATMENT", 76, 98], ["healing coatings", "TREATMENT", 122, 138], ["the textile", "TREATMENT", 163, 174], ["tear", "PROBLEM", 196, 200], ["abrasion", "PROBLEM", 208, 216], ["healing", "OBSERVATION_MODIFIER", 122, 129], ["coatings", "OBSERVATION_MODIFIER", 130, 138], ["tear", "OBSERVATION", 196, 200], ["abrasion", "OBSERVATION", 208, 216]]], ["From an aesthetic point of view an intact coating is desirable, but the coating should also maintain functionality as long as possible.", [["an intact coating", "TREATMENT", 32, 49], ["the coating", "TREATMENT", 68, 79], ["intact", "OBSERVATION", 35, 41], ["coating", "OBSERVATION_MODIFIER", 42, 49]]], ["Prolonged barrier properties such as waterproofness, electrical (Blaiszik et al., 2012) and thermal conductivity and recovered hydrophobicity and/or oleophobicity (Wang et al., 2013; Diki c et al., 2012) can be achieved.Antibacterial and antifungal propertiesNumerous fabrics are claimed to have antimicrobial efficacy.", [["barrier", "ANATOMY", 10, 17], ["Prolonged barrier properties", "TREATMENT", 0, 28], ["thermal conductivity", "PROBLEM", 92, 112], ["recovered hydrophobicity", "PROBLEM", 117, 141], ["oleophobicity", "PROBLEM", 149, 162], ["Antibacterial", "TREATMENT", 220, 233], ["antifungal properties", "TREATMENT", 238, 259], ["antimicrobial efficacy", "TREATMENT", 296, 318], ["barrier properties", "OBSERVATION_MODIFIER", 10, 28], ["hydrophobicity", "OBSERVATION_MODIFIER", 127, 141], ["antifungal", "OBSERVATION_MODIFIER", 238, 248]]], ["Sorbtek/Amy Silver-based antimicrobial Characteristics: Total moisture control combined with silver-based antimicrobial.", [["Silver", "CHEMICAL", 12, 18], ["silver", "CHEMICAL", 93, 99], ["Silver", "CHEMICAL", 12, 18], ["silver", "CHEMICAL", 93, 99], ["Sorbtek", "SIMPLE_CHEMICAL", 0, 7], ["Amy Silver", "SIMPLE_CHEMICAL", 8, 18], ["silver", "SIMPLE_CHEMICAL", 93, 99], ["Sorbtek", "TREATMENT", 0, 7], ["Total moisture control", "TREATMENT", 56, 78], ["silver-based antimicrobial", "TREATMENT", 93, 119]]], ["Available in comfort and performance stretch.Thermolite freshFX Polyester insulation with antimicrobial additive spun into fibresCharacteristics: Polyester insulation with sliver-based antimicrobial additive spun into fibres to protect against odours.", [["fibres", "ANATOMY", 218, 224], ["Polyester", "CHEMICAL", 64, 73], ["Polyester", "SIMPLE_CHEMICAL", 146, 155], ["Thermolite freshFX Polyester insulation", "TREATMENT", 45, 84], ["antimicrobial additive", "TREATMENT", 90, 112], ["Polyester insulation", "TREATMENT", 146, 166], ["sliver-based antimicrobial additive spun", "TREATMENT", 172, 212], ["Polyester insulation", "OBSERVATION", 64, 84], ["Polyester insulation", "OBSERVATION", 146, 166]]], ["Provides lightweight warmth with added freshness that lasts for life of product.VisaEndurance brand of fabricsCharacteristics: Performance active-wear fabrics that fights odours, wicks moisture away from skin, dries quickly and releases stains in wash.", [["skin", "ANATOMY", 204, 208], ["skin", "ORGAN", 204, 208], ["skin", "ANATOMY", 204, 208]]], ["Knit, breathable, soft hand, wicks perspiration away from body, dries quickly, fights odours, releases stains.VisaEndurance brand of fabricsiSyS AG Dispersed silver chloride solution Ionic form of silver has triple effect on bacteria: destruction of cell membrane, deactivation of cell metabolism, destruction of cell division.", [["soft hand", "ANATOMY", 18, 27], ["body", "ANATOMY", 58, 62], ["cell membrane", "ANATOMY", 250, 263], ["cell", "ANATOMY", 281, 285], ["cell", "ANATOMY", 313, 317], ["fabricsiSyS AG", "CHEMICAL", 133, 147], ["silver chloride", "CHEMICAL", 158, 173], ["silver", "CHEMICAL", 197, 203], ["silver chloride", "CHEMICAL", 158, 173], ["silver", "CHEMICAL", 197, 203], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["fabricsiSyS AG", "SIMPLE_CHEMICAL", 133, 147], ["silver chloride", "SIMPLE_CHEMICAL", 158, 173], ["silver", "SIMPLE_CHEMICAL", 197, 203], ["cell membrane", "CELLULAR_COMPONENT", 250, 263], ["cell", "CELL", 281, 285], ["cell", "CELL", 313, 317], ["VisaEndurance brand of fabricsiSyS AG Dispersed silver chloride solution Ionic", "TREATMENT", 110, 188], ["bacteria", "PROBLEM", 225, 233], ["destruction of cell membrane", "PROBLEM", 235, 263], ["cell metabolism", "PROBLEM", 281, 296], ["destruction of cell division", "PROBLEM", 298, 326], ["soft hand", "ANATOMY", 18, 27], ["body", "ANATOMY", 58, 62], ["triple effect", "OBSERVATION_MODIFIER", 208, 221], ["destruction", "OBSERVATION", 235, 246], ["cell membrane", "OBSERVATION", 250, 263], ["cell metabolism", "OBSERVATION", 281, 296], ["cell division", "OBSERVATION", 313, 326]]], ["The product is based on nanotechnological sol-gel process: iSyS AG is combined with reactive organiceinorganic binder (iSyS MTX).Sanitised T27-22Suspension of silver chloride in water Product has excellent wash and light fastness.", [["iSyS AG", "CHEMICAL", 59, 66], ["MTX", "CHEMICAL", 124, 127], ["T27-22Suspension of silver chloride", "CHEMICAL", 139, 174], ["MTX", "CHEMICAL", 124, 127], ["silver chloride", "CHEMICAL", 159, 174], ["iSyS AG", "SIMPLE_CHEMICAL", 59, 66], ["reactive organiceinorganic binder", "SIMPLE_CHEMICAL", 84, 117], ["iSyS", "SIMPLE_CHEMICAL", 119, 123], ["MTX", "SIMPLE_CHEMICAL", 124, 127], ["silver chloride", "SIMPLE_CHEMICAL", 159, 174], ["nanotechnological sol-gel process", "TREATMENT", 24, 57], ["iSyS AG", "PROBLEM", 59, 66], ["reactive organiceinorganic binder (iSyS MTX", "TREATMENT", 84, 127], ["Sanitised T27", "TREATMENT", 129, 142], ["silver chloride in water Product", "TREATMENT", 159, 191], ["light fastness", "PROBLEM", 215, 229], ["excellent", "OBSERVATION_MODIFIER", 196, 205], ["wash", "OBSERVATION", 206, 210]]], ["Product blocks respiration and food intake of bacteria and acts on cell membrane which inhibits cell functions.Sanitised T27-22Sanitised TH22-27 Dispersion of zinc pyrithione To obtain wash-fastness the compound needs to be linked with a binder or put into wash-resistant coating.", [["cell membrane", "ANATOMY", 67, 80], ["cell", "ANATOMY", 96, 100], ["T27-22Sanitised TH22-27", "CHEMICAL", 121, 144], ["zinc", "CHEMICAL", 159, 163], ["T27-22Sanitised TH22-27", "CHEMICAL", 121, 144], ["zinc pyrithione", "CHEMICAL", 159, 174], ["cell membrane", "CELLULAR_COMPONENT", 67, 80], ["cell", "CELL", 96, 100], ["zinc pyrithione", "SIMPLE_CHEMICAL", 159, 174], ["Product blocks respiration", "PROBLEM", 0, 26], ["bacteria", "PROBLEM", 46, 54], ["cell membrane", "TREATMENT", 67, 80], ["zinc pyrithione", "TREATMENT", 159, 174], ["a binder", "TREATMENT", 236, 244], ["blocks", "OBSERVATION_MODIFIER", 8, 14], ["respiration", "OBSERVATION_MODIFIER", 15, 26], ["cell functions", "OBSERVATION", 96, 110]]], ["Product acts on cell membrane of microorganism.Sanitised T27-22Ultra-Fresh Silpure FBR-5 Ultra-Fresh Silpure FBR-5 Activator (Part A) is an aqueous dispersion of a silver compound.", [["cell membrane", "ANATOMY", 16, 29], ["T27-22Ultra", "CHEMICAL", 57, 68], ["silver compound", "CHEMICAL", 164, 179], ["silver", "CHEMICAL", 164, 170], ["cell membrane", "CELLULAR_COMPONENT", 16, 29], ["Part A", "SIMPLE_CHEMICAL", 126, 132], ["silver compound", "SIMPLE_CHEMICAL", 164, 179], ["microorganism", "PROBLEM", 33, 46], ["Sanitised", "TEST", 47, 56], ["Fresh Silpure FBR", "TREATMENT", 69, 86], ["Ultra-Fresh Silpure FBR", "TREATMENT", 89, 112], ["a silver compound", "TREATMENT", 162, 179], ["cell membrane", "OBSERVATION", 16, 29], ["microorganism", "OBSERVATION", 33, 46]]], ["Ultra-Fresh Silpure FBR-5 (Part B) is specifically formulated to combine with Part A.Sanitised T27-22Combined product is engineered for controlled release of silver ions providing control of bacterial growth.Ultra-Fresh DW-56One of the active compounds in Ultra-Fresh DW-56 is bis(1-hydroxy-2(1H)pyridinethionato-O,S)-(T-4) zinc.Ultra-Fresh DW-56Aqueous suspension designed to control growth of fungi, bacteria and algae in polyurethane foams, aqueous coatings and textiles.", [["FBR-5", "CHEMICAL", 20, 25], ["T27-22Combined", "CHEMICAL", 95, 109], ["silver ions", "CHEMICAL", 158, 169], ["DW-56One", "CHEMICAL", 220, 228], ["DW-56", "CHEMICAL", 268, 273], ["bis", "CHEMICAL", 277, 280], ["1-hydroxy-2(1H)pyridinethionato-O", "CHEMICAL", 281, 314], ["DW-56Aqueous", "CHEMICAL", 341, 353], ["silver", "CHEMICAL", 158, 164], ["bis(1-hydroxy-2(1H)pyridinethionato-O,S)-(T-4) zinc.", "CHEMICAL", 277, 329], ["polyurethane", "CHEMICAL", 424, 436], ["Part B", "SIMPLE_CHEMICAL", 27, 33], ["silver ions", "SIMPLE_CHEMICAL", 158, 169], ["DW-56", "SIMPLE_CHEMICAL", 268, 273], ["bis(1-hydroxy-2(1H)pyridinethionato-O,S)-(T-4) zinc.", "SIMPLE_CHEMICAL", 277, 329], ["algae", "SIMPLE_CHEMICAL", 415, 420], ["Ultra", "TEST", 0, 5], ["Fresh Silpure FBR", "TREATMENT", 6, 23], ["controlled release of silver ions", "TREATMENT", 136, 169], ["bacterial growth", "PROBLEM", 191, 207], ["Ultra-", "TEST", 208, 214], ["bis", "TEST", 277, 280], ["hydroxy", "TEST", 283, 290], ["pyridinethionato", "TEST", 296, 312], ["Ultra", "TEST", 329, 334], ["Fresh DW-56Aqueous suspension", "TREATMENT", 335, 364], ["fungi", "PROBLEM", 395, 400], ["bacteria", "PROBLEM", 402, 410], ["algae in polyurethane foams", "TREATMENT", 415, 442], ["aqueous coatings", "TREATMENT", 444, 460], ["bacterial growth", "OBSERVATION", 191, 207], ["polyurethane foams", "OBSERVATION", 424, 442], ["aqueous coatings", "OBSERVATION", 444, 460]]], ["Effective in preventing infestation of house dust mites in treated articles.Ultra-Fresh DW-56Smart durable and self-healing textile coatings Clearly, antimicrobial effectiveness is directed not only by the product applied but also by the concentration used.", [["DW-56Smart", "CHEMICAL", 88, 98], ["Ultra", "TEST", 76, 81], ["Fresh DW", "TEST", 82, 90], ["self-healing textile coatings", "TREATMENT", 111, 140], ["antimicrobial effectiveness", "TREATMENT", 150, 177], ["dust mites", "OBSERVATION", 45, 55]]], ["Table 4 .4 shows typical concentrations of antimicrobial textile additives and their limit values according to OEKO-TEX \u00ae 100 voluntary labeling (OEKO-TEX \u00ae , 2015).Ultra-Fresh DW-56Antimicrobial efficiency is expressed only as a binary annotation (growth or inhibition) or the area of inhibition for leaching substances in, for example, the agar diffusion test (eg, DIN EN ISO 20645 e 2001, AATCC 147) .", [["DW-56Antimicrobial", "CHEMICAL", 177, 195], ["antimicrobial textile additives", "TREATMENT", 43, 74], ["Ultra", "TEST", 165, 170], ["leaching substances", "PROBLEM", 301, 320], ["the agar diffusion test", "TEST", 338, 361], ["antimicrobial textile", "OBSERVATION", 43, 64]]], ["Quantitative test methods are also possible in which the bacterial reduction is expressed in log scale (eg, JIS L 1902, DIN EN 1276, AATCC100, ASTM E 2149-01, ASTME 2180-01).", [["Quantitative test methods", "TEST", 0, 25], ["the bacterial reduction", "PROBLEM", 53, 76], ["AATCC100", "TEST", 133, 141], ["ASTM E", "TEST", 143, 149], ["ASTME", "TEST", 159, 164], ["bacterial reduction", "OBSERVATION", 57, 76]]], ["In such tests reports, negative numbers denote bacterial growth instead of a reduction of the number of bacterial colony-forming units.", [["colony", "ANATOMY", 114, 120], ["bacterial colony-forming units", "PROTEIN", 104, 134], ["bacterial growth", "PROBLEM", 47, 63], ["bacterial colony", "PROBLEM", 104, 120], ["bacterial growth", "OBSERVATION", 47, 63], ["bacterial colony", "OBSERVATION", 104, 120]]], ["An overview of available test methods and their preferred use is nicely described in Pinho et al. (2011) and Llc (2010) .", [["available test methods", "TEST", 15, 37], ["Llc", "ANATOMY", 109, 112]]], ["Table 4 .5 summarises some antimicrobial effectiveness results against Staphylococcus aureus obtained from various antimicrobial textile treatments.Ultraviolet resistanceFrom the wealth of available UV stabilisers, it may be difficult to identify the most-suited one for a specific application.", [["Staphylococcus aureus", "DISEASE", 71, 92], ["Staphylococcus aureus", "ORGANISM", 71, 92], ["Staphylococcus aureus", "SPECIES", 71, 92], ["Staphylococcus aureus", "SPECIES", 71, 92], ["some antimicrobial effectiveness", "TREATMENT", 22, 54], ["Staphylococcus aureus", "PROBLEM", 71, 92], ["various antimicrobial textile treatments", "TREATMENT", 107, 147], ["Ultraviolet", "TREATMENT", 148, 159], ["UV stabilisers", "TREATMENT", 199, 213], ["a specific application", "TREATMENT", 271, 293], ["antimicrobial textile treatments", "OBSERVATION", 115, 147]]], ["The properties and action mode of a given UV stabiliser may already point towards its usefulness as a top coating (UV absorber), as a dispersed additive in a binder (quencher or peroxide decomposer), or even chemically linked to a dye if possible (sterically hindered amines).", [["peroxide", "CHEMICAL", 178, 186], ["amines", "CHEMICAL", 268, 274], ["peroxide", "CHEMICAL", 178, 186], ["amines", "CHEMICAL", 268, 274], ["peroxide", "SIMPLE_CHEMICAL", 178, 186], ["amines", "SIMPLE_CHEMICAL", 268, 274], ["a given UV stabiliser", "TREATMENT", 34, 55], ["a top coating (UV absorber", "TREATMENT", 100, 126], ["a binder (quencher or peroxide decomposer", "TREATMENT", 156, 197]]], ["The chart in Fig. 4 .7 illustrates the effect of various types of UV stabilisers in an acrylic textile coating combined with a red pigment.", [["red pigment", "ANATOMY", 127, 138], ["UV stabilisers", "TREATMENT", 66, 80], ["an acrylic textile coating", "TREATMENT", 84, 110], ["a red pigment", "TREATMENT", 125, 138], ["UV stabilisers", "OBSERVATION", 66, 80], ["acrylic textile coating", "OBSERVATION", 87, 110], ["red pigment", "OBSERVATION", 127, 138]]], ["This chart is not intended to discriminate between good or bad UV stabilisers; nonetheless, it shows what could happen if UV stabilisers were randomly dispersed and mixed in a typical textile coating formulation.Ultraviolet resistanceAs an example, care must be taken when mixing UV stabilisers.", [["UV stabilisers", "TREATMENT", 122, 136], ["a typical textile coating formulation", "TREATMENT", 174, 211], ["Ultraviolet resistanceAs", "TREATMENT", 212, 236], ["mixing UV stabilisers", "TREATMENT", 273, 294]]], ["Hindered amine light stabilisers combined with triazine actually accelerated UV ageing.", [["amine", "CHEMICAL", 9, 14], ["triazine", "CHEMICAL", 47, 55], ["amine", "CHEMICAL", 9, 14], ["triazine", "CHEMICAL", 47, 55], ["amine light stabilisers", "SIMPLE_CHEMICAL", 9, 32], ["triazine", "SIMPLE_CHEMICAL", 47, 55], ["Hindered amine light stabilisers", "TREATMENT", 0, 32], ["triazine", "TREATMENT", 47, 55]]], ["Clearly in this case, the UV absorber (triazine) should have been applied as a top coat.", [["triazine", "CHEMICAL", 39, 47], ["triazine", "CHEMICAL", 39, 47], ["triazine", "SIMPLE_CHEMICAL", 39, 47], ["the UV absorber (triazine)", "TREATMENT", 22, 48], ["a top coat", "TREATMENT", 77, 87]]], ["The same holds for metal oxides, alleged UV absorbers.", [["metal oxides", "CHEMICAL", 19, 31], ["metal oxides", "SIMPLE_CHEMICAL", 19, 31], ["metal oxides", "TREATMENT", 19, 31], ["alleged UV absorbers", "TREATMENT", 33, 53], ["UV absorbers", "OBSERVATION", 41, 53]]], ["However, the mixture of CeO and ZnO in this particular case shows a synergistic acceleration of ageing.", [["CeO", "CHEMICAL", 24, 27], ["ZnO", "CHEMICAL", 32, 35], ["CeO", "CHEMICAL", 24, 27], ["ZnO", "CHEMICAL", 32, 35], ["CeO", "SIMPLE_CHEMICAL", 24, 27], ["ZnO", "SIMPLE_CHEMICAL", 32, 35], ["CeO and ZnO", "TREATMENT", 24, 35]]], ["Although the mode of action of the various UV stabilisers is well known, it remains sensible to test them for your specific application and challenge them with a well-chosen test method.Infrared reflectionA textile can be finished or coated with IR-reflective additives added to a binder system.", [["the various UV stabilisers", "TREATMENT", 31, 57], ["Infrared reflectionA textile", "TREATMENT", 186, 214], ["IR-reflective additives", "TREATMENT", 246, 269], ["a binder system", "TREATMENT", 279, 294]]], ["Depending on the additive used, up to 70% of the incident IR radiation can be reflected.", [["the incident IR radiation", "TREATMENT", 45, 70]]], ["This percentage will be influenced by the binder type, colour, other additives present and the coating thickness.Infrared reflectionAt Centexbel, a two-layered PVC-coated polyester fabric was made with 15 wt% of mica pigments incorporated into the top layer.", [["PVC", "CHEMICAL", 160, 163], ["polyester", "CHEMICAL", 171, 180], ["a two-layered PVC-coated polyester fabric", "TREATMENT", 146, 187], ["mica pigments", "TREATMENT", 212, 225], ["binder type", "OBSERVATION_MODIFIER", 42, 53], ["top", "OBSERVATION_MODIFIER", 248, 251], ["layer", "OBSERVATION_MODIFIER", 252, 257]]], ["After gelling, the solar reflectance was recorded according to EN 410 ( Fig. 4.8) , which showed that 62% of the solar radiation was reflected.Infrared reflectionAttention should be paid to full coverage of the surface of the coating by the additives; this will block penetration of the IR light into the polymer more efficiently (Figs 4.9 and 4.10) .", [["surface", "ANATOMY", 211, 218], ["surface", "CELLULAR_COMPONENT", 211, 218], ["the solar reflectance", "TEST", 15, 36], ["the solar radiation", "TREATMENT", 109, 128], ["Infrared reflection", "TEST", 143, 162], ["the additives", "TREATMENT", 237, 250], ["the IR light into the polymer", "TREATMENT", 283, 312], ["Figs", "TEST", 331, 335]]], ["Lower concentrations of the pigments (less than 15 wt%) resulted in incomplete coverage of the surface and therefore a lower reflection rate.", [["surface", "ANATOMY", 95, 102], ["surface", "CELLULAR_COMPONENT", 95, 102], ["Lower concentrations of the pigments", "PROBLEM", 0, 36], ["a lower reflection rate", "TEST", 117, 140], ["concentrations", "OBSERVATION_MODIFIER", 6, 20], ["pigments", "OBSERVATION_MODIFIER", 28, 36], ["incomplete", "OBSERVATION_MODIFIER", 68, 78], ["coverage", "OBSERVATION_MODIFIER", 79, 87], ["surface", "OBSERVATION_MODIFIER", 95, 102], ["lower reflection", "OBSERVATION", 119, 135]]], ["Augmenting the pigment concentration even more is also not advised: Once the surface is covered, this technology shows its full potential.", [["surface", "ANATOMY", 77, 84], ["pigment", "TISSUE", 15, 22], ["surface", "CELLULAR_COMPONENT", 77, 84], ["pigment concentration", "OBSERVATION", 15, 36]]], ["Inserting the pigments in both the top and base layers does not improve the rate of reflection, which again shows that the predominant part of the reflection takes place at the surface.New generation of architectural fabricsDevelopments in the building industry have shown a clear evolution of traditional construction in buildings with sensible and adaptable envelopes equipped with sensors and able to interact with the surrounding environment on the basis of inputs such as temperature, humidity and solar radiation.", [["surface", "ANATOMY", 177, 184], ["surface", "CELLULAR_COMPONENT", 177, 184], ["traditional construction", "TREATMENT", 294, 318], ["solar radiation", "TREATMENT", 503, 518], ["pigments", "OBSERVATION_MODIFIER", 14, 22], ["both", "ANATOMY_MODIFIER", 26, 30], ["top", "OBSERVATION_MODIFIER", 35, 38], ["base", "ANATOMY_MODIFIER", 43, 47], ["layers", "ANATOMY_MODIFIER", 48, 54], ["improve", "OBSERVATION_MODIFIER", 64, 71], ["reflection", "OBSERVATION_MODIFIER", 84, 94], ["predominant", "OBSERVATION_MODIFIER", 123, 134], ["reflection", "OBSERVATION", 147, 157], ["surface", "OBSERVATION_MODIFIER", 177, 184], ["architectural fabrics", "OBSERVATION", 203, 224], ["clear", "OBSERVATION_MODIFIER", 275, 280], ["solar radiation", "OBSERVATION", 503, 518]]], ["For structures designed for extreme applications (eg, large-span structures prone to fluttering and ponding, industrial applications characterised by high working temperatures, biogas basins with corrosive gases), there is a need for continuous monitoring to highlight anomalies and avoid progressive propagation of the initial damage.", [["extreme applications (eg", "TREATMENT", 28, 52], ["large-span structures", "TREATMENT", 54, 75], ["fluttering", "PROBLEM", 85, 95], ["industrial applications", "TREATMENT", 109, 132], ["biogas basins", "TREATMENT", 177, 190], ["corrosive gases", "TEST", 196, 211], ["continuous monitoring", "TEST", 234, 255], ["highlight anomalies", "PROBLEM", 259, 278], ["the initial damage", "PROBLEM", 316, 334], ["large", "OBSERVATION_MODIFIER", 54, 59]]], ["The progressive miniaturisation of the sensor and the innovative manufacturing techniques for technical fabrics and foils resulted in new prospects for a new generation of sensible technical fabrics equipped with sensors focussing on temperature monitoring, pressure monitoring, and chemical sensing of noxious gasses.New generation of architectural fabricsTemperature monitoring of tensile structures is of particular interest for PVC-coated fabrics.", [["PVC", "CHEMICAL", 432, 435], ["technical fabrics", "TREATMENT", 94, 111], ["sensible technical fabrics", "TREATMENT", 172, 198], ["temperature monitoring", "TEST", 234, 256], ["pressure monitoring", "TEST", 258, 277], ["noxious gasses", "TEST", 303, 317], ["architectural fabrics", "PROBLEM", 336, 357], ["tensile structures", "PROBLEM", 383, 401], ["PVC-coated fabrics", "TREATMENT", 432, 450], ["progressive", "OBSERVATION_MODIFIER", 4, 15], ["architectural", "OBSERVATION_MODIFIER", 336, 349], ["fabricsTemperature", "OBSERVATION", 350, 368], ["tensile structures", "OBSERVATION", 383, 401]]], ["PVC-coated fabrics for tensile structures have a glass transition temperature roughly between 70 C and 90 C (Sen, 2007; Wypych, 2008) .", [["PVC", "CHEMICAL", 0, 3], ["PVC", "CHEMICAL", 0, 3], ["PVC", "TEST", 0, 3], ["tensile structures", "PROBLEM", 23, 41], ["a glass transition temperature", "PROBLEM", 47, 77]]], ["To signal a pending failure, temperature sensors can be mounted on the construction after erection.", [["a pending failure", "PROBLEM", 10, 27], ["temperature sensors", "TREATMENT", 29, 48]]], ["In addition, the wiring compromises the aesthetics of the often admired organic shapes that can be achieved in textile architecture.New generation of architectural fabricsTo overcome these issues, miniature temperature sensors are integrated into hybrid fabrics with integrated electric leads (Heyse et al., 2015) .", [["organic shapes", "PROBLEM", 72, 86], ["architectural fabrics", "PROBLEM", 150, 171], ["these issues", "PROBLEM", 183, 195], ["miniature temperature sensors", "PROBLEM", 197, 226], ["organic shapes", "OBSERVATION", 72, 86], ["textile architecture", "OBSERVATION", 111, 131], ["architectural fabrics", "OBSERVATION", 150, 171]]], ["Electronic sensors are well known for their accuracy and ease of data acquisition, but for fabrics, connecting the monitor to the sensor fabric remains an issue of intense research (Chapman, 2012) .", [["data acquisition", "TEST", 65, 81], ["fabrics", "TREATMENT", 91, 98]]], ["Alternative to electronics, thermochromic pigments also respond to variations in temperature.", [["thermochromic pigments", "TREATMENT", 28, 50], ["variations in temperature", "PROBLEM", 67, 92], ["thermochromic pigments", "OBSERVATION", 28, 50]]], ["Apart from liquid crystals, the temperature resolution of these materials is limited (Seeboth and L\u20ac otzsch, 2013) .", [["liquid crystals", "PROBLEM", 11, 26], ["the temperature resolution of these materials", "PROBLEM", 28, 73], ["liquid crystals", "OBSERVATION_MODIFIER", 11, 26]]], ["However, integrated in a coating, the spatial resolution is considerably higher than the point-wise electronic sensors.", [["a coating", "TREATMENT", 23, 32], ["spatial", "OBSERVATION_MODIFIER", 38, 45], ["resolution", "OBSERVATION_MODIFIER", 46, 56], ["considerably", "OBSERVATION_MODIFIER", 60, 72], ["higher", "OBSERVATION_MODIFIER", 73, 79]]], ["In addition, a quick visual inspection will indicate hot spots in real time.", [["a quick visual inspection", "TEST", 13, 38], ["hot spots", "PROBLEM", 53, 62]]], ["Although such thermochromic coatings may not be suitable for larger structures, they can be advantageous for quality control during welding of the seams where high enough temperatures have to be reached to ensure proper connection of the fabric parts ( Fig. 4.11) .New generation of architectural fabricsUnfortunately, tensile structures are not always used for the purposes for which they are designed.", [["such thermochromic coatings", "PROBLEM", 9, 36], ["larger structures", "PROBLEM", 61, 78], ["high enough temperatures", "PROBLEM", 159, 183], ["New generation of architectural fabrics", "PROBLEM", 265, 304], ["thermochromic coatings", "OBSERVATION", 14, 36], ["may not be", "UNCERTAINTY", 37, 47], ["architectural fabrics", "OBSERVATION", 283, 304]]], ["In case of a defect, the user points to the manufacturer although misuse is sometimes the real cause of failure (Huntington, 2004; Seidel and Sturge, 2009 ).", [["a defect", "PROBLEM", 11, 19], ["failure", "PROBLEM", 104, 111], ["defect", "OBSERVATION", 13, 19], ["failure", "OBSERVATION", 104, 111]]], ["Common failure is caused by corrosive gases emitted by, for example, cattle or biological waste.", [["cattle", "SPECIES", 69, 75], ["cattle", "SPECIES", 69, 75], ["Common failure", "PROBLEM", 0, 14], ["corrosive gases", "PROBLEM", 28, 43], ["failure", "OBSERVATION", 7, 14], ["corrosive", "OBSERVATION_MODIFIER", 28, 37]]], ["For two of such gases, an irreversible indicator patch has been developed.", [["such gases", "TEST", 11, 21], ["an irreversible indicator patch", "TREATMENT", 23, 54], ["irreversible", "OBSERVATION_MODIFIER", 26, 38], ["indicator patch", "OBSERVATION", 39, 54]]], ["Colour will change upon exposure to ammonia or hydrogen sulphide, indicating that the fabric properties can no longer be guaranteed (Fig. 4.12) .Protective clothingProtective clothing is a comprehensive field because it contains garments for firefighters, fishermen, welders, divers, sports enthusiasts, motorcyclists, surgeons and military personnel.", [["ammonia", "CHEMICAL", 36, 43], ["hydrogen sulphide", "CHEMICAL", 47, 64], ["ammonia", "CHEMICAL", 36, 43], ["hydrogen sulphide", "CHEMICAL", 47, 64], ["ammonia", "SIMPLE_CHEMICAL", 36, 43], ["hydrogen sulphide", "SIMPLE_CHEMICAL", 47, 64], ["ammonia", "TREATMENT", 36, 43], ["hydrogen sulphide", "TREATMENT", 47, 64], ["the fabric properties", "TREATMENT", 82, 103], ["Protective clothing", "TREATMENT", 145, 164], ["no longer", "UNCERTAINTY", 108, 117]]], ["Specific suits have been developed for environments with chemical and/or biological danger, extreme temperatures, and so on.", [["extreme temperatures", "PROBLEM", 92, 112]]], ["Each garment has specific properties adapted to the intended use, but a common demand is longevity.", [["longevity", "OBSERVATION", 89, 98]]], ["Besides an economical advantage, a more durable coating will result in prolonged protection, and in certain cases it can save lives.Protective clothingIn most cases protective clothing consists of multiple layers.", [["layers", "TISSUE", 206, 212], ["Protective clothing", "TREATMENT", 132, 151], ["multiple", "OBSERVATION_MODIFIER", 197, 205], ["layers", "OBSERVATION_MODIFIER", 206, 212]]], ["The outer layer of the laminate, often coated, is most prone to wear and tear.", [["outer layer", "ANATOMY", 4, 15], ["The outer layer of the laminate", "TREATMENT", 0, 31], ["tear", "PROBLEM", 73, 77], ["outer", "OBSERVATION_MODIFIER", 4, 9], ["layer", "OBSERVATION_MODIFIER", 10, 15], ["laminate", "OBSERVATION_MODIFIER", 23, 31], ["coated", "OBSERVATION_MODIFIER", 39, 45], ["tear", "OBSERVATION", 73, 77]]], ["The durability and therefore the lifetime of protective clothing can be prolonged by the use of wear-and tear-resistant coatings.", [["protective clothing", "TREATMENT", 45, 64], ["tear-resistant coatings", "TREATMENT", 105, 128], ["durability", "OBSERVATION_MODIFIER", 4, 14], ["resistant coatings", "OBSERVATION", 110, 128]]], ["Hence, the outer layer can be functionalised to improve abrasion/scratch/rub resistance and UV stability by incorporating specific additives.Protective clothingFrequently used high-performance fibres such as p-aramid (PA) and m-aramid have poor resistance to abrasion.", [["outer layer", "ANATOMY", 11, 22], ["abrasion", "DISEASE", 259, 267], ["p-aramid", "CHEMICAL", 208, 216], ["p-aramid", "SIMPLE_CHEMICAL", 208, 216], ["PA", "SIMPLE_CHEMICAL", 218, 220], ["m-aramid", "SIMPLE_CHEMICAL", 226, 234], ["the outer layer", "TREATMENT", 7, 22], ["abrasion", "PROBLEM", 56, 64], ["scratch", "PROBLEM", 65, 72], ["rub resistance", "PROBLEM", 73, 87], ["UV stability", "TREATMENT", 92, 104], ["Protective clothing", "TREATMENT", 141, 160], ["poor resistance to abrasion", "PROBLEM", 240, 267], ["abrasion", "OBSERVATION", 56, 64], ["scratch", "OBSERVATION", 65, 72], ["rub resistance", "OBSERVATION", 73, 87], ["UV stability", "OBSERVATION", 92, 104], ["poor resistance", "OBSERVATION", 240, 255], ["abrasion", "OBSERVATION", 259, 267]]], ["Thus they can be combined with fibres that have superior abrasion-resistant properties, protected by a PU coating (Mao, 2014) .", [["fibres", "ANATOMY", 31, 37], ["superior abrasion", "PROBLEM", 48, 65], ["resistant properties", "PROBLEM", 66, 86], ["a PU coating", "TREATMENT", 101, 113], ["superior", "OBSERVATION_MODIFIER", 48, 56], ["abrasion", "OBSERVATION", 57, 65], ["resistant properties", "OBSERVATION_MODIFIER", 66, 86], ["PU coating", "OBSERVATION_MODIFIER", 103, 113]]], ["The durability of such a protective coating can be improved with additives.Protective clothingThe following example of a functionalised PU coating in protective clothing demonstrates the possibilities.", [["a protective coating", "TREATMENT", 23, 43], ["Protective clothing", "TREATMENT", 75, 94], ["a functionalised PU coating", "TREATMENT", 119, 146], ["protective clothing", "TREATMENT", 150, 169], ["durability", "OBSERVATION_MODIFIER", 4, 14]]], ["Fishermen in the North Atlantic currently use heavyweight PVC-coated garments.", [["PVC", "CHEMICAL", 58, 61], ["heavyweight PVC", "TREATMENT", 46, 61]]], ["Within the FP7 project Safe@Sea (Anon, 2016a) a lightweight alternative was developed based on PU-coated PA (De Vilder et al., 2012) .", [["a lightweight alternative", "TREATMENT", 46, 71]]], ["In changing from a PVC-coated textile to a PU-coated one, an improvement in abrasion resistance was already noticeable.", [["abrasion", "DISEASE", 76, 84], ["PVC", "CHEMICAL", 19, 22], ["a PVC", "TREATMENT", 17, 22], ["a PU-coated one", "TREATMENT", 41, 56], ["abrasion resistance", "PROBLEM", 76, 95], ["improvement", "OBSERVATION_MODIFIER", 61, 72], ["abrasion resistance", "OBSERVATION", 76, 95]]], ["By incorporating specific additives into the PU coating, resistance to abrasion could be even further increased.", [["abrasion", "DISEASE", 71, 79], ["the PU coating", "TREATMENT", 41, 55], ["resistance to abrasion", "PROBLEM", 57, 79], ["PU coating", "OBSERVATION_MODIFIER", 45, 55], ["abrasion", "OBSERVATION", 71, 79], ["increased", "OBSERVATION_MODIFIER", 102, 111]]], ["Besides improved comfort owing to the lighter weight, prolonged durability of the garment was achieved (ie, less weight loss was observed) (Table 4 .6).Protective clothingIn many protective garments, the inner layer makes contact with the body of the person and is subjected to abrasion to a lesser extent.", [["inner layer", "ANATOMY", 204, 215], ["body", "ANATOMY", 239, 243], ["weight loss", "DISEASE", 113, 124], ["abrasion", "DISEASE", 278, 286], ["inner layer", "TISSUE", 204, 215], ["body", "ORGANISM_SUBDIVISION", 239, 243], ["person", "SPECIES", 251, 257], ["prolonged durability of the garment", "TREATMENT", 54, 89], ["less weight loss", "PROBLEM", 108, 124], ["Protective clothing", "TREATMENT", 152, 171], ["abrasion", "PROBLEM", 278, 286], ["improved", "OBSERVATION_MODIFIER", 8, 16], ["comfort", "OBSERVATION", 17, 24], ["garment", "OBSERVATION", 82, 89], ["many", "OBSERVATION_MODIFIER", 174, 178], ["protective garments", "OBSERVATION", 179, 198], ["inner", "OBSERVATION_MODIFIER", 204, 209], ["layer", "OBSERVATION_MODIFIER", 210, 215], ["contact", "OBSERVATION", 222, 229], ["abrasion", "OBSERVATION", 278, 286], ["lesser extent", "OBSERVATION_MODIFIER", 292, 305]]], ["This fabric can be finished with additives such as solegel (Brzezi nski et al., 2011) or silicones to diminish the impact of the abrading action.Securing cargoAlthough securing cargo may sound self-evident, correct loading and securing of cargo is not a trivial task (Rosi et al., 2012) .", [["silicones", "SIMPLE_CHEMICAL", 89, 98], ["This fabric", "TREATMENT", 0, 11], ["additives", "TREATMENT", 33, 42], ["silicones", "TREATMENT", 89, 98], ["the abrading action", "TREATMENT", 125, 144]]], ["Proper knowledge of the cargo mass, shape, content and expected accelerations, and appropriate use of securing tools and aids are prerequisites for the safe transportation of goods around the globe.", [["the cargo mass", "PROBLEM", 20, 34], ["expected accelerations", "PROBLEM", 55, 77], ["cargo mass", "OBSERVATION", 24, 34], ["shape", "OBSERVATION_MODIFIER", 36, 41], ["accelerations", "OBSERVATION_MODIFIER", 64, 77], ["globe", "ANATOMY", 192, 197]]], ["Unfortunately, it is estimated that up to 25% of all accidents in the EU in which trucks are involved result from to inadequate securing of cargo (Copsey, 2010) .", [["accidents", "DISEASE", 53, 62]]], ["One of the most recognised tools is the use of flat fabric webbing slings and lashes that have to comply with EN 12195 standards.", [["flat fabric webbing slings", "TREATMENT", 47, 73], ["slings", "OBSERVATION", 67, 73]]], ["Periodic inspection is voluntary and is based on subjective, visual inspections focusing on (ASME, 2014):Securing cargo\u2022 Acid or caustic burns \u2022 Melting or charring \u2022 Holes, tears, cuts or snags \u2022 Broken or worn stitching in load-bearing splices \u2022 Excessive abrasive wear \u2022 Knots in any part of the sling \u2022 Discolouration and brittle or stiff areas \u2022 Fittings that are pitted, corroded, cracked, bent, twisted, gouged or broken \u2022 Clear labels indicating lashing capacity It is obvious that these observations can discriminate between reliable and potentially unsafe lashings but there is no clear threshold value, and if one is set, it is imposed arbitrarily.", [["Acid", "CHEMICAL", 121, 125], ["burns", "DISEASE", 137, 142], ["Acid", "SIMPLE_CHEMICAL", 121, 125], ["Periodic inspection", "TEST", 0, 19], ["cargo\u2022 Acid", "TREATMENT", 114, 125], ["caustic burns", "TREATMENT", 129, 142], ["charring \u2022 Holes", "TREATMENT", 156, 172], ["tears", "PROBLEM", 174, 179], ["snags", "TREATMENT", 189, 194], ["Excessive abrasive wear", "PROBLEM", 248, 271], ["Discolouration", "PROBLEM", 307, 321], ["brittle or stiff areas", "PROBLEM", 326, 348], ["pitted", "PROBLEM", 369, 375], ["lashing capacity", "PROBLEM", 454, 470], ["abrasive wear", "OBSERVATION", 258, 271], ["sling", "OBSERVATION", 299, 304], ["Discolouration", "OBSERVATION", 307, 321], ["pitted", "OBSERVATION_MODIFIER", 369, 375], ["corroded", "OBSERVATION_MODIFIER", 377, 385], ["no", "UNCERTAINTY", 588, 590]]], ["In addition, a given lashing may appear to be in good conditionThe road ahead for smart lashingsIn the framework of a transnational collective research project between small and medium size enterprise associations and research organisations (Rescotex), research is focussing on identifying thresholds for UV ageing, abrasion, and repeated tensioning of flat fabric lashings for cargo securing.", [["abrasion", "DISEASE", 316, 324], ["UV ageing", "TREATMENT", 305, 314], ["abrasion", "PROBLEM", 316, 324], ["flat fabric lashings", "TREATMENT", 353, 373], ["cargo securing", "TREATMENT", 378, 392], ["small", "OBSERVATION_MODIFIER", 168, 173], ["medium size", "OBSERVATION_MODIFIER", 178, 189], ["abrasion", "OBSERVATION", 316, 324], ["flat fabric", "OBSERVATION_MODIFIER", 353, 364]]], ["This section highlights the use of smart coatings to indicate excessive UV exposure of tie-down straps.The road ahead for smart lashingsAlthough the lashings are UV stabilised according to the standard, there is no indication as to what extent this stabilisation should be.", [["This section", "TREATMENT", 0, 12], ["smart coatings", "TREATMENT", 35, 49], ["excessive UV exposure", "TREATMENT", 62, 83], ["tie-down straps", "TREATMENT", 87, 102], ["excessive", "OBSERVATION_MODIFIER", 62, 71], ["UV exposure", "OBSERVATION", 72, 83], ["UV stabilised", "OBSERVATION", 162, 175], ["no indication", "UNCERTAINTY", 212, 225], ["stabilisation", "OBSERVATION", 249, 262]]], ["Moreover, a given belt will last longer if it is used in mild UV conditions (eg, indoor, sporadically) compared with severe UV conditions (eg, southern Europe, long-distance open transport).", [["mild UV conditions", "PROBLEM", 57, 75], ["severe UV conditions", "PROBLEM", 117, 137], ["long-distance open transport", "TREATMENT", 160, 188]]], ["As a result, there is no general rule of thumb to assess the safety of a used belt with respect to UV ageing.", [["thumb", "ORGANISM_SUBDIVISION", 41, 46], ["general rule of thumb", "PROBLEM", 25, 46], ["a used belt", "TREATMENT", 71, 82], ["no", "UNCERTAINTY", 22, 24], ["thumb", "ANATOMY", 41, 46]]], ["To counteract this concern, a coating has been developed using a mixture of UV stabilisers to be printed on the belt.", [["UV stabilisers", "TREATMENT", 76, 90]]], ["In case of UV damage, the print will discolour and indicate the level of UV damage endured by the belt so far.", [["UV damage", "PROBLEM", 11, 20], ["UV damage", "PROBLEM", 73, 82], ["UV damage", "OBSERVATION", 11, 20], ["UV damage", "OBSERVATION", 73, 82]]], ["At UV exposures above 1000 h (EN14836, QUV accelerated ageing test), the replace text is clearly visible and indicates that the belt has endured too much UV irradiation to be used safely.Future trendsBecause textiles are used in an increasing number of technical applications, durability is increasing in importance.", [["UV irradiation", "TREATMENT", 154, 168], ["technical applications", "TREATMENT", 253, 275], ["increasing", "OBSERVATION_MODIFIER", 291, 301]]], ["Still, new end applications are detected in which durability in various environments are a prerequisite.", [["new end applications", "TREATMENT", 7, 27], ["new", "OBSERVATION_MODIFIER", 7, 10], ["end", "OBSERVATION_MODIFIER", 11, 14], ["durability", "OBSERVATION_MODIFIER", 50, 60]]], ["For instance, in the AtwSea Project (http://www.atsea-project.eu/), coated textiles were developed for use as a substrate for growing seaweed.", [["seaweed", "ORGANISM_SUBDIVISION", 134, 141]]], ["For this application, a unique balance between antifouling properties and seaweed anchoring points is crucial.Future trendsThe concept of self-healing coating is most developed in the field of automotives, aerospace, and building (concrete).", [["this application", "TREATMENT", 4, 20], ["a unique balance between antifouling properties", "TREATMENT", 22, 69], ["self-healing coating", "PROBLEM", 138, 158], ["healing", "OBSERVATION_MODIFIER", 143, 150], ["coating", "OBSERVATION", 151, 158], ["most developed", "OBSERVATION_MODIFIER", 162, 176]]], ["A known example is the Scratch Shield clear coat developed by Nissan and already implemented in their cars and on iPhones (Anon, 2016b) .", [["Scratch Shield", "OBSERVATION", 23, 37]]], ["In the future, self-healing coatings based on the microcapsule technology or an intrinsic approach can be expected.", [["self-healing coatings", "TREATMENT", 15, 36], ["the microcapsule technology", "TREATMENT", 46, 73], ["an intrinsic approach", "TREATMENT", 77, 98]]], ["The self-healing coating will be able to repair at an early stage of damage, enhancing the durability and prolonging the lifetime of the coated textile.Future trendsAll textile areas will benefit from these developments (eg, protective clothing, architectural textile, cargo securing).ConclusionsCoated textiles are being used in a wide range of end applications in which the textile is employed as a long-lasting solution.", [["The self-healing coating", "TREATMENT", 0, 24], ["repair", "TREATMENT", 41, 47], ["damage", "PROBLEM", 69, 75], ["the coated textile", "TREATMENT", 133, 151], ["All textile areas", "TREATMENT", 165, 182], ["protective clothing", "TREATMENT", 225, 244], ["architectural textile", "TREATMENT", 246, 267], ["ConclusionsCoated textiles", "TREATMENT", 285, 311], ["end applications", "TREATMENT", 346, 362], ["a long-lasting solution", "TREATMENT", 399, 422], ["damage", "OBSERVATION", 69, 75], ["durability", "OBSERVATION_MODIFIER", 91, 101]]], ["It is clear that the durability of textile coatings is an important property.", [["the durability of textile coatings", "TREATMENT", 17, 51], ["clear", "OBSERVATION", 6, 11], ["durability", "OBSERVATION_MODIFIER", 21, 31], ["textile coatings", "OBSERVATION", 35, 51]]], ["In this chapter some smart technologies were presented enabling the enhancement of the durability of coated textiles, properties that can be realised with these technologies and some (future) applications in which these durable coated textiles can be implemented.Sources of further informationTextile chemicals (Lacasse and Baumann, 2004) Smart coatings (Aguilar and Rom an, 2014)", [["these technologies", "TREATMENT", 155, 173], ["these durable coated textiles", "TREATMENT", 214, 243], ["Smart coatings (Aguilar and Rom an", "TREATMENT", 339, 373], ["durability", "OBSERVATION_MODIFIER", 87, 97], ["coated textiles", "OBSERVATION", 101, 116]]]], "4d3106db43f239c584e54e58189236f4db8ae285": [["PASSIVE IMMUNITY IN THE CONTEXT OF COVID-19Passive immunity is conferred by the transfer of pathogen-specific antibodies and, in the case of CP, innate humoral immune factors, to patients at-risk of developing or actively suffering from infection.", [["infection", "DISEASE", 237, 246], ["COVID-19Passive", "CELL", 35, 50], ["patients", "ORGANISM", 179, 187], ["pathogen-specific antibodies", "PROTEIN", 92, 120], ["innate humoral immune factors", "PROTEIN", 145, 174], ["patients", "SPECIES", 179, 187], ["specific antibodies", "TEST", 101, 120], ["CP", "PROBLEM", 141, 143], ["innate humoral immune factors", "TREATMENT", 145, 174], ["infection", "PROBLEM", 237, 246], ["infection", "OBSERVATION", 237, 246]]], ["The pathogen-specific antibodies include all immunoglobulin isotypes (IgG, IgM, IgA, and IgE) and nonspecified humoral innate immunity factors in CP or high purity polyclonal IgG and its subclasses in H-IG.", [["immunoglobulin isotypes", "GENE_OR_GENE_PRODUCT", 45, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["IgM", "GENE_OR_GENE_PRODUCT", 75, 78], ["IgA", "GENE_OR_GENE_PRODUCT", 80, 83], ["IgE", "GENE_OR_GENE_PRODUCT", 89, 92], ["CP", "SIMPLE_CHEMICAL", 146, 148], ["IgG", "GENE_OR_GENE_PRODUCT", 175, 178], ["H-IG", "SIMPLE_CHEMICAL", 201, 205], ["pathogen-specific antibodies", "PROTEIN", 4, 32], ["immunoglobulin isotypes", "PROTEIN", 45, 68], ["IgG", "PROTEIN", 70, 73], ["IgM", "PROTEIN", 75, 78], ["IgA", "PROTEIN", 80, 83], ["IgE", "PROTEIN", 89, 92], ["nonspecified humoral innate immunity factors", "PROTEIN", 98, 142], ["high purity polyclonal IgG", "PROTEIN", 152, 178], ["The pathogen", "TEST", 0, 12], ["specific antibodies", "TEST", 13, 32], ["all immunoglobulin isotypes", "TEST", 41, 68], ["IgG", "TEST", 70, 73], ["IgM", "TEST", 75, 78], ["IgA", "TEST", 80, 83], ["IgE", "TEST", 89, 92], ["nonspecified humoral innate immunity factors", "PROBLEM", 98, 142], ["CP", "PROBLEM", 146, 148], ["immunoglobulin isotypes", "OBSERVATION", 45, 68]]], ["In viral diseases, antibodies exert effect by viral neutralization (blocking viral cell entry and, therefore, replication), complement activation, opsonization, and antibody-dependent cellular cytotoxicity mediation.", [["cell", "ANATOMY", 83, 87], ["cellular", "ANATOMY", 184, 192], ["viral diseases", "DISEASE", 3, 17], ["cell", "CELL", 83, 87], ["cellular", "CELL", 184, 192], ["antibodies", "PROTEIN", 19, 29], ["viral diseases", "PROBLEM", 3, 17], ["antibodies exert effect", "PROBLEM", 19, 42], ["viral neutralization", "PROBLEM", 46, 66], ["opsonization", "TEST", 147, 159], ["antibody", "TEST", 165, 173], ["dependent cellular cytotoxicity mediation", "PROBLEM", 174, 215], ["viral diseases", "OBSERVATION", 3, 17], ["cellular cytotoxicity", "OBSERVATION", 184, 205]]], ["Viral neutralization is antigen-specific; other antiviral activities are antigen-nonspecific and are effected in part via Fc:FcReceptor interactions.", [["Fc", "GENE_OR_GENE_PRODUCT", 122, 124], ["FcReceptor", "GENE_OR_GENE_PRODUCT", 125, 135], ["Viral neutralization", "TEST", 0, 20], ["neutralization", "OBSERVATION", 6, 20]]], ["In SARS-CoV-2 infection, the principle target antigen associated with neutralization is the Spike protein, which is responsible for SARS-CoV-2 attachment to epithelial cells, including pneumocytes.", [["epithelial cells", "ANATOMY", 157, 173], ["pneumocytes", "ANATOMY", 185, 196], ["SARS-CoV-2 infection", "DISEASE", 3, 23], ["SARS-CoV-2", "ORGANISM", 3, 13], ["Spike", "GENE_OR_GENE_PRODUCT", 92, 97], ["CoV-2", "GENE_OR_GENE_PRODUCT", 137, 142], ["epithelial cells", "CELL", 157, 173], ["pneumocytes", "CELL", 185, 196], ["Spike protein", "PROTEIN", 92, 105], ["epithelial cells", "CELL_TYPE", 157, 173], ["pneumocytes", "CELL_TYPE", 185, 196], ["SARS-CoV-2", "SPECIES", 3, 13], ["SARS", "PROBLEM", 3, 7], ["CoV", "PROBLEM", 8, 11], ["2 infection", "PROBLEM", 12, 23], ["the principle target antigen", "PROBLEM", 25, 53], ["neutralization", "PROBLEM", 70, 84], ["the Spike protein", "PROBLEM", 88, 105], ["SARS", "PROBLEM", 132, 136], ["CoV", "PROBLEM", 137, 140], ["epithelial cells", "PROBLEM", 157, 173], ["pneumocytes", "PROBLEM", 185, 196], ["SARS", "OBSERVATION", 3, 7], ["CoV", "OBSERVATION_MODIFIER", 8, 11], ["infection", "OBSERVATION", 14, 23], ["neutralization", "OBSERVATION", 70, 84], ["responsible for", "UNCERTAINTY", 116, 131], ["epithelial cells", "OBSERVATION", 157, 173], ["pneumocytes", "OBSERVATION", 185, 196]]], ["The antibodies in COVID-19 passive immunotherapies are polyclonal in nature, with multiple epitopes against SARS-CoV-2 paratopes, including the receptor-binding domain in the Spike protein.PASSIVE IMMUNITY IN THE CONTEXT OF COVID-19Both CP and H-IG depend on plasma collected from patients who have recovered from the diseases.", [["plasma", "ANATOMY", 259, 265], ["H", "CHEMICAL", 244, 245], ["Spike", "GENE_OR_GENE_PRODUCT", 175, 180], ["H-IG", "SIMPLE_CHEMICAL", 244, 248], ["plasma", "ORGANISM_SUBSTANCE", 259, 265], ["patients", "ORGANISM", 281, 289], ["antibodies", "PROTEIN", 4, 14], ["epitopes", "PROTEIN", 91, 99], ["SARS-CoV-2 paratopes", "PROTEIN", 108, 128], ["receptor-binding domain", "PROTEIN", 144, 167], ["Spike protein", "PROTEIN", 175, 188], ["patients", "SPECIES", 281, 289], ["The antibodies", "TEST", 0, 14], ["COVID", "TEST", 18, 23], ["passive immunotherapies", "TREATMENT", 27, 50], ["polyclonal in nature", "PROBLEM", 55, 75], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["COVID", "TEST", 224, 229], ["CP", "PROBLEM", 237, 239], ["the diseases", "PROBLEM", 314, 326], ["diseases", "OBSERVATION", 318, 326]]], ["The US Food and Drug Administration (FDA) has provided nonbinding recommendations for CP donation: donors must have had documented infection with SARS-CoV-2 (real-time polymerase chain reaction or serology) and at least 28 days from resolution of symptoms or at least 14 days without symptoms and a negative real-time polymerase chain reaction test.", [["infection", "DISEASE", 131, 140], ["SARS", "DISEASE", 146, 150], ["donors", "ORGANISM", 99, 105], ["SARS-CoV", "SPECIES", 146, 154], ["CP donation", "TREATMENT", 86, 97], ["documented infection", "PROBLEM", 120, 140], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["serology", "TEST", 197, 205], ["symptoms", "PROBLEM", 247, 255], ["symptoms", "PROBLEM", 284, 292], ["infection", "OBSERVATION", 131, 140]]], ["4 CP has been used compassionately in this pandemic and is currently in clinical trials via an expanded access program in the United States, managed by the COVID-19 Convalescent Plasma Project (CCPP19.org).", [["CP", "CHEMICAL", 2, 4], ["an expanded access program", "TREATMENT", 92, 118]]], ["In a published report of 10 critically ill patients in China, 200 mL of plasma with titers of at least 1:640 on top of supportive care improved signs and symptoms in critically ill patients.", [["plasma", "ANATOMY", 72, 78], ["critically ill", "DISEASE", 28, 42], ["critically ill", "DISEASE", 166, 180], ["patients", "ORGANISM", 43, 51], ["plasma", "ORGANISM_SUBSTANCE", 72, 78], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 181, 189], ["plasma", "TREATMENT", 72, 78], ["titers", "TREATMENT", 84, 90], ["supportive care", "TREATMENT", 119, 134], ["symptoms", "PROBLEM", 154, 162]]], ["5 Assuming an average normal level of IgG, 200 mL equates to ~ 2 g of IgG, or 0.03 g/kg in a 70 kg adult.", [["IgG", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["IgG", "PROTEIN", 38, 41], ["IgG", "PROTEIN", 70, 73], ["IgG", "TEST", 38, 41], ["IgG", "TEST", 70, 73]]], ["The process for using CP as a therapy is straightforward and efficient: one or two units of fresh, frozen, and virus-inactivated plasma (~ 250-500 mL, or up to ~ 5 g of IgG) collected from individual convalescent patient(s) is administered to blood group-matched patients.", [["plasma", "ANATOMY", 129, 135], ["blood", "ANATOMY", 243, 248], ["CP", "CHEMICAL", 22, 24], ["CP", "SIMPLE_CHEMICAL", 22, 24], ["plasma", "ORGANISM_SUBSTANCE", 129, 135], ["IgG", "GENE_OR_GENE_PRODUCT", 169, 172], ["patient", "ORGANISM", 213, 220], ["blood", "ORGANISM_SUBSTANCE", 243, 248], ["patients", "ORGANISM", 263, 271], ["IgG", "PROTEIN", 169, 172], ["patient", "SPECIES", 213, 220], ["patients", "SPECIES", 263, 271], ["CP", "PROBLEM", 22, 24], ["a therapy", "TREATMENT", 28, 37], ["fresh, frozen", "TREATMENT", 92, 105], ["virus", "TREATMENT", 111, 116], ["plasma", "TEST", 129, 135], ["IgG", "TEST", 169, 172]]], ["Although CP is screened for neutralization titers, the titers are not standardized, and the dose of antibodies (including IgG) and other immune factors is unknown.", [["IgG", "GENE_OR_GENE_PRODUCT", 122, 125], ["antibodies", "PROTEIN", 100, 110], ["IgG", "PROTEIN", 122, 125], ["immune factors", "PROTEIN", 137, 151], ["CP", "PROBLEM", 9, 11], ["neutralization titers", "PROBLEM", 28, 49], ["the titers", "TEST", 51, 61], ["antibodies", "TEST", 100, 110], ["IgG", "TEST", 122, 125], ["other immune factors", "PROBLEM", 131, 151]]], ["The FDA recommends that CP neutralization titers are at least 1:160.", [["CP neutralization titers", "TEST", 24, 48]]], ["4 H-IG is a drug derived from convalescent plasma.", [["plasma", "ANATOMY", 43, 49], ["H-IG", "CHEMICAL", 2, 6], ["4", "SIMPLE_CHEMICAL", 0, 1], ["H-IG", "SIMPLE_CHEMICAL", 2, 6], ["convalescent", "ORGANISM", 30, 42], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["convalescent plasma", "TEST", 30, 49]]], ["H-IG is produced following normal IG production processes, via a fractionation process that results in a purified mix of IgGs in subclass ratios that mimic human IgG subclass mixtures (in this case, to ratios in COVID-19 convalescent patients).", [["H-IG", "CHEMICAL", 0, 4], ["H-IG", "SIMPLE_CHEMICAL", 0, 4], ["IgGs", "GENE_OR_GENE_PRODUCT", 121, 125], ["human", "ORGANISM", 156, 161], ["IgG", "GENE_OR_GENE_PRODUCT", 162, 165], ["patients", "ORGANISM", 234, 242], ["IgGs", "PROTEIN", 121, 125], ["human", "SPECIES", 156, 161], ["patients", "SPECIES", 234, 242], ["human", "SPECIES", 156, 161], ["a fractionation process", "TREATMENT", 63, 86], ["subclass ratios", "TEST", 129, 144], ["human IgG subclass mixtures", "PROBLEM", 156, 183], ["ratios", "TEST", 202, 208], ["COVID", "TEST", 212, 217]]], ["The product will have a diverse set of polyclonal antibodies against SARS-CoV-2, with a standard, measured neutralization titer prior to release.", [["SARS", "DISEASE", 69, 73], ["SARS-CoV-2", "ORGANISM", 69, 79], ["polyclonal antibodies", "PROTEIN", 39, 60], ["SARS-CoV", "SPECIES", 69, 77], ["polyclonal antibodies", "TEST", 39, 60], ["SARS", "PROBLEM", 69, 73], ["a standard, measured neutralization titer", "TREATMENT", 86, 127]]], ["The final product is finished to a precise concentration of IgG (10% solution is common).", [["IgG", "GENE_OR_GENE_PRODUCT", 60, 63], ["IgG", "PROTEIN", 60, 63], ["a precise concentration of IgG", "TREATMENT", 33, 63]]], ["As a drug, H-IG is regulated by health authorities, and several biopharmaceutical companies with specific infrastructure to produce plasma-derived therapies have announced H-IG programs.H-IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPYManufacturing clinical and commercial supply of H-IG depends on plasma collection.", [["plasma", "ANATOMY", 132, 138], ["plasma", "ANATOMY", 306, 312], ["H-IG", "CHEMICAL", 290, 294], ["H-IG", "SIMPLE_CHEMICAL", 11, 15], ["plasma", "ORGANISM_SUBSTANCE", 132, 138], ["H-IG", "SIMPLE_CHEMICAL", 172, 176], ["H-IG", "SIMPLE_CHEMICAL", 290, 294], ["plasma", "ORGANISM_SUBSTANCE", 306, 312], ["plasma-derived therapies", "TREATMENT", 132, 156], ["plasma collection", "PROBLEM", 306, 323]]], ["In the United States, Europe, Japan, and China, there is established and highly regulated plasma collection infrastructure that is being mobilized now to collect plasma from the increasing number of convalescent patients in these regions.", [["plasma", "ANATOMY", 90, 96], ["plasma", "ANATOMY", 162, 168], ["plasma", "ORGANISM_SUBSTANCE", 90, 96], ["plasma", "ORGANISM_SUBSTANCE", 162, 168], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["highly regulated plasma collection infrastructure", "PROBLEM", 73, 122], ["plasma collection", "OBSERVATION", 90, 107], ["increasing", "OBSERVATION_MODIFIER", 178, 188], ["number", "OBSERVATION_MODIFIER", 189, 195], ["convalescent", "OBSERVATION_MODIFIER", 199, 211]]], ["Once collected and pooled, plasma is manufactured into H-IG through a series of steps that can take several months: fractionation, purification, incubation, release testing, finishing, and packaging.", [["plasma", "ANATOMY", 27, 33], ["H-IG", "CHEMICAL", 55, 59], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["H-IG", "SIMPLE_CHEMICAL", 55, 59], ["fractionation", "TREATMENT", 116, 129], ["purification", "TREATMENT", 131, 143], ["release testing", "TEST", 157, 172], ["packaging", "TREATMENT", 189, 198]]], ["The process ensures product purity, pathogen safety, and adequate titers of neutralizing antibodies before release for clinical use.", [["neutralizing antibodies", "PROTEIN", 76, 99], ["neutralizing antibodies", "TREATMENT", 76, 99], ["product purity", "OBSERVATION", 20, 34]]], ["H-IG may be stored up to 3 years depending on conditions.", [["H-IG", "CHEMICAL", 0, 4], ["H-IG", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["Further, H-IGs may be manufactured at commercial scale, following the process outlined above, with manufacturing runs that can process up to 20,000 L of plasma.H-IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPYThe H-IG is expected to behave pharmacokinetically like IG (i.v.).", [["plasma", "ANATOMY", 153, 159], ["H", "CHEMICAL", 220, 221], ["H-IGs", "SIMPLE_CHEMICAL", 9, 14], ["plasma", "ORGANISM_SUBSTANCE", 153, 159], ["H-IG", "GENE_OR_GENE_PRODUCT", 220, 224], ["IG", "SIMPLE_CHEMICAL", 272, 274], ["H-IGs", "TREATMENT", 9, 14]]], ["Table 1 shows an example of pharmacokinetic (PK) characteristics for a commercially available IG (i.v.) product.", [["IG", "SIMPLE_CHEMICAL", 94, 96]]], ["6 The short time of maximum plasma concentration (T max ) and long T1-2 suggest that a single infusion of H-IG may be sufficient for treatment in the acute disease settings.", [["plasma", "ANATOMY", 28, 34], ["H-IG", "CHEMICAL", 106, 110], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["H-IG", "SIMPLE_CHEMICAL", 106, 110], ["maximum plasma concentration", "TEST", 20, 48], ["a single infusion of H-IG", "TREATMENT", 85, 110], ["treatment", "TREATMENT", 133, 142], ["the acute disease settings", "TREATMENT", 146, 172], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["disease", "OBSERVATION", 156, 163]]], ["In upcoming studies, it is important to confirm that the PK of SARS-CoV-2 specific antibodies administered therapeutically in an active disease state is similar the PK of IG (i.v.).H-IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPYTo assess PDs, animal models may be a key mainstay in COVID-19.", [["SARS", "DISEASE", 63, 67], ["PK", "GENE_OR_GENE_PRODUCT", 57, 59], ["SARS-CoV-2", "ORGANISM", 63, 73], ["IG", "SIMPLE_CHEMICAL", 171, 173], ["COVID-19", "CELL", 291, 299], ["SARS-CoV-2 specific antibodies", "PROTEIN", 63, 93], ["SARS-CoV", "SPECIES", 63, 71], ["upcoming studies", "TEST", 3, 19], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["2 specific antibodies", "TREATMENT", 72, 93], ["an active disease state", "PROBLEM", 126, 149], ["COVID", "TEST", 291, 296], ["active", "OBSERVATION_MODIFIER", 129, 135], ["disease", "OBSERVATION", 136, 143]]], ["Preclinical studies using human transgenic ACE2 mice and non-human primates will provide prospective understandings of minimal protective titers that can substantiate human dosing, evaluate efficacy in a therapeutic setting, and address key safety risks (as discussed below).", [["human", "ORGANISM", 26, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["mice", "ORGANISM", 48, 52], ["non-human primates", "ORGANISM", 57, 75], ["human", "ORGANISM", 167, 172], ["ACE2", "PROTEIN", 43, 47], ["human", "SPECIES", 26, 31], ["mice", "SPECIES", 48, 52], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 26, 31], ["mice", "SPECIES", 48, 52], ["human", "SPECIES", 167, 172], ["Preclinical studies", "TEST", 0, 19], ["human transgenic ACE2 mice", "TREATMENT", 26, 52], ["minimal protective titers", "TREATMENT", 119, 144], ["human dosing", "TREATMENT", 167, 179]]], ["Ongoing preclinical experiments can substantiate the proposed clinical dose through pharmacometric modeling of the PK/PD relationship.", [["PK", "GENE_OR_GENE_PRODUCT", 115, 117], ["the PK/PD relationship", "TREATMENT", 111, 133]]], ["However, due to the urgency of the pandemic and the speed of clinical development in this situation, these experiments will run concurrently with pivotal clinical trials.", [["the urgency", "PROBLEM", 16, 27], ["the pandemic", "PROBLEM", 31, 43], ["pivotal clinical trials", "TREATMENT", 146, 169]]], ["Thus, the early reads on PD may come from human therapy trials.H-IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPYAlthough the clinical dose will be defined in clinical trials, in vitro neutralization titers of the finished product will inform dose selection.", [["PD", "DISEASE", 25, 27], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["PD", "TREATMENT", 25, 27], ["human therapy trials", "TREATMENT", 42, 62], ["vitro neutralization titers", "TREATMENT", 185, 212], ["dose selection", "TREATMENT", 249, 263]]], ["Based on assessments done in our own laboratories, the current estimate is that the dose will range from 0.1 to 0.5g/kg, given i.v. once (every 28 days if used for prophylaxis).", [["assessments", "TEST", 9, 20], ["prophylaxis", "TREATMENT", 164, 175]]], ["The experience to date with CP as therapy suggests that a lower dose may be effective: this will be tested in randomized clinical trials.H-IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPYTo date, no high-quality clinical trial has demonstrated convincing efficacy and safety of H-IG in coronavirus epidemics.", [["CP", "CHEMICAL", 28, 30], ["H-IG", "CHEMICAL", 284, 288], ["coronavirus epidemics", "DISEASE", 292, 313], ["H-IG", "SIMPLE_CHEMICAL", 284, 288], ["coronavirus", "ORGANISM", 292, 303], ["CP", "PROBLEM", 28, 30], ["therapy", "TREATMENT", 34, 41], ["a lower dose", "TREATMENT", 56, 68], ["coronavirus epidemics", "PROBLEM", 292, 313]]], ["Thus, randomized controlled trials are needed now to establish the benefit-risk balance of this intervention for COVID-19 and to guide future H-IG use in new, emerging epidemics.", [["H-IG", "CHEMICAL", 142, 146], ["H-IG", "SIMPLE_CHEMICAL", 142, 146], ["randomized controlled trials", "TREATMENT", 6, 34], ["this intervention", "TREATMENT", 91, 108], ["COVID", "TEST", 113, 118]]], ["Target indications for the COVID-19 H-IG include treatment and prevention.", [["H-IG", "CHEMICAL", 36, 40], ["H-IG", "SIMPLE_CHEMICAL", 36, 40], ["COVID-19 H-IG", "DNA", 27, 40], ["the COVID", "TREATMENT", 23, 32], ["IG", "TREATMENT", 38, 40], ["treatment", "TREATMENT", 49, 58], ["prevention", "TREATMENT", 63, 73]]], ["In coronavirus diseases, including COVID-19, endogenous antibody production is nondetectable early in disease (< 5-7 days).", [["coronavirus diseases", "DISEASE", 3, 23], ["coronavirus", "ORGANISM", 3, 14], ["COVID-19", "GENE_OR_GENE_PRODUCT", 35, 43], ["endogenous antibody", "PROTEIN", 45, 64], ["coronavirus diseases", "PROBLEM", 3, 23], ["COVID", "TEST", 35, 40], ["endogenous antibody production", "PROBLEM", 45, 75], ["coronavirus diseases", "OBSERVATION", 3, 23], ["antibody production", "OBSERVATION", 56, 75], ["nondetectable", "OBSERVATION_MODIFIER", 79, 92], ["early", "OBSERVATION_MODIFIER", 93, 98]]], ["In COVID-19, ~ 95% of patients convert within 14 days of symptom onset, and IgM and IgG seroconversion seems to occur simultaneously and plateaus after 6 days.", [["patients", "ORGANISM", 22, 30], ["IgM", "GENE_OR_GENE_PRODUCT", 76, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 84, 87], ["IgM", "PROTEIN", 76, 79], ["IgG", "PROTEIN", 84, 87], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 3, 8], ["symptom onset", "PROBLEM", 57, 70], ["IgM", "TEST", 76, 79], ["IgG seroconversion", "PROBLEM", 84, 102]]], ["7 Thus, patients who have rapidly progressing yet early disease may benefit from the antibody boost that would come from H-IG.", [["patients", "ORGANISM", 8, 16], ["H-IG", "ORGANISM", 121, 125], ["patients", "SPECIES", 8, 16], ["early disease", "PROBLEM", 50, 63], ["the antibody boost", "TREATMENT", 81, 99]]], ["Randomized, placebo controlled clinical trials in treatment paradigms are anticipated to begin in Summer 2020.H-IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPYIn prevention, the initial targeted population could be pre-exposure prophylaxis in front-line healthcare providers (HCPs).", [["placebo", "TREATMENT", 12, 19], ["treatment paradigms", "TREATMENT", 50, 69], ["A SUSTAINABLE IMMUNOTHERAPYIn prevention", "TREATMENT", 139, 179], ["pre-exposure prophylaxis", "TREATMENT", 222, 246]]], ["To date, several hundred HCPs have died from COVID-19.", [["COVID-19", "CHEMICAL", 45, 53], ["COVID", "TEST", 45, 50]]], ["8 High infection rates in HCPs translate to direct and indirect harm: as the individual HCP is infected and suffers from the disease and is a potential fomite for new infection, additional HCPs are called in to care for patients and are at higher risk for infection.ANTIBODY-DEPENDENT ENHANCEMENT AND SAFETY CONCERNSIn general, i.v.", [["infection", "DISEASE", 7, 16], ["infection", "DISEASE", 167, 176], ["infection", "DISEASE", 256, 265], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["High infection rates", "PROBLEM", 2, 22], ["the disease", "PROBLEM", 121, 132], ["new infection", "PROBLEM", 163, 176], ["infection", "PROBLEM", 256, 265], ["ANTIBODY", "TEST", 266, 274], ["High", "OBSERVATION_MODIFIER", 2, 6], ["infection", "OBSERVATION", 7, 16], ["infected", "OBSERVATION", 95, 103], ["disease", "OBSERVATION", 125, 132], ["infection", "OBSERVATION", 167, 176], ["infection", "OBSERVATION", 256, 265], ["DEPENDENT ENHANCEMENT", "OBSERVATION_MODIFIER", 275, 296]]], ["IgG is well-tolerated and the safety profile is well known.", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "PROTEIN", 0, 3], ["IgG", "TEST", 0, 3]]], ["Common adverse reactions are mild and self-limiting, but severe adverse effects, including thrombosis, renal dysfunction, and death, are known to occur in high-risk patients.", [["renal", "ANATOMY", 103, 108], ["thrombosis", "DISEASE", 91, 101], ["renal dysfunction", "DISEASE", 103, 120], ["death", "DISEASE", 126, 131], ["renal", "ORGAN", 103, 108], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["Common adverse reactions", "PROBLEM", 0, 24], ["severe adverse effects", "PROBLEM", 57, 79], ["thrombosis", "PROBLEM", 91, 101], ["renal dysfunction", "PROBLEM", 103, 120], ["death", "PROBLEM", 126, 131], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["self-limiting", "OBSERVATION_MODIFIER", 38, 51], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["adverse", "OBSERVATION", 64, 71], ["thrombosis", "OBSERVATION", 91, 101], ["renal", "ANATOMY", 103, 108], ["dysfunction", "OBSERVATION", 109, 120]]], ["Little is known about the safety of CP or H-IGs when used to manage coronavirus infections.", [["CP", "CHEMICAL", 36, 38], ["H-IGs", "CHEMICAL", 42, 47], ["coronavirus infections", "DISEASE", 68, 90], ["CP", "SIMPLE_CHEMICAL", 36, 38], ["H-IGs", "SIMPLE_CHEMICAL", 42, 47], ["coronavirus", "ORGANISM", 68, 79], ["CP", "PROBLEM", 36, 38], ["H-IGs", "TREATMENT", 42, 47], ["coronavirus infections", "PROBLEM", 68, 90]]], ["There is a theoretical concern that H-IG against coronavirus, including SARS-CoV-2, may potentiate disease via a mechanism called antibody-dependent enhancement (ADE), and earlier studies of H-IG in SARS and Middle East respiratory www.cts-journal.comPassive Immunotherapy for COVID-19Morabito and Gangadharan syndrome (MERS) have not provided enough information to extrapolate to COVID-19.", [["H-IG", "CHEMICAL", 36, 40], ["coronavirus", "DISEASE", 49, 60], ["H-IG", "CHEMICAL", 191, 195], ["SARS", "DISEASE", 199, 203], ["Gangadharan syndrome", "DISEASE", 298, 318], ["COVID-19", "CHEMICAL", 381, 389], ["H-IG", "SIMPLE_CHEMICAL", 36, 40], ["coronavirus", "ORGANISM", 49, 60], ["SARS-CoV-2", "ORGANISM", 72, 82], ["H-IG", "GENE_OR_GENE_PRODUCT", 191, 195], ["COVID-19", "DNA", 381, 389], ["SARS-CoV", "SPECIES", 72, 80], ["coronavirus", "PROBLEM", 49, 60], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["disease", "PROBLEM", 99, 106], ["dependent enhancement", "PROBLEM", 139, 160], ["earlier studies", "TEST", 172, 187], ["SARS", "PROBLEM", 199, 203], ["Immunotherapy", "TREATMENT", 259, 272], ["COVID", "TEST", 277, 282], ["Gangadharan syndrome", "PROBLEM", 298, 318], ["COVID", "TEST", 381, 386]]], ["ADE describes two basic phenomena mediated by virus-specific antibodies: enhanced viral infection and enhanced immunologic response in the advanced disease, independent from viral load.", [["viral infection", "DISEASE", 82, 97], ["virus-specific antibodies", "PROTEIN", 46, 71], ["two basic phenomena", "PROBLEM", 14, 33], ["specific antibodies", "TEST", 52, 71], ["enhanced viral infection", "PROBLEM", 73, 97], ["enhanced immunologic response", "PROBLEM", 102, 131], ["the advanced disease", "PROBLEM", 135, 155], ["viral load", "PROBLEM", 174, 184], ["viral infection", "OBSERVATION", 82, 97], ["advanced disease", "OBSERVATION", 139, 155], ["viral load", "OBSERVATION", 174, 184]]], ["There are no data to date to suggest that ADE occurs in COVID-19, but research in this space is relatively immature.", [["ADE", "DISEASE", 42, 45], ["COVID", "TEST", 56, 61], ["no", "UNCERTAINTY", 10, 12], ["relatively", "OBSERVATION_MODIFIER", 96, 106], ["immature", "OBSERVATION", 107, 115]]], ["The strongest set of data on ADE in coronavirus infections come from SARS-CoV.", [["coronavirus infections", "DISEASE", 36, 58], ["SARS", "DISEASE", 69, 73], ["coronavirus", "ORGANISM", 36, 47], ["SARS-CoV", "ORGANISM", 69, 77], ["coronavirus", "SPECIES", 36, 47], ["SARS-CoV", "SPECIES", 69, 77], ["coronavirus infections", "PROBLEM", 36, 58]]], ["In vitro data suggest that although anti-Spike protein serum inhibits viral entry into epithelial cells incubating in SARS-CoV inoculated medium, there is enhanced uptake of virus in immune cells via FcgammaRII (not ACE2) 9 : whether this uptake enhances immune pathology requires scientific evaluation.", [["serum", "ANATOMY", 55, 60], ["epithelial cells", "ANATOMY", 87, 103], ["immune cells", "ANATOMY", 183, 195], ["anti-Spike", "GENE_OR_GENE_PRODUCT", 36, 46], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["epithelial cells", "CELL", 87, 103], ["SARS-CoV", "ORGANISM", 118, 126], ["immune cells", "CELL", 183, 195], ["FcgammaRII", "GENE_OR_GENE_PRODUCT", 200, 210], ["ACE2", "GENE_OR_GENE_PRODUCT", 216, 220], ["anti-Spike protein", "PROTEIN", 36, 54], ["epithelial cells", "CELL_TYPE", 87, 103], ["immune cells", "CELL_TYPE", 183, 195], ["FcgammaRII (not ACE2) 9", "PROTEIN", 200, 223], ["SARS-CoV", "SPECIES", 118, 126], ["vitro data", "TEST", 3, 13], ["anti-Spike protein serum", "TEST", 36, 60], ["epithelial cells", "TEST", 87, 103], ["SARS", "PROBLEM", 118, 122], ["CoV inoculated medium", "PROBLEM", 123, 144], ["enhanced uptake of virus", "PROBLEM", 155, 179], ["this uptake enhances immune pathology", "PROBLEM", 234, 271], ["scientific evaluation", "TEST", 281, 302], ["epithelial cells", "OBSERVATION", 87, 103], ["uptake of virus", "OBSERVATION", 164, 179]]], ["Additional in vivo results from a macaque model showed that induction of anti-SARS-CoV Spike IgG resulted in enhanced-acute lung injury, related to enhanced pro-inflammatory morphological changes in alveolar macrophage.", [["lung", "ANATOMY", 124, 128], ["alveolar macrophage", "ANATOMY", 199, 218], ["lung injury", "DISEASE", 124, 135], ["macaque", "ORGANISM", 34, 41], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 73, 86], ["IgG", "GENE_OR_GENE_PRODUCT", 93, 96], ["lung", "ORGAN", 124, 128], ["alveolar macrophage", "CELL", 199, 218], ["anti-SARS-CoV Spike IgG", "PROTEIN", 73, 96], ["alveolar macrophage", "CELL_TYPE", 199, 218], ["anti-SARS-CoV", "SPECIES", 73, 86], ["a macaque model", "TEST", 32, 47], ["anti-SARS-CoV Spike IgG", "TEST", 73, 96], ["acute lung injury", "PROBLEM", 118, 135], ["enhanced pro-inflammatory morphological changes in alveolar macrophage", "PROBLEM", 148, 218], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["lung", "ANATOMY", 124, 128], ["injury", "OBSERVATION", 129, 135], ["enhanced", "OBSERVATION_MODIFIER", 148, 156], ["pro-inflammatory morphological", "OBSERVATION", 157, 187], ["alveolar macrophage", "OBSERVATION", 199, 218]]], ["10 Additional preclinical animal studies are needed to understand whether H-IGs at high neutralization titers will enhance antibody-dependent immune pathology.", [["H-IGs", "CHEMICAL", 74, 79], ["H-IGs", "SIMPLE_CHEMICAL", 74, 79], ["Additional preclinical animal studies", "TEST", 3, 40], ["high neutralization titers", "TEST", 83, 109], ["antibody", "TEST", 123, 131], ["dependent immune pathology", "PROBLEM", 132, 158]]], ["Human data to correlate these findings do not exist, yet, it is important to note that in SARS ~ 80% of patients developed acute respiratory distress syndrome (ARDS), coincidentally with IgG seroconversion.", [["respiratory", "ANATOMY", 129, 140], ["SARS", "DISEASE", 90, 94], ["acute respiratory distress syndrome", "DISEASE", 123, 158], ["ARDS", "DISEASE", 160, 164], ["Human", "ORGANISM", 0, 5], ["patients", "ORGANISM", 104, 112], ["IgG", "GENE_OR_GENE_PRODUCT", 187, 190], ["IgG", "PROTEIN", 187, 190], ["Human", "SPECIES", 0, 5], ["patients", "SPECIES", 104, 112], ["Human", "SPECIES", 0, 5], ["SARS", "TEST", 90, 94], ["acute respiratory distress syndrome", "PROBLEM", 123, 158], ["ARDS", "PROBLEM", 160, 164], ["IgG seroconversion", "PROBLEM", 187, 205], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory distress syndrome", "OBSERVATION", 129, 158], ["ARDS", "OBSERVATION", 160, 164], ["IgG seroconversion", "OBSERVATION", 187, 205]]], ["Preclinical and clinical correlation in COVID-19 are needed.PASSIVE IMMUNOTHERAPY AS A PLATFORM FOR THIS AND FUTURE EPIDEMICSPassive immunotherapy from convalescent plasma and H-IG drugs may be effective in future epidemics caused by novel or known pathogens, to target pathogens against which no existing direct antiviral therapy exists.", [["plasma", "ANATOMY", 165, 171], ["H-IG", "CHEMICAL", 176, 180], ["COVID-19", "CELL", 40, 48], ["convalescent", "ORGANISM", 152, 164], ["plasma", "ORGANISM_SUBSTANCE", 165, 171], ["H-IG", "SIMPLE_CHEMICAL", 176, 180], ["COVID", "TEST", 40, 45], ["EPIDEMICSPassive immunotherapy", "TREATMENT", 116, 146], ["convalescent plasma and H-IG drugs", "TREATMENT", 152, 186], ["epidemics", "PROBLEM", 214, 223], ["known pathogens", "PROBLEM", 243, 258], ["existing direct antiviral therapy", "TREATMENT", 297, 330], ["antiviral therapy", "OBSERVATION", 313, 330]]], ["As H-IG therapies become available, rapid and cost-effective distribution needs to be ensured to optimize the full potential of this therapy.", [["H-IG", "GENE_OR_GENE_PRODUCT", 3, 7], ["H-IG therapies", "TREATMENT", 3, 17], ["this therapy", "TREATMENT", 128, 140]]]], "fa62ea902ffb1bcea8d41841958205137cf0ca9f": [["A c c e p t e d M a n u s c r i p t 4 The Department of Homeland Security (DHS) has proven itself ill-equipped to manage the spread of COVID-19 in its detention facilities.", [["COVID-19", "CHEMICAL", 135, 143], ["a n u s", "TEST", 18, 25]]], ["There have been over 1, 200 confirmed COVID-19 cases across 52 facilities run by the DHS's Immigration and Customs Enforcement (ICE) agency [1] .", [["COVID", "TEST", 38, 43]]], ["Of those tested, more than 50% of ICE detainees have been positive for COVID-19, including 155 COVID-19-positive detainees at the Otay Mesa Detention Center in San Diego, where one detainee has died from the illness [1, 2] .", [["illness", "DISEASE", 208, 215], ["ICE detainees", "TEST", 34, 47], ["COVID", "TEST", 71, 76], ["COVID", "TEST", 95, 100]]], ["Children have not been spared.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["In one Chicago facility where the DHS's Office of Refugee Resettlement (ORR) places unaccompanied migrant minors, 42 children have tested positive for COVID-19 [3] .", [["children", "ORGANISM", 117, 125], ["children", "SPECIES", 117, 125], ["COVID", "TEST", 151, 156]]]], "ea649aa902789b1a6424f1697c66b35f29f223a6": [["INTRODUCTIONIl existe trois d\u00e9terminants principaux \u00e0 la survenue d'une infection : l'environnement dans lequel les soins sont dispens\u00e9s ; le type d'actes r\u00e9alis\u00e9s ; et l'\u00e9tat du patient.SUMMARYThe objective of this article is to detail the strategies involving environmental samples in ambulance as other elements relative to the control of the infectious risk in the context of rescue and assistance.", [["infection", "DISEASE", 72, 81], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 179, 186], ["rescue and assistance", "TREATMENT", 380, 401], ["infectious", "OBSERVATION", 346, 356]]], ["Environmental samples are not compulsory but are of interest in the context of a method validation process or in that of an educational approach.", [["samples", "ANATOMY", 14, 21], ["a method validation process", "TREATMENT", 79, 106]]], ["In these two situations, environmental samples must be integrated in a surveillance strategy mentioning in particular the choice of the type of samples, by favoring whenever possible the agar sample, the surfaces concerned, or even the ideal moment to take the sample.", [["a surveillance strategy", "TREATMENT", 69, 92], ["the agar sample", "TEST", 183, 198]]], ["If the samples contribute to the formalization of a risk at a given time and place, the infectious risk in ambulances must be continuously controlled by the application of various measures complementary to the maintenance such as hand hygiene, reasoned use of wearing gloves or even wearing a mask when there is a risk of projection.SUMMARYLa prise en charge pr\u00e9-hospitali\u00e8re peut donc, du fait de ces 3 facteurs, dans certaines situations s'av\u00e9rer particuli\u00e8rement favorable \u00e0 la survenue d'infections.", [["samples", "ANATOMY", 7, 14], ["hand", "ANATOMY", 230, 234], ["d'infections", "DISEASE", 490, 502], ["hand", "ORGANISM_SUBDIVISION", 230, 234], ["various measures complementary", "TREATMENT", 172, 202], ["hand hygiene", "TREATMENT", 230, 242], ["gloves", "TREATMENT", 268, 274], ["a mask", "TREATMENT", 291, 297], ["d'infections", "PROBLEM", 490, 502], ["infectious", "OBSERVATION", 88, 98]]], ["Si la prise en charge peut \u00eatre initi\u00e9e dans un environnement non d\u00e9di\u00e9 aux soins (domicile, ext\u00e9rieur, etc.), elle sera poursuivie de fa\u00e7on privil\u00e9gi\u00e9e dans une ambulance ou v\u00e9hicule de secours et d'assistance aux victimes (VSAV).", [["Si", "CHEMICAL", 0, 2]]], ["Ces derniers sont donc le th\u00e9\u00e2tre de gestes plus ou moins invasifs sur des victimes plus ou moins fragilis\u00e9es par des pathologies sous-jacentes ainsi que par la situation ayant motiv\u00e9e l'intervention des secours.", [["Ces derniers sont donc le th\u00e9\u00e2tre de gestes plus ou moins invasifs sur des victimes plus ou moins fragilis\u00e9es par des pathologies sous-jacentes ainsi que par la situation ayant motiv\u00e9e l'intervention des secours", "SPECIES", 0, 211]]], ["Les diff\u00e9rents micro-organismes (MO), qu'il s'agisse de bact\u00e9ries (notamment de bact\u00e9ries multir\u00e9sistantes (BMR)), virus (principalement grippe, gastro-ent\u00e9rite ou encore le SARS-CoV-2) champignons (aspergillus) ou encore de parasites (gale, poux), ont la capacit\u00e9 de survivre plus ou moins longuement dans l'environnement de quelques heures \u00e0 plusieurs jours voire quelques mois.", [["gastro-ent\u00e9rite ou encore le SARS-CoV-2) champignons", "SPECIES", 145, 197], ["virus", "PROBLEM", 115, 120], ["principalement", "TEST", 122, 136], ["grippe", "TEST", 137, 143], ["gastro", "TEST", 145, 151], ["le SARS", "PROBLEM", 171, 178], ["CoV", "TEST", 179, 182], ["champignons (aspergillus)", "PROBLEM", 186, 211], ["ont la capacit\u00e9", "TREATMENT", 249, 264], ["gastro", "ANATOMY", 145, 151]]], ["L'environnement joue donc le r\u00f4le de r\u00e9servoir susceptible d'\u00eatre \u00e0 l'origine d'une infection chez la victime prise en charge mais \u00e9galement \u00e0 une contamination des secouristes lors de la prise en charge de la victime.", [["infection", "DISEASE", 84, 93], ["L'environnement joue", "TREATMENT", 0, 20], ["une contamination des", "TREATMENT", 143, 164]]], ["Le r\u00f4le de la contamination des surfaces, tout comme de l'\u00e9quipement m\u00e9dical dans la survenue d'infection a \u00e9t\u00e9 d\u00e9montr\u00e9 dans de nombreuses \u00e9tudes [1] [2] [3] [4] .", [["infection", "DISEASE", 96, 105], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 147, 162], ["'infection", "PROBLEM", 95, 105]]], ["Les contr\u00f4les de l'eau (recherche de l\u00e9gionelles et de Pseudomonas aeruginosa) ne seront indiqu\u00e9s que dans les rares cas o\u00f9 un point d'eau serait pr\u00e9sent dans le VSAV.", [["Pseudomonas aeruginosa", "PROBLEM", 55, 77]]], ["En effet, y compris en milieu hospitalier, la Soci\u00e9t\u00e9 fran\u00e7aise d'hygi\u00e8ne hospitali\u00e8re (SF2H) dans ses recommandations R14 et R15 recommande fortement en routine de ne pas r\u00e9aliser de contr\u00f4le microbiologique de surfaces pour la recherche de virus, de bact\u00e9ries multir\u00e9sistantes ou autres micro-organismes \u00e0 potentiel \u00e9pid\u00e9mique [5] .", [["en routine de ne pas r\u00e9aliser", "TREATMENT", 151, 180]]], ["Cela est int\u00e9ressant lors d'un changement de m\u00e9thode d'entretien (exemple : mise Article original en place de la technique vapeur, changement de produit, etc.) pour s'assurer que cette derni\u00e8re est compatible avec l'organisation du service (encombrement, compatibilit\u00e9 avec les surfaces \u00e0 nettoyer), ou pour valider une gestuelle/technique en vue d'\u00e9tablir un protocole.", [["s'assurer que cette derni\u00e8re est compatible avec l'organisation du service (encombrement, compatibilit\u00e9 avec les surfaces \u00e0 nettoyer), ou pour valider une gestuelle/technique en vue d'\u00e9tablir un protocole", "SPECIES", 165, 369], ["la technique vapeur", "TREATMENT", 110, 129]]], ["Lorsque la d\u00e9marche est en lien avec une autre technique (ex. : d\u00e9sinfection par voie a\u00e9rienne, changement du sch\u00e9ma d'entretien, etc.) il sera propos\u00e9 de tester des surfaces plus ou moins accessibles de fa\u00e7on \u00e0 identifier des points critiques.M\u00e9thode d'analyse retenueElle est \u00e0 d\u00e9finir en lien avec le laboratoire prestataire en fonction du type de r\u00e9sultat attendu, elle pourra \u00e9galement prendre en compte le co\u00fbt de l'analyse.Identification des pr\u00e9leveursAfin de pouvoir garantir la validit\u00e9 du r\u00e9sultat de l'analyse, le laboratoire peut demander \u00e0 ce que le pr\u00e9l\u00e8vement soit effectu\u00e9 selon une m\u00e9thodologie pr\u00e9cise qui peut n\u00e9cessiter l'intervention d'un pr\u00e9leveur qualifi\u00e9 ou \u00e0 d\u00e9faut d'un pr\u00e9leveur propre \u00e0 la structure sous r\u00e9serve d'utilisation des m\u00e9thodes de standardisation du pr\u00e9l\u00e8vement (ex. : applicateur ou gabarit cf. Tableau I).Qualification des r\u00e9sultatsIl n'existe pas de valeurs normales attendues r\u00e9glementairement.", [["Tableau I", "PROTEIN", 836, 845], ["Lorsque la d\u00e9marche est en lien avec une autre technique (ex. : d\u00e9sinfection par voie a\u00e9rienne, changement du sch\u00e9ma d'entretien", "SPECIES", 0, 128], ["il sera propos\u00e9 de tester des surfaces", "TREATMENT", 136, 174], ["Elle est", "TEST", 269, 277], ["Qualification des r\u00e9sultatsIl", "TEST", 847, 876]]], ["Lors de la comparaison de techniques/produits : les r\u00e9sultats seront consid\u00e9r\u00e9s comme acceptables s'ils sont comparables ou meilleurs (moindre contamination) que ceux obtenus avec la technique ou le produit de r\u00e9f\u00e9rence.Visualisation de la contamination dans le cadre d'une d\u00e9marche p\u00e9dagogiqueLa d\u00e9marche p\u00e9dagogique consiste \u00e0 faire prendre conscience aux secouristes du risque infectieux potentiel, pour la victime et eux-m\u00eames, li\u00e9 \u00e0 une contamination des mains, ou encore, de l'environnement (surfaces, mat\u00e9riel, tenue, etc.).", [["pour la victime et eux", "TEST", 402, 424]]], ["Les pr\u00e9l\u00e8vements refl\u00e8teront alors l'exposition de la victime et des professionnels dans le VSAV \u00e0 diff\u00e9rents temps T. \u00c0 l'instar de l'objectif de validation d'une m\u00e9thode, l'\u00e9laboration d'une strat\u00e9gie de pr\u00e9l\u00e8vement reste la m\u00eame avec en plus l'identification et la tra\u00e7abilit\u00e9 des temps consid\u00e9r\u00e9s, la Tableau I. Synth\u00e8se des caract\u00e9ristiques des principaux types de contr\u00f4les de surface. le risque auquel sont expos\u00e9es les victimes prises en charge dans le VSAV (il est attendu que ces pr\u00e9l\u00e8vements soient peu contamin\u00e9s) ; la contamination li\u00e9es \u00e0 la prise en charge de la victime (ces pr\u00e9l\u00e8vements sont les plus contamin\u00e9s) ; et l'efficacit\u00e9 du nettoyage et la n\u00e9cessit\u00e9 de cibler certaines surfaces potentiellement contamin\u00e9es et oubli\u00e9es.", [["et la tra\u00e7abilit\u00e9 des temps consid\u00e9r\u00e9s", "TREATMENT", 262, 300], ["la Tableau I. Synth\u00e8se des caract\u00e9ristiques des", "TREATMENT", 302, 349], ["contamin\u00e9s", "TEST", 514, 524], ["la contamination", "TEST", 528, 544], ["la prise en charge de la victime (ces pr\u00e9l\u00e8vements sont les plus contamin\u00e9s", "TREATMENT", 553, 628], ["et l'efficacit\u00e9 du nettoyage", "TREATMENT", 632, 660]]], ["Il est \u00e9galement possible de coupler une strat\u00e9gie de pr\u00e9l\u00e8vement \u00e0 d'autres approches p\u00e9dagogiques telles que : Article original les audits de pratique qui sont chronophages, mais tr\u00e8s informatifs notamment sur la technique de r\u00e9alisation de l'entretien ; les techniques \u00ab fluo \u00bb qui sont de plus en plus souvent utilis\u00e9es dans un contexte p\u00e9dagogique tels que les \u00ab tutos fluo \u00bb disponibles sur YouTube montrant notamment une contamination des surfaces et des mains li\u00e9es au port de gants et illustr\u00e9e sur la Fig. 2 [7 -9] .", [["Il est \u00e9galement", "TREATMENT", 0, 16], ["une contamination des surfaces et des mains li\u00e9es au port", "TREATMENT", 424, 481]]], ["Ces approches combin\u00e9es permettent de minimiser les limites des pr\u00e9l\u00e8vements de surface.LIMITES DES PR\u00c9L\u00c8VEMENTS DE SURFACESChaque technique pr\u00e9sente des avantages et des limites propres (d\u00e9taill\u00e9es dans le Tableau I), mais d'une mani\u00e8re g\u00e9n\u00e9rale les contr\u00f4les pr\u00e9sentent des limites communes.", [["Ces", "TEST", 0, 3]]], ["Micro-organismes identifi\u00e9s : les pr\u00e9l\u00e8vements ciblent plus particuli\u00e8rement les bact\u00e9ries ou les champignons, la recherche d'autres agents infectieux (virus, ou parasites) doit quant \u00e0 elle faire l'objet d'une d\u00e9marche particuli\u00e8re pour laquelle la pertinence de l'indication est \u00e0 discuter.", [["Micro-organismes", "TEST", 0, 16], ["les pr\u00e9l\u00e8vements ciblent", "PROBLEM", 30, 54], ["la recherche d'autres agents", "TREATMENT", 111, 139]]], ["Au temps T et au niveau d'une surface S : les pr\u00e9l\u00e8vements m\u00eames s'ils sont r\u00e9alis\u00e9s dans les r\u00e8gles de l'art ne permettent pas d'avoir une vision parfaite.", [["Au temps", "CHEMICAL", 0, 8], ["Au", "CHEMICAL", 0, 2], ["Au temps", "TEST", 0, 8]]], ["En effet, ils ne permettent d'avoir un reflet de la situation au temps T de la r\u00e9alisation du pr\u00e9l\u00e8vement et uniquement pour la surface S ayant fait l'objet du pr\u00e9l\u00e8vement.", [["du pr\u00e9l\u00e8vement", "OBSERVATION", 157, 171]]], ["La capacit\u00e9 des diff\u00e9rentes techniques \u00e0 \u00ab d\u00e9crocher \u00bb des bact\u00e9ries sur des surfaces n'est jamais parfaite, et les diff\u00e9rentes techniques ne sont pas \u00e9quivalentes.", [["La capacit\u00e9 des diff\u00e9rentes techniques", "TREATMENT", 0, 38]]], ["Il est ainsi pr\u00e9conis\u00e9 de privil\u00e9gier la technique du pr\u00e9l\u00e8vement g\u00e9los\u00e9 chaque fois que possible.", [["Il est ainsi pr\u00e9conis\u00e9 de privil\u00e9gier la technique du pr\u00e9l\u00e8vement g\u00e9los\u00e9 chaque", "TREATMENT", 0, 79]]], ["Les analyses peuvent repr\u00e9senter un co\u00fbt qu'il convient de ne pas n\u00e9gliger.", [["Les analyses", "TEST", 0, 12]]], ["D\u00e9lai de r\u00e9sultat : hormis la technique d'ATPm\u00e9trie qui permet le rendu d'un r\u00e9sultat imm\u00e9diat, les techniques de cultures prennent plus ou moins de temps selon le type de r\u00e9sultats attendus.MA\u00ceTRISE DU RISQUE INFECTIEUX DANS LES VSAVSi la r\u00e9alisation de pr\u00e9l\u00e8vements d'environnement permet d'objectiver la contamination d'une surface S \u00e0 un temps T, le risque de contamination est quant \u00e0 lui permanent et n\u00e9cessite pour pr\u00e9venir tout risque d'infection, la mise en place syst\u00e9matique de mesures barri\u00e8re pour l'ensemble des personnes prises en charges.", [["d'infection", "DISEASE", 443, 454], ["hormis la technique", "TREATMENT", 20, 39], ["les techniques de cultures", "TEST", 96, 122], ["d'environnement", "TEST", 268, 283], ["permet", "TEST", 284, 290], ["la contamination", "TEST", 304, 320], ["temps", "TEST", 342, 347], ["lui permanent et n\u00e9cessite pour pr\u00e9venir", "TREATMENT", 390, 430], ["d'infection", "PROBLEM", 443, 454]]], ["Elle est assur\u00e9e par l'utilisation d'un produit hydro-alcoolique sur des mains propres et s\u00e8ches, selon une proc\u00e9dure permettant une d\u00e9sinfection de l'ensemble de la surface des mains ; port de gants.", [["et s\u00e8ches", "PROBLEM", 87, 96]]], ["Le port de gants n'est attendu que lorsqu'il existe un risque de contact avec des liquides biologiques (sang, urines, selles, etc.) ou avec les muqueuses de la victime ou lors de la manipulation d'objet piquant coupant ou tranchant.", [["Le port", "TREATMENT", 0, 7]]], ["D\u00e8s lors que les gants ne sont plus indiqu\u00e9s ils doivent \u00eatre \u00f4t\u00e9s et \u00e9limin\u00e9s.", [["D\u00e8s lors que les gants ne", "CHEMICAL", 0, 25]]], ["Cette pratique, non conforme aux bonnes pratiques de port de gants, occasionne une contamination \u00e9lev\u00e9e de l'environnement avec le risque de ne pas avoir un entretien suffisant (oubli de surfaces manipul\u00e9es) avant la prise en charge d'une autre victime et sont donc \u00e0 fort risque de transmission crois\u00e9e.", [["Cette pratique", "CHEMICAL", 0, 14], ["l'environnement avec le risque de ne pas avoir un entretien suffisant (oubli de surfaces manipul\u00e9es) avant la prise en charge d'une autre victime et sont donc \u00e0 fort risque de transmission crois\u00e9e", "SPECIES", 107, 303]]], ["Risque particulier : le port de gants est \u00e9galement attendu si une gale est suspect\u00e9e chez la victime prise en charge (prurit important au niveau des mains), dans ce cas-l\u00e0 les gants doivent \u00eatre port\u00e9s pour tous contacts avec la victime et les manches de la tenue professionnelle seront baiss\u00e9es.", [["Risque particulier : le port de gants est \u00e9galement attendu si une gale est suspect\u00e9e chez la victime prise en charge (prurit important au niveau des mains", "SPECIES", 0, 155], ["le port", "TREATMENT", 21, 28]]], ["Un lavage des mains \u00e0 l'eau et au savon devra \u00eatre r\u00e9alis\u00e9 apr\u00e8s le retrait des gants.", [["Un lavage des", "TREATMENT", 0, 13], ["lavage", "OBSERVATION", 3, 9]]], ["La pr\u00e9vention de la transmission par voie a\u00e9rienne est, quant \u00e0 elle, assur\u00e9e par le port de masque dont la nature d\u00e9pend des situations : port d'un masque chirurgical : le masque chirurgical, conforme \u00e0 la norme EN 14 683, doit \u00eatre port\u00e9 par toute personne (victimes comme secouristes) pr\u00e9sentant une toux.", [["le", "ANATOMY", 170, 172]]], ["Risques particuliers : certaines pathologies se transmettent via des gouttelettes et n\u00e9cessite le port d'un masque par les agents notamment en p\u00e9riode \u00e9pid\u00e9mique, il s'agit notamment de la grippe ou encore du SARS-CoV-2 ; port d'un masque FFP2 : le port de ces masques, conformes \u00e0 la norme EN 149, est attendu par les secouristes exclusivement, chaque fois qu'il existe un risque d'a\u00e9rosolisation (exemple : utilisation de l'aspirateur \u00e0 mucosit\u00e9).", [["certaines pathologies", "PROBLEM", 23, 44], ["des gouttelettes et n\u00e9cessite le port d'un masque par les agents", "TREATMENT", 65, 129], ["CoV", "TEST", 214, 217], ["port d'un masque FFP2", "TREATMENT", 222, 243], ["le port", "TREATMENT", 246, 253], ["est", "TEST", 299, 302]]], ["En cas de risque d'a\u00e9rosolisation il convient de compl\u00e9ter l'\u00e9quipement des agents par des lunettes de protection.", [["En cas de risque d'a\u00e9rosolisation il", "TREATMENT", 0, 36]]], ["Lors de la prise en charge d'une victime qui tousse, (quelle que soit l'origine de la toux, tuberculose ou autre pathologie infectieuse), le port d'un masque chirurgical par la victime permet une protection efficace.", [["le port d'un", "TREATMENT", 138, 150], ["chirurgical par la victime permet une protection efficace", "TREATMENT", 158, 215]]], ["Le port de masque (chirurgical ou FFP2) par les secouristes est particuli\u00e8rement important si la victime ne peut pas \u00eatre masqu\u00e9e.", [["Le port", "TREATMENT", 0, 7], ["chirurgical ou FFP2", "TREATMENT", 19, 38]]], ["Ces mesures, tr\u00e8s g\u00e9n\u00e9rales, permettent donc une ma\u00eetrise du risque infectieux quelle que soit la nature de l'agent infectieux (bact\u00e9rie, virus, etc.).", [["Ces mesures", "TEST", 0, 11]]], ["D'une mani\u00e8re g\u00e9n\u00e9rale, la ma\u00eetrise du risque infectieux implique un respect des mesures barri\u00e8res telles que l'hygi\u00e8ne des mains, le port de gants restreint aux indications o\u00f9 ils sont attendus et au port de masque dans les situations \u00e0 risque de projection.D\u00e9claration de liens d'int\u00e9r\u00eatsLes auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eats.", [["le port", "TREATMENT", 131, 138], ["et au port", "TREATMENT", 195, 205]]]], "1ce070b560682829a99046ba35ab613e0ae4963d": [["IntroductionLateral flow immunoassays (LFIA) offer a rapid point-of-care (POC) approach to novel coronavirus (SARS-CoV-2) antibody testing.", [["coronavirus", "ORGANISM", 97, 108], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 110, 120], ["IntroductionLateral flow immunoassays", "TEST", 0, 37], ["novel coronavirus", "TEST", 91, 108], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["antibody testing", "TEST", 122, 138]]], ["On a population level, by conducting seroprevalence surveys through widespread random sampling of the general public, and by adjusting for the sensitivity and specificity characteristics of the LFIA used, it is possible to estimate the levels of past infection with SARS-CoV-2 in the community (3) .IntroductionHowever, testing hundreds of thousands of people would be impractical if it required a blood sample to be drawn followed by processing in a laboratory.", [["blood sample", "ANATOMY", 398, 410], ["infection", "DISEASE", 251, 260], ["SARS", "DISEASE", 266, 270], ["CoV-2", "ORGANISM", 271, 276], ["people", "ORGANISM", 353, 359], ["blood", "ORGANISM_SUBSTANCE", 398, 403], ["people", "SPECIES", 353, 359], ["SARS-CoV", "SPECIES", 266, 274], ["seroprevalence surveys", "TEST", 37, 59], ["the sensitivity", "TEST", 139, 154], ["past infection", "PROBLEM", 246, 260], ["a blood sample", "TEST", 396, 410], ["infection", "OBSERVATION", 251, 260]]], ["One solution is to use self-sampling and selftesting in the home with participants reporting results to the researchers.", [["participants", "SPECIES", 70, 82], ["self-sampling", "TREATMENT", 23, 36]]], ["However, there is limited understanding of public acceptability and usability of these LFIAs in the home setting, as most are currently designed as POC tests performed by healthcare professionals.IntroductionSelf-sampling and self-testing are widely used in healthcare for monitoring, for example in diabetes management (4) , and for diagnostics, for example for HIV (5, 6) .", [["diabetes", "DISEASE", 300, 308], ["HIV", "SPECIES", 363, 366], ["HIV", "SPECIES", 363, 366], ["POC tests", "TEST", 148, 157], ["self-testing", "TEST", 226, 238], ["monitoring", "TEST", 273, 283], ["diabetes management", "TREATMENT", 300, 319], ["diagnostics", "TEST", 334, 345], ["HIV", "PROBLEM", 363, 366]]], ["There are many advantages in terms of uptake, cost, patient activation and scale (4, 6) , but also potential disadvantages in relation to validity, usability and practicality which should be explored (6, 7) .", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["many", "OBSERVATION_MODIFIER", 10, 14], ["advantages", "OBSERVATION", 15, 25]]], ["Usability research on HIV selftesting has generally found good acceptability, the devices easy to use and high validity in interpretation of self-reported test results (7) (8) (9) .", [["HIV", "ORGANISM", 22, 25], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 22, 25]]], ["However, these HIV test kits were designed for selfsampling and self-testing and went through several iterations before designs were appropriate for home use and therefore the same levels of acceptability and usability for home-based self-testing for SARS-CoV-2 antibody using LFIAs cannot be assumed.", [["SARS", "DISEASE", 251, 255], ["HIV", "ORGANISM", 15, 18], ["SARS-CoV-2", "ORGANISM", 251, 261], ["LFIAs", "SIMPLE_CHEMICAL", 277, 282], ["SARS-CoV-2 antibody", "PROTEIN", 251, 270], ["HIV", "SPECIES", 15, 18], ["SARS-CoV", "SPECIES", 251, 259], ["these HIV test kits", "TEST", 9, 28], ["selfsampling", "PROBLEM", 47, 59], ["self-testing", "TEST", 64, 76], ["SARS", "PROBLEM", 251, 255], ["CoV", "TEST", 256, 259]]], ["As part of the REal-time Assessment of Community Transmission (REACT) programme (10), we evaluated the acceptability and usability of LFIAs for use in large seroprevalence surveys of SARS-CoV-2 antibody in the community.IntroductionA c c e p t e d M a n u s c r i p t 5LFIAs usedWe evaluated two LFIAs with different usability characteristics from five LFIAs being validated in parallel in our laboratory-based study (11).", [["SARS", "DISEASE", 183, 187], ["SARS-CoV-2", "ORGANISM", 183, 193], ["SARS-CoV-2 antibody", "PROTEIN", 183, 202], ["t 5LFIAs", "DNA", 266, 274], ["SARS-CoV", "SPECIES", 183, 191], ["SARS", "TEST", 183, 187], ["CoV", "TEST", 188, 191], ["a n u s", "TEST", 250, 257], ["based study", "TEST", 405, 416]]], ["Both LFIAs required a blood sample from a finger-prick and produced a self-read test result after 10 or 15 minutes.", [["blood sample", "ANATOMY", 22, 34], ["finger", "ANATOMY", 42, 48], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["a blood sample", "TEST", 20, 34], ["a finger-prick", "TEST", 40, 54]]], ["LFIA1 (Guangzhou Wondfo Biotech Co Ltd) was a cassette-based system containing a \"control\" indicator line and a \"test\" indicator line (for detection of combined IgM and IgG antibodies).", [["IgM", "GENE_OR_GENE_PRODUCT", 161, 164], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 169, 183], ["LFIA1", "PROTEIN", 0, 5], ["IgM", "PROTEIN", 161, 164], ["IgG antibodies", "PROTEIN", 169, 183], ["a cassette-based system", "TREATMENT", 44, 67], ["a \"test", "TEST", 110, 117], ["combined IgM and IgG antibodies", "PROBLEM", 152, 183]]], ["LFIA2LFIAs used(Fortress Orient Gene Biotech Co Ltd) was a cassette-based system containing a \"control\" indicator line and separate indicator lines for IgM and IgG ( Figure 1 ).Study design and samplingIn early May 2020 we carried out rapid, iterative public involvement and a pilot usability study including an online forum with four discussion groups (n=37), a study of LFIA1 test use with volunteers (n=44) and a broader public sample (n=234), and a nested observation and interview study (n=25).", [["IgM", "GENE_OR_GENE_PRODUCT", 152, 155], ["IgG", "GENE_OR_GENE_PRODUCT", 160, 163], ["LFIA2LFIAs", "PROTEIN", 0, 10], ["IgM", "PROTEIN", 152, 155], ["IgG", "PROTEIN", 160, 163], ["a cassette-based system", "TREATMENT", 57, 80], ["a \"control\" indicator line", "TREATMENT", 92, 118], ["IgM", "TEST", 152, 155], ["Study design", "TEST", 177, 189], ["sampling", "TEST", 194, 202], ["rapid, iterative public involvement", "PROBLEM", 235, 270], ["a pilot usability study", "TEST", 275, 298], ["a study", "TEST", 361, 368], ["a broader public sample", "TEST", 414, 437], ["a nested observation", "TEST", 451, 471], ["interview study", "TEST", 476, 491]]], ["Further details on the methods, including how we recruited participants from our existing involvement networks, are available online (Supplement, S1).Study design and samplingThe test kits dispatched in the pilot study included one test cassette, one button-activated 28G lancet and a 2ml plastic pipette, alongside an instruction booklet also containing a weblink to an instructional video.", [["participants", "SPECIES", 59, 71], ["Study design", "TEST", 150, 162], ["sampling", "TEST", 167, 175], ["The test kits", "TEST", 175, 188], ["the pilot study", "TEST", 203, 218], ["a 2ml plastic pipette", "TREATMENT", 283, 304], ["an instruction booklet", "TREATMENT", 316, 338]]], ["Based on findings from the pilot study, for the larger population-based usability study, the lancet and pipette were replaced with two pressure-activated 23G (larger) lancets and a smaller 1ml plastic pipette, respectively.", [["the pilot study", "TEST", 23, 38], ["based usability study", "TEST", 66, 87], ["the lancet and pipette", "TREATMENT", 89, 111], ["two pressure-activated 23G (larger) lancets", "TREATMENT", 131, 174], ["a smaller 1ml plastic pipette", "TREATMENT", 179, 208]]], ["The design and language in the instructional booklet and video were changed and an alcohol wipe was also included in the kit.Study design and samplingA c c e p t e d M a n u s c r i p t 6 In late May 2020 we carried out a larger population-based usability study of a representative sample of the adult population (aged 18 years and over) in England.", [["alcohol", "CHEMICAL", 83, 90], ["alcohol", "CHEMICAL", 83, 90], ["alcohol", "SIMPLE_CHEMICAL", 83, 90], ["an alcohol wipe", "TREATMENT", 80, 95], ["Study design", "TEST", 125, 137], ["sampling", "TEST", 142, 150], ["a n u s", "TEST", 168, 175]]], ["We allowed up to four adults aged 18 and over in the household to register for the study.", [["the study", "TEST", 79, 88]]], ["Self-testing LFIA kits were then posted to each registered individual.", [["Self-testing LFIA kits", "TEST", 0, 22]]], ["On completion of the test, participants recorded their interpretation of the result as part of an online survey, with the option of uploading a photograph of the test result.", [["participants", "SPECIES", 27, 39], ["the test", "TEST", 17, 25], ["the test result", "TEST", 158, 173]]], ["Reminder letters were sent to participants who had not completed the online survey or uploaded a photograph within 10 days of test kits being dispatched.Study outcomesMetrics to evaluate usability and acceptability were based on the HIV self-testing literature (5, 6, 8) and were measured as the percentage of participants responding to specific closed questions in the online survey.", [["participants", "SPECIES", 30, 42], ["participants", "SPECIES", 310, 322], ["test kits", "TEST", 126, 135], ["Study outcomesMetrics", "TEST", 153, 174], ["the HIV self-testing literature", "TEST", 229, 260]]], ["The main outcome was usability of the LFIA kits.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This was defined as a participant's ability to complete the antibody test, and how easy or difficult it was to understand the instructions and complete each step in the process.", [["participant", "SPECIES", 22, 33], ["the antibody test", "TEST", 56, 73]]], ["Acceptability was measured in terms of people consenting to and using the provided self-test, and the proportion who reported they would be willing to repeat a self-administered finger-prick antibody test in the future.Data AnalysisAnalyses were conducted in Stata (version 15.0, StataCorp, Texas, USA).Data AnalysisData obtained from the questionnaires on acceptability and usability were summarised by counts and descriptive statistics, and comparisons were made between LFIA1 and LFIA2 using Pearson's chisquared test.Data AnalysisMultivariate regression was used to identify sociodemographic factors independently associated with the proportion of participants conducting the test that achieved a valid result.", [["people", "ORGANISM", 39, 45], ["finger-prick antibody", "PROTEIN", 178, 199], ["LFIA1", "DNA", 473, 478], ["LFIA2", "DNA", 483, 488], ["people", "SPECIES", 39, 45], ["participants", "SPECIES", 652, 664], ["finger-prick antibody test", "TEST", 178, 204], ["Data AnalysisAnalyses", "TEST", 219, 240], ["Data AnalysisData", "TEST", 303, 320], ["Pearson's chisquared test", "TEST", 495, 520], ["the test", "TEST", 676, 684]]], ["Variables that appeared to be associated (p<0.05) in the unadjusted analyses were considered in the adjusted analyses.", [["the unadjusted analyses", "TEST", 53, 76]]], ["Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were estimated.", [["CI", "TEST", 57, 59]]], ["Associations with a p-value <0.05 in the adjusted analyses were considered statistically significant.Data AnalysisAgreement between participant-interpreted and clinician-interpreted result for test outcomes (negative, IgG positive, invalid, unable to read) was assessed using the Fleiss Kappa statistic.", [["IgG", "PROTEIN", 218, 221], ["a p-value", "TEST", 18, 27], ["the adjusted analyses", "TEST", 37, 58], ["test outcomes", "TEST", 193, 206], ["IgG", "TEST", 218, 221]]], ["A c c e p t e d M a n u s c r i p t 8 (11).", [["t 8", "DNA", 34, 37], ["a n u s", "TEST", 18, 25]]], ["Therefore, we used the same operational definition of positivity for LFIA2.", [["LFIA2", "GENE_OR_GENE_PRODUCT", 69, 74], ["LFIA2", "PROTEIN", 69, 74], ["LFIA2", "TEST", 69, 74]]], ["Participants were informed in the instructions to consider IgM results as negative.EthicsThe study obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787).ResultsOverall, 315 members of the public contributed feedback during the involvement and pilot.", [["IgM", "GENE_OR_GENE_PRODUCT", 59, 62], ["IgM", "PROTEIN", 59, 62], ["Participants", "SPECIES", 0, 12], ["IgM", "TEST", 59, 62]]], ["This led to changes in the design and language used in the instructional video and booklet, the type and number of lancets and the size of pipette in the LFIA kits (further details available online, Supplement S1).ResultsFor the national study, 25,000 household invitation letters were sent, and 17,411 individuals registered for the study from 8,508 households.", [["lancets", "TREATMENT", 115, 122], ["the national study", "TEST", 225, 243], ["the study", "TEST", 330, 339], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["Due to the maximum number of kits we had available for the study, 14,400 participants were selected at random from those who registered.ResultsThus, 10,600 LFIA1 kits were distributed, with 8,754 individual user surveys completed (82.6% response rate), and 3,800 LFIA2 kits were distributed, with 2,957 individual user surveys completed (77.8% response rate).", [["participants", "ORGANISM", 73, 85], ["participants", "SPECIES", 73, 85], ["the study", "TEST", 55, 64], ["LFIA1 kits", "TEST", 156, 166], ["response rate", "TEST", 237, 250], ["LFIA2 kits", "TEST", 263, 273], ["response rate", "TEST", 344, 357]]], ["Baseline characteristics of study participants are shown in Table 1 .", [["participants", "SPECIES", 34, 46]]], ["The median age of participants across LFIA1 and LFIA2 was 51.0 years (range 18 to 95).", [["participants", "ORGANISM", 18, 30], ["participants", "SPECIES", 18, 30]]], ["There were some differences between LFIA1 and LFIA2 participants by ethnicity, region and household size.AcceptabilityAcceptability of self-testing was high ( A c c e p t e d M a n u s c r i p t 9 As in the pilot, most respondents were willing to perform another finger-prick antibody test in the future (LFIA1: 98.3%; LFIA2: 97.0%).", [["participants", "SPECIES", 52, 64], ["self-testing", "TEST", 135, 147], ["a n u s", "TEST", 177, 184], ["finger-prick antibody test", "TEST", 263, 289], ["LFIA1", "TEST", 305, 310], ["LFIA2", "TEST", 319, 324], ["size", "OBSERVATION_MODIFIER", 100, 104]]], ["Only a minority preferred to do the antibody test in a clinical care or community setting than at home.", [["the antibody test", "TEST", 32, 49]]], ["As with the pilot study, respondents with children showed a high willingness to perform the antibody test on them, and this proportion increased with the age of the children (Table 2) .UsabilityIn the pilot study most people (86.5%, 225/260) who attempted the test managed to complete it.UsabilityHowever, significant usability issues were identified, including challenges with the lancet to obtain a blood drop and the pipette to transfer the blood to the sample well.", [["blood", "ANATOMY", 401, 406], ["blood", "ANATOMY", 444, 449], ["sample", "ANATOMY", 457, 463], ["children", "ORGANISM", 42, 50], ["children", "ORGANISM", 165, 173], ["people", "ORGANISM", 218, 224], ["blood", "ORGANISM_SUBSTANCE", 401, 406], ["blood", "ORGANISM_SUBSTANCE", 444, 449], ["children", "SPECIES", 42, 50], ["children", "SPECIES", 165, 173], ["people", "SPECIES", 218, 224], ["the pilot study", "TEST", 8, 23], ["the antibody test", "TEST", 88, 105], ["the pilot study", "TEST", 197, 212], ["the test", "TEST", 256, 264], ["significant usability issues", "PROBLEM", 306, 334], ["a blood drop", "TEST", 399, 411], ["significant", "OBSERVATION_MODIFIER", 306, 317], ["usability", "OBSERVATION", 318, 327]]], ["The problems with the lancet led to some participants using alternative objects to draw blood, including pins and sewing needles, while others opened the lancet casing to access the blade.", [["blood", "ANATOMY", 88, 93], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["participants", "SPECIES", 41, 53], ["blood", "TEST", 88, 93], ["pins and sewing needles", "TREATMENT", 105, 128], ["the lancet casing", "TREATMENT", 150, 167]]], ["Some people reported minor problems putting buffer into the buffer well.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["minor", "OBSERVATION_MODIFIER", 21, 26], ["problems", "OBSERVATION", 27, 35]]], ["This led to the inclusion of two lancets and changes to the instructions for the national study.UsabilityIn the national study, almost all participants who attempted the antibody test reported completing it (97.5% for LFIA1 and 97.8% for LFIA2) ( Table 2) .", [["participants", "ORGANISM", 139, 151], ["participants", "SPECIES", 139, 151], ["two lancets", "TREATMENT", 29, 40], ["the national study", "TEST", 77, 95], ["the national study", "TEST", 108, 126], ["the antibody test", "TEST", 166, 183], ["LFIA1", "TEST", 218, 223]]], ["Reasons for not completing the test are shown in the table.", [["the test", "TEST", 27, 35]]], ["Of LFIA1 participants who reported damaging the test, the majority reported either accidentally removing the entire lid off the buffer bottle and spilling the solution all over the test cassette or putting the blood and buffer in the wrong well.", [["blood", "ANATOMY", 210, 215], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["participants", "SPECIES", 9, 21], ["the buffer bottle", "TREATMENT", 124, 141], ["the blood and buffer", "TREATMENT", 206, 226]]], ["For LFIA2, few participants damaged the test and they all reported putting the blood and buffer in the wrong well.UsabilityAbout one in four participants asked someone to help them to administer the test.", [["blood", "ANATOMY", 79, 84], ["participants", "ORGANISM", 15, 27], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["participants", "SPECIES", 15, 27], ["participants", "SPECIES", 141, 153], ["the test", "TEST", 36, 44], ["the blood and buffer", "TREATMENT", 75, 95], ["the test", "TEST", 195, 203]]], ["Most found the instructions easy to understand (Figures 3), but as in the pilot, participants reported some difficulties in performing the test.", [["participants", "SPECIES", 81, 93], ["some difficulties", "PROBLEM", 103, 120], ["the test", "TEST", 135, 143]]], ["For LFIA1, difficulties with using the pipette were reported by 17.7%Usability(1,512/8,521) of participants.", [["participants", "SPECIES", 95, 107], ["LFIA1", "PROBLEM", 4, 9], ["the pipette", "TREATMENT", 35, 46]]], ["In addition, 10.6% (908/8,556) had difficulties applying the blood to A c c e p t e d M a n u s c r i p t 10 the sample well ( Figure 3 ).", [["blood", "ANATOMY", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["the blood", "TEST", 57, 66], ["a n u s", "TEST", 88, 95], ["the sample", "TEST", 109, 119]]], ["Therefore, for LFIA2 the instructions were changed to omit the use of the pipette and instead directly transfer blood from the finger-prick site to the sample well.", [["blood", "ANATOMY", 112, 117], ["sample", "ANATOMY", 152, 158], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["LFIA2", "PROTEIN", 15, 20], ["finger-prick site", "DNA", 127, 144], ["LFIA2", "TREATMENT", 15, 20], ["the pipette", "TREATMENT", 70, 81], ["finger", "ANATOMY", 127, 133]]], ["However, participants still found creating a blood drop from the finger-prick site (23.2%; 664/2,862) and then applying the blood to the well (31.3%; 894/2,858) difficult.", [["blood", "ANATOMY", 45, 50], ["blood", "ANATOMY", 124, 129], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["participants", "SPECIES", 9, 21], ["a blood drop", "PROBLEM", 43, 55], ["finger", "ANATOMY", 65, 71]]], ["LFIA2 was deployed after LFIA1 because there was a delay in arrival of LFIA2 from the supplier.", [["LFIA2", "GENE_OR_GENE_PRODUCT", 0, 5], ["LFIA2", "GENE_OR_GENE_PRODUCT", 71, 76], ["LFIA2", "PROTEIN", 0, 5], ["LFIA2", "PROTEIN", 71, 76]]], ["Overall, 7.4% of LFIA1 and 4.8% of LFIA2 participants reported an invalid result (Table 3 ).", [["LFIA1", "CANCER", 17, 22], ["participants", "SPECIES", 41, 53], ["Overall", "TEST", 0, 7], ["LFIA1", "TEST", 17, 22]]], ["There was some variation in the proportion of participant-reported invalid results using LFIA1 by age and gender.", [["LFIA1", "PROTEIN", 89, 94], ["some variation", "PROBLEM", 10, 24], ["variation", "OBSERVATION_MODIFIER", 15, 24]]], ["The higher the number of participants registered for the study in the same household, the lower the odds of the participant reporting an invalid result.", [["participants", "SPECIES", 25, 37], ["participant", "SPECIES", 112, 123], ["the study", "TEST", 53, 62], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["No sociodemographic factors were associated with a participant-reported invalid result using LFIA2 (Table 4 ).UsabilityAfter adjusting for sociodemographic differences between LFIA1 and LFIA2 participants, there was no difference between LFIA1 and LFIA2 in terms of being able to read the result (1.1% vs. 0.81%; aOR 0.76 (95% CI: 0.48-1.2); p 0.24).", [["participant", "SPECIES", 51, 62], ["participants", "SPECIES", 192, 204], ["sociodemographic factors", "PROBLEM", 3, 27], ["aOR", "TEST", 313, 316], ["CI", "TEST", 327, 329]]], ["But a lower percentage of invalid test results were reported by LFIA2 participants (7.9% vs. 4.8%; aOR 0.64 (95% CI: 0.53-0.77); p <0.001).", [["participants", "SPECIES", 70, 82], ["aOR", "TEST", 99, 102], ["CI", "TEST", 113, 115]]], ["Table 5 shows concordance between participant and clinician interpreted results in the national study.", [["the national study", "TEST", 83, 101]]], ["For LFIA1, there was substantial agreement overall (kappa 0.72 (95% CI: 0.71-0.73); p<0.001), however there were important differences: while there was 100.0% agreement for results reported as negative, and 98.5% agreement for invalid results, a clinician confirmed only 62.8% of participantreported positives.", [["LFIA1", "PROTEIN", 4, 9], ["kappa", "TEST", 52, 57], ["CI", "TEST", 68, 70]]], ["Visible reasons (from the photograph) were insufficient blood volume to cover the bottom of the sample well, or insufficient movement of the blood and buffer solution across the result window.", [["blood", "ANATOMY", 56, 61], ["sample", "ANATOMY", 96, 102], ["blood", "ANATOMY", 141, 146], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["insufficient blood volume", "PROBLEM", 43, 68], ["the blood and buffer solution", "TREATMENT", 137, 166]]], ["In addition, the clinician was able to interpret the results of all but four out of 66 A c c e p t e d M a n u s c r i p t 11 (6.1%) tests from the photographs of results participants reported as \"unable to read\".", [["participants", "SPECIES", 171, 183], ["a n u s", "TEST", 105, 112], ["t", "TEST", 121, 122], ["tests", "TEST", 133, 138], ["the photographs", "TEST", 144, 159]]], ["The four results unreadable by the clinician were because blood had leaked out of the sample well and obscured the result window.", [["blood", "ANATOMY", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["blood", "PROBLEM", 58, 63]]], ["Of participant-reported unable to read results, 78.8% were clinicianinterpreted as invalid (for all these tests, the control and \"test\" lines were both absent).", [["participant", "SPECIES", 3, 14], ["all these tests", "TEST", 96, 111], ["the control", "TREATMENT", 113, 124], ["\"test\" lines", "TREATMENT", 129, 141]]], ["The clinician could not interpret the results from 10 photographs reported as readable results by participants, reasons included blurred photographs and shadowing obscuring the indicator lines.DiscussionOverall, we found that self-testing with the two LFIA kit designs used in this study was highly acceptable among adults living in England.", [["adults", "ORGANISM", 316, 322], ["participants", "SPECIES", 98, 110], ["blurred photographs", "PROBLEM", 129, 148], ["shadowing obscuring the indicator lines", "PROBLEM", 153, 192], ["self-testing", "TEST", 226, 238], ["the two LFIA kit designs", "TREATMENT", 244, 268], ["this study", "TEST", 277, 287], ["indicator lines", "OBSERVATION", 177, 192]]], ["High acceptability of in home self-testing is in keeping with self-sampling and self-testing studies in diabetes management (4), and HIV diagnostics (5, 6) .DiscussionThe majority of participants who attempted the test successfully completed it despite some continued difficulties with using the pipette (LFIA1), creating a drop of blood from the finger-prick site (LFIA2) and applying the blood to the sample well (LFIA1 and LFIA2).", [["blood", "ANATOMY", 332, 337], ["blood", "ANATOMY", 390, 395], ["sample", "ANATOMY", 403, 409], ["diabetes", "DISEASE", 104, 112], ["participants", "ORGANISM", 183, 195], ["blood", "ORGANISM_SUBSTANCE", 332, 337], ["finger", "ORGANISM_SUBDIVISION", 347, 353], ["blood", "ORGANISM_SUBSTANCE", 390, 395], ["finger-prick site", "PROTEIN", 347, 364], ["participants", "SPECIES", 183, 195], ["HIV", "SPECIES", 133, 136], ["self-testing studies", "TEST", 80, 100], ["diabetes management", "TREATMENT", 104, 123], ["HIV diagnostics", "TEST", 133, 148], ["the test", "TEST", 210, 218], ["the pipette (LFIA1", "TREATMENT", 292, 310], ["a drop of blood", "PROBLEM", 322, 337], ["finger", "ANATOMY", 347, 353]]], ["Based on these findings, we proportion of invalid tests for LFIA2 could reflect the better designed buffer bottle (which was a significant issue for LFIA1), better performance characteristics of LFIA2 over LFIA1 (e.g. easier movement of the blood and buffer solution across the result window), or improved ability to get sufficient blood in the sample well using the direct blood transfer technique over using a pipette.DiscussionParticipants' ability to obtain a valid test result using LFIA1 varied marginally by age and gender and increased with the number of participants registered for the study in the same household.", [["blood", "ANATOMY", 241, 246], ["blood", "ANATOMY", 332, 337], ["sample", "ANATOMY", 345, 351], ["blood", "ANATOMY", 374, 379], ["LFIA2", "SIMPLE_CHEMICAL", 60, 65], ["LFIA2", "SIMPLE_CHEMICAL", 195, 200], ["blood", "ORGANISM_SUBSTANCE", 241, 246], ["blood", "ORGANISM_SUBSTANCE", 332, 337], ["blood", "ORGANISM_SUBSTANCE", 374, 379], ["LFIA2", "PROTEIN", 60, 65], ["LFIA1", "PROTEIN", 488, 493], ["participants", "SPECIES", 563, 575], ["invalid tests", "TEST", 42, 55], ["LFIA2", "TREATMENT", 60, 65], ["the blood and buffer solution", "TREATMENT", 237, 266], ["the direct blood transfer technique", "TREATMENT", 363, 398], ["a pipette", "TREATMENT", 410, 419], ["a valid test", "TEST", 462, 474], ["the study", "TEST", 591, 600], ["increased", "OBSERVATION_MODIFIER", 534, 543]]], ["The latter observation is not surprising as observing another household member performing the test is likely to improve the performance of others in the same household.", [["the test", "TEST", 90, 98]]], ["No sociodemographic differences in obtaining a valid result were found for LFIA2.DiscussionOf note, about one in four participants reported that they had help administering the test, irrespective of LFIA used.", [["LFIA2", "PROTEIN", 75, 80], ["participants", "SPECIES", 118, 130], ["a valid result", "TEST", 45, 59], ["LFIA2", "PROBLEM", 75, 80], ["the test", "TEST", 173, 181]]], ["However, comparing those that had help to those that did not, we found no difference in ability to complete the test (97.7% vs. 98.2%; p 0.08) or reported invalid results (6.1% vs. 7.0%; p 0.06).DiscussionOverall, there was good agreement between self-reported results and those reported by a clinician.DiscussionTherefore, our findings broadly support self-reporting of home-based test results using LFIAs.", [["the test", "TEST", 108, 116], ["p", "TEST", 135, 136], ["p", "TEST", 187, 188]]], ["But the public and individual health impact of misinterpreting a test result that is negative but read as positive is a concern as an individual could falsely conclude that they have antibodies for SARS-CoV-2 and may change their behaviour as a result.", [["SARS", "DISEASE", 198, 202], ["SARS-CoV-2", "ORGANISM", 198, 208], ["antibodies", "PROTEIN", 183, 193], ["SARS-CoV", "SPECIES", 198, 206], ["a test result", "TEST", 63, 76], ["antibodies", "TEST", 183, 193], ["SARS", "PROBLEM", 198, 202], ["CoV", "TEST", 203, 206]]], ["To mitigate against this, and given the scientific Our study is original because focusing on the acceptability and usability of LFIAs for self-testing for SARS-CoV-2 antibody in a home-based setting has not been done at such scale in the general population.", [["SARS", "DISEASE", 155, 159], ["SARS-CoV-2", "ORGANISM", 155, 165], ["SARS-CoV-2 antibody", "PROTEIN", 155, 174], ["SARS-CoV", "SPECIES", 155, 163], ["Our study", "TEST", 51, 60], ["LFIAs", "TEST", 128, 133], ["self-testing", "TEST", 138, 150], ["SARS", "TEST", 155, 159], ["CoV", "TEST", 160, 163]]], ["It provides an attractive solution for conducting large seroprevalence surveys.", [["an attractive solution", "TREATMENT", 12, 34]]], ["The study has, however, some limitations.", [["The study", "TEST", 0, 9]]], ["Study participants may not be representative of the general adult population of England.", [["participants", "SPECIES", 6, 18], ["may not be", "UNCERTAINTY", 19, 29]]], ["However, we had data on the England population profile (2011 census data (13)), as well as the study registration profile and survey completion profile of the study participants which gave us an indication of response bias.", [["participants", "SPECIES", 165, 177], ["the study registration profile", "TEST", 91, 121], ["the study", "TEST", 155, 164], ["response bias", "PROBLEM", 209, 222], ["response bias", "OBSERVATION", 209, 222]]], ["Our sample was broadly similar to the England population profile.", [["Our sample", "TEST", 0, 10]]], ["In addition, the usability study was conducted in parallel with our laboratorybased study of performance characteristics of LFIAs.", [["the usability study", "TEST", 13, 32], ["our laboratorybased study", "TEST", 64, 89], ["LFIAs", "PROBLEM", 124, 129]]], ["As such, we did not know the accuracy of the LFIAs chosen for the usability study at the time, or whether either would perform well enough in the laboratory to be considered for the large national seroprevalence study planned as part of the REACT programme (10).", [["the usability study", "TEST", 62, 81], ["the large national seroprevalence study", "TEST", 178, 217]]], ["However, given that the majority of commercially available LFIAs have a similar cassette-based design and test result read out to LFIA1 or LFIA2 we were confident that our results would be generalisable and applicable to whichever LFIA was finally selected.", [["LFIAs", "CANCER", 59, 64], ["LFIA", "CANCER", 231, 235], ["LFIA1", "DNA", 130, 135], ["LFIA2", "DNA", 139, 144], ["test result", "TEST", 106, 117]]], ["Findings from our laboratory-based study, including the performance characteristics of LFIA1 and LFIA2 are forthcoming (11).ConclusionsOverall, our study has demonstrated that home-based self-testing LFIAs for use in large communitybased seroprevalence surveys of SARS-CoV-2 antibody are both acceptable and feasible.", [["SARS", "DISEASE", 264, 268], ["LFIA1", "GENE_OR_GENE_PRODUCT", 87, 92], ["SARS-CoV-2", "ORGANISM", 264, 274], ["LFIA1", "DNA", 87, 92], ["LFIA2", "DNA", 97, 102], ["SARS-CoV-2 antibody", "PROTEIN", 264, 283], ["SARS-CoV", "SPECIES", 264, 272], ["our laboratory", "TEST", 14, 28], ["based study", "TEST", 29, 40], ["our study", "TEST", 144, 153], ["SARS", "TEST", 264, 268], ["CoV-2 antibody", "TEST", 269, 283]]], ["Although this study identified a few usability issues, these have now been addressed.", [["this study", "TEST", 9, 19], ["a few usability issues", "PROBLEM", 31, 53], ["few", "OBSERVATION_MODIFIER", 33, 36]]], ["LFIA2, Fortress Orient Gene, has been selected for a large national seroprevalence study as part of the REACT programme.ConclusionsThis decision was based on criteria including the usability and acceptability determined in this study, A c c e p t e d M a n u s c r i p t 21 years where asked whether they would carry out the test on children of that age living in their households.", [["children", "ORGANISM", 333, 341], ["LFIA2", "DNA", 0, 5], ["Fortress Orient Gene", "DNA", 7, 27], ["children", "SPECIES", 333, 341], ["a large national seroprevalence study", "TEST", 51, 88], ["this study", "TEST", 223, 233]]], ["Denominator is th e number of participants who reported having children of that age living in their household.", [["children", "ORGANISM", 63, 71], ["participants", "SPECIES", 30, 42], ["children", "SPECIES", 63, 71]]]], "PMC7299103": [["Acute cervical spinal cord injury (SCI) is a severe, life-threatening condition causing functional impairments and affects multiple body systems including the respiratory system.1 Coronavirus disease 2019 (COVID-19) resulting from severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) infection, which is currently pandemic, also causes severe respiratory problems2.", [["cervical spinal cord", "ANATOMY", 6, 26], ["body", "ANATOMY", 132, 136], ["respiratory system", "ANATOMY", 159, 177], ["respiratory", "ANATOMY", 350, 361], ["cervical spinal cord injury", "DISEASE", 6, 33], ["SCI", "DISEASE", 35, 38], ["functional impairments", "DISEASE", 88, 110], ["Coronavirus disease", "DISEASE", 180, 199], ["COVID-19", "CHEMICAL", 206, 214], ["acute respiratory syndrome coronavirus", "DISEASE", 238, 276], ["infection", "DISEASE", 291, 300], ["respiratory problems2", "DISEASE", 350, 371], ["cervical spinal cord", "MULTI-TISSUE_STRUCTURE", 6, 26], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 231, 278], ["SAR-CoV-2", "ORGANISM", 280, 289], ["CoV-2", "SPECIES", 284, 289], ["severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2", "SPECIES", 231, 289], ["Acute cervical spinal cord injury", "PROBLEM", 0, 33], ["a severe, life-threatening condition", "PROBLEM", 43, 79], ["functional impairments", "PROBLEM", 88, 110], ["multiple body systems", "PROBLEM", 123, 144], ["1 Coronavirus disease", "PROBLEM", 178, 199], ["COVID", "TEST", 206, 211], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 231, 276], ["infection", "PROBLEM", 291, 300], ["severe respiratory problems2", "PROBLEM", 343, 371], ["cervical", "ANATOMY_MODIFIER", 6, 14], ["spinal cord", "ANATOMY", 15, 26], ["injury", "OBSERVATION", 27, 33], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["respiratory system", "ANATOMY", 159, 177], ["Coronavirus disease", "OBSERVATION", 180, 199], ["severe", "OBSERVATION_MODIFIER", 231, 237], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["respiratory syndrome", "OBSERVATION", 244, 264], ["infection", "OBSERVATION", 291, 300], ["severe", "OBSERVATION_MODIFIER", 343, 349], ["respiratory problems2", "OBSERVATION", 350, 371]]], ["In this case report, we present a patient who had these two devastating health conditions concurrently, resulting in catastrophic consequences to both the patient and related healthcare staff.", [["patient", "ORGANISM", 34, 41], ["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 34, 41], ["patient", "SPECIES", 155, 162], ["catastrophic consequences", "PROBLEM", 117, 142]]]], "bf59c4a430b86090ae777db7047388ddec9aa13d": [["1 One ordinary workday while waiting on a notoriously slow copy machine, I realized that \"my\" line \"If you're ready, I am ready\" was playing in my head.", [["head", "ANATOMY", 147, 151], ["head", "ORGANISM_SUBDIVISION", 147, 151], ["head", "ANATOMY", 147, 151]]], ["I was struck by hearing the words as descriptive of what's at stake in relationships where partners fail each other, where people get wounded, and where possibilities for transformation could lead to change in future relationships.", [["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129], ["transformation", "PROBLEM", 171, 185]]]], "7e2b72aea9e9c8acefc493e40012c482e139c4dc": [["INTRODUCTIONStrategies to combat the ongoing COVID-19 pandemic vary greatly.", [["the ongoing COVID", "TEST", 33, 50]]], ["A proposal briefly floated in the United Kingdom involved an early transition from containment to mitigation.", [["early transition", "OBSERVATION", 61, 77]]], ["1 Serious concerns have been expressed regarding this approach, citing the potential catastrophic loss of lives.", [["this approach", "TREATMENT", 49, 62], ["catastrophic", "OBSERVATION_MODIFIER", 85, 97], ["loss", "OBSERVATION", 98, 102]]], ["Many countries such as China have imposed drastic measures such as strict travel bans and the complete lockdown of entire cities.", [["drastic measures", "TREATMENT", 42, 58]]], ["2, 3 These strategies are not sustainable in the long term due to its highly deleterious impact on the economy and livelihoods.", [["highly", "OBSERVATION_MODIFIER", 70, 76], ["deleterious", "OBSERVATION", 77, 88]]], ["4, 5 This calls for a complementary solution as countries seek to lift their lockdown measures.INTRODUCTIONSingapore has received significant attention with regard to its crisis management approach to the ongoing COVID-19 outbreak and is regarded as the \"gold standard\" by international researchers in a recent study.", [["a complementary solution", "TREATMENT", 20, 44], ["its crisis management", "TREATMENT", 167, 188], ["the ongoing COVID", "TEST", 201, 218], ["a recent study", "TEST", 302, 316]]], ["7 On January 28, 2020, the Ministry of Health decided to activate the National Centre for Infectious Diseases Screening Centre.", [["Infectious Diseases", "DISEASE", 90, 109]]], ["On January 31, 2020, the country's designated screening centre was fully operational.INTRODUCTIONThe screening centre is housed in National Centre for Infectious Diseases, adjacent to its partnering hospital, Tan Tock Seng Hospital.", [["Infectious Diseases", "DISEASE", 151, 170], ["Infectious Diseases", "PROBLEM", 151, 170], ["Infectious", "OBSERVATION", 151, 161]]], ["As the national screening centre, it receives patients referred from primary health care clinics nationwide, walk-ins, immigration checkpoints, home quarantine, and Government Quarantine Facilities.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["The screening centre is operational round the clock and is run by the Tan Tock Seng Hospital Emergency Department (ED), in collaboration with NationalINTRODUCTIONCentre for Infectious Diseases's Infectious Diseases Department.", [["Infectious Diseases", "DISEASE", 173, 192], ["Infectious Diseases", "DISEASE", 195, 214]]], ["As of 8 April 2020, the screening centre had screened more than 14,000 patients, with daily attendances ranging from 50-500 patients.INTRODUCTIONThis paper aims to describe our experiences in running the screening centre including the pre-outbreak preparatory phase, infrastructure planning to facilitate patient flow, and coordinating a \"whole-ofhospital\" approach to support our wide-net surveillance efforts.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 124, 132], ["patient", "ORGANISM", 305, 312], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 124, 132], ["patient", "SPECIES", 305, 312], ["infrastructure planning", "TREATMENT", 267, 290], ["a \"whole-ofhospital\" approach", "TREATMENT", 336, 365]]], ["We will discuss the challenges encountered in the course of operations and solutions used.LESSONS FROM SARSThe Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) outbreak in 2003 had previously been considered as the biggest health care crisis in Singapore.", [["Acute Respiratory Syndrome coronavirus", "DISEASE", 118, 156], ["SARS-CoV) outbreak", "DISEASE", 158, 176], ["SARS-CoV", "ORGANISM", 158, 166], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 111, 156], ["SARS-CoV", "SPECIES", 158, 166], ["operations and solutions", "TREATMENT", 60, 84], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 111, 156], ["Severe", "OBSERVATION_MODIFIER", 111, 117], ["Acute", "OBSERVATION_MODIFIER", 118, 123], ["Respiratory Syndrome coronavirus", "OBSERVATION", 124, 156]]], ["A total of 238 probable SARS cases were identified, with 33 reported deaths (14% case fatality rate).", [["SARS", "DISEASE", 24, 28], ["deaths", "DISEASE", 69, 75], ["SARS cases", "PROBLEM", 24, 34], ["fatality rate", "TEST", 86, 99]]], ["A total of 97 (41%) health care workers were also infected over the course of the outbreak.", [["total", "OBSERVATION_MODIFIER", 2, 7], ["infected", "OBSERVATION", 50, 58]]], ["8 The valuable insights gained from tackling the SARS crisis have been factored heavily into our evolved response for future emerging infectious diseases.", [["SARS", "DISEASE", 49, 53], ["infectious diseases", "DISEASE", 134, 153], ["the SARS crisis", "PROBLEM", 45, 60], ["emerging infectious diseases", "PROBLEM", 125, 153], ["infectious", "OBSERVATION", 134, 144]]], ["This includes the importance of a widenet surveillance strategy, early identification and isolation of confirmed cases, preventing nosocomial transmission, and occupational exposure as summarized in a previous review.", [["a widenet surveillance strategy", "TREATMENT", 32, 63]]], ["9 However, the screening centre team is cognizant that although it is important to incorporate these lessons, it is just as important to pay attention to the unique dif-ferences of COVID-19, particularly its increased transmissibility, 10, 11 albeit decreased fatality rates.PURPOSE-BUILT INFRASTRUCTURE TO FACILITATE PATIENT FLOWOne of the key lessons from combating the SARS and the 2009 H1N1 outbreaks is recognizing the need for a facility dedicated to the containment of infectious disease outbreaks.", [["SARS", "DISEASE", 372, 376], ["H1N1", "DISEASE", 390, 394], ["infectious disease outbreaks", "DISEASE", 476, 504], ["COVID", "TEST", 181, 186], ["the SARS", "PROBLEM", 368, 376], ["infectious disease outbreaks", "PROBLEM", 476, 504], ["infectious", "OBSERVATION", 476, 486]]], ["The National Centre for Infectious Diseases was built and conceptualized for this purpose.", [["Infectious Diseases", "DISEASE", 24, 43], ["Infectious Diseases", "PROBLEM", 24, 43], ["Infectious", "OBSERVATION", 24, 34]]], ["It is a 330-bed facility with 5 negative pressure wards and 2 intensive care wards.", [["5 negative pressure wards", "TREATMENT", 30, 55]]], ["12 The National Centre for Infectious Diseases also houses a large screening centre that is used for small, medium, and large scale outbreaks and the National Public Health Laboratory equipped with a biosafety-level 3 containment facility.PURPOSE-BUILT INFRASTRUCTURE TO FACILITATE PATIENT FLOWThe screening centre has a capacity for 22 trolley beds and 99 ambulatory patients when chairs are spaced 2 metres apart.", [["Infectious Diseases", "DISEASE", 27, 46], ["patients", "ORGANISM", 368, 376], ["patients", "SPECIES", 368, 376], ["small, medium, and large scale outbreaks", "PROBLEM", 101, 141], ["PATIENT FLOW", "TEST", 282, 294], ["large", "OBSERVATION_MODIFIER", 120, 125]]], ["Seating capacity can be increased to 181 when chairs are spaced 1.5 metres apart instead.", [["Seating capacity", "PROBLEM", 0, 16]]], ["This is in line with local and international guidelines on droplet precautions.", [["droplet precautions", "TREATMENT", 59, 78]]], ["13-15 It is further divided into 2 areas: a High Risk wing and a Low Risk wing ( Figure 1 ).PURPOSE-BUILT INFRASTRUCTURE TO FACILITATE PATIENT FLOWThe screening centre is located in the Central Region of Singapore, 16 providing easy access to members of the public for screening.", [["a High Risk wing", "PROBLEM", 42, 58], ["PATIENT FLOW", "TEST", 135, 147], ["screening", "TEST", 269, 278], ["High Risk", "OBSERVATION_MODIFIER", 44, 53], ["Central", "ANATOMY_MODIFIER", 186, 193]]], ["Within promptly directed to the High or Low risk wing based on a rapid assessment of their different epidemiological risk factors as stipulated on the sorting form.", [["a rapid assessment", "TEST", 63, 81]]], ["Each patient is assigned a seat number that is recorded for contact tracing purposes.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["Contact tracing is also facilitated by a real-time location system 18 patient tracker tagged to each patient and closed-circuit television monitoring.", [["patient", "ORGANISM", 70, 77], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 70, 77], ["patient", "SPECIES", 101, 108], ["closed-circuit television monitoring", "TEST", 113, 149]]], ["Patients are instructed to remain seated and any patient movement within the screening centre is under strict staff supervision.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 49, 56], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 49, 56]]], ["Non-ambulatory patients conveyed by ambulances are placed in trolleys and are directly sited in consultation rooms after the initial sorting.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["These consultation rooms are also used for physical examinations as necessary, ensuring that patients' privacy is respected.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["physical examinations", "TEST", 43, 64]]], ["Unstable patients are attended to immediately in the resuscitation room.PURPOSE-BUILT INFRASTRUCTURE TO FACILITATE PATIENT FLOWAll staff entering the screening centre are required to wear full personal protective equipment (PPE).", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["This consists of a hair cap, goggles, N95 mask, disposable gowns with knitted cuffs, and gloves.", [["hair cap", "ANATOMY", 19, 27], ["hair cap", "MULTI-TISSUE_STRUCTURE", 19, 27], ["a hair cap", "TREATMENT", 17, 27], ["N95 mask", "TREATMENT", 38, 46], ["disposable gowns", "TREATMENT", 48, 64], ["knitted cuffs", "TREATMENT", 70, 83], ["gloves", "TREATMENT", 89, 95], ["hair", "OBSERVATION_MODIFIER", 19, 23], ["cap", "OBSERVATION_MODIFIER", 24, 27], ["N95 mask", "OBSERVATION", 38, 46], ["knitted cuffs", "OBSERVATION", 70, 83]]], ["19 They are also tagged with real-time location system to facilitate contact trac-WIDE-NET SURVEILLANCE APPROACH AND CLOSE MONITORING OF LOCAL HOTSPOTSThe key direction for the screening centre is to limit community transmission of COVID-19.", [["COVID-19", "CHEMICAL", 232, 240], ["COVID", "TEST", 232, 237]]], ["This is particularly important due to the Close contacts, as identified by contact tracing teams from Ministry of Health working round the clock, are swiftly notified and instructed to practice self-isolation and social distancing; a proportion may be quarantined according to the risk assessment.", [["self-isolation", "TREATMENT", 194, 208], ["the risk assessment", "TEST", 277, 296]]], ["They are also reminded to return to the screening centre promptly for evaluation and testing should they develop symptoms.", [["evaluation", "TEST", 70, 80], ["testing", "TEST", 85, 92], ["symptoms", "PROBLEM", 113, 121]]], ["As the country's designated screening centre, the National Centre for Infectious Diseases screening centre had screened more than 14,000 patients as of 8 April 2020, which is \u223c70% of the country's screening workload.WIDE-NET SURVEILLANCE APPROACH AND CLOSE MONITORING OF LOCAL HOTSPOTSRapid isolation of confirmed cases and close contacts limit community transmission, as part of efforts to \"flatten\" the epidemic curve and avoid an epidemic peak that overwhelms health care services.", [["Infectious Diseases", "DISEASE", 70, 89], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["LOCAL HOTSPOTSRapid isolation", "TREATMENT", 271, 300], ["the epidemic curve", "PROBLEM", 401, 419]]], ["20 We are of the belief that the wide-net surveillance approach has contributed to a ratio of 1.8 undetected cases for every detected COVID-19 patient, 1 one of the lowest in the world.PRE-OUTBREAK PREPARATORY PHASE AND TIMELINEThe Tan cases started on January 2, 2020.", [["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150]]], ["As the number of patients increased, the ED overflow protocols were implemented.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["the ED overflow protocols", "TREATMENT", 37, 62], ["increased", "OBSERVATION_MODIFIER", 26, 35]]], ["At its peak, \u223c60 patients were screened at the ED per day in addition to the usual ED attendances.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["peak", "OBSERVATION_MODIFIER", 7, 11]]], ["The decision was then made by Ministry of Health to activate the National Centre for Infectious Diseases Screening Centre on January 28, 2020 (D) once patient numbers met the threshold capacity.", [["Infectious Diseases", "DISEASE", 85, 104], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158]]], ["The screening centre commenced its operations on January 29, 2020 (D+1) and was fully operational by January 31, 2020 (D+3).PRE-OUTBREAK PREPARATORY PHASE AND TIMELINEThe screening centre was able to attain full operational status within a short span of 3 days due to the pre-outbreak preparatory work and planning as laid out in Figure 3 .PRE-OUTBREAK PREPARATORY PHASE AND TIMELINEAs early as the second quarter of 2018, the Tan Tock Seng Hospital ED, in collaboration with the various stakeholders, developed standard operating procedures in the following domains, including medical, nursing, operations, logistics, pharmacy, radiology, security, housekeeping, food and beverage, transport, and mortuary.", [["standard operating procedures", "TREATMENT", 512, 541]]], ["As stipulated inWHOLE-OF-HOSPITAL APPROACHTo sustain round the clock operations, we adopted a \"whole-of- Augmented medical personnel are assigned a 10-day rotation in the screening centre.CHALLENGESOver the course of operations, the screening team encountered several challenges, mainly in the area of communications, surges in patient attendance, and staff morale.", [["patient", "ORGANISM", 328, 335], ["patient", "SPECIES", 328, 335]]], ["These challenges and theF I G U R E 4Daily attendances at the National Centre for Infectious Diseases Screening Centre (Information updated as of 8 April 2020)F I G U R E 4respective solutions used will be further elaborated on in the subsequent paragraphs.Communications-the crucial linkTheSurges in patient attendanceSudden increases in patient attendance ( Figure 4) when a new (large) cluster was identified in the local community, or the week after a travel advisory was issued for overseas Singaporeans to return.", [["Infectious Diseases", "DISEASE", 82, 101], ["patient", "ORGANISM", 301, 308], ["patient", "ORGANISM", 339, 346], ["patient", "SPECIES", 301, 308], ["patient", "SPECIES", 339, 346], ["I G U R E 4respective solutions", "TREATMENT", 161, 192]]], ["22 Pre-planned contingency procedures were promptly enacted and manpower was augmented from our standby roster, which was made possible due to the \"whole-of-hospital\" approach that we adopted.", [["contingency procedures", "TREATMENT", 15, 37]]], ["Seating arrangements were revised (chairs spaced 1.5 meters apart instead of 2 meters) to increase seating capacity from 99 to 181.Staff wellbeingThe leadership team is well aware of the potential psychological and physical stresses experienced by the screening centre staff during the outbreak.", [["seating capacity", "TEST", 99, 115]]], ["23CONCLUSIONIn the past decade alone, the international community has experienced 2 major pandemics: the 2009 H1N1 pandemic and the current COVID-19 pandemic.", [["H1N1", "DISEASE", 110, 114], ["the current COVID", "TEST", 128, 145], ["pandemic", "PROBLEM", 149, 157]]], ["With a population density of 8,358/km 2 , as well as her status as a major transport hub for international travel, Singapore is inherently vulnerable to the threat of infectious diseases outbreaks, similar to many major cities such as New York City (10,194/km 2 ), Paris (21,498/km 2 ), and Manila (42,857/km 2 ).", [["infectious diseases", "DISEASE", 167, 186], ["infectious diseases outbreaks", "PROBLEM", 167, 196], ["population", "OBSERVATION_MODIFIER", 7, 17], ["density", "OBSERVATION", 18, 25], ["infectious", "OBSERVATION", 167, 177]]], ["These include a pre-outbreak response plan with detailed standard operating procedures, a purpose-built infrastructure, meticulously designed layout and patient flow, a wide-net surveillance strategy, and a \"whole-of-hospital\" approach to manpower augmentation.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["patient flow", "TEST", 153, 165], ["manpower augmentation", "TREATMENT", 239, 260]]], ["Early data from a recent local study 26 have demonstrated the efficacy of these containment strategies whereby the 7day moving average of the interval from symptom onset to isolation declined significantly for both imported and local cases, from 9.0 and 18.0 days to 0.9 and 3.1 days.", [["a recent local study", "TEST", 16, 36], ["these containment strategies", "TREATMENT", 74, 102], ["symptom", "PROBLEM", 156, 163]]]], "PMC7220610": [["The use of urban open spaces is essential.", [["urban open spaces", "TREATMENT", 11, 28], ["essential", "OBSERVATION_MODIFIER", 32, 41]]], ["A time during which city governments have, to different degrees, restricted access to urban open spaces and during which officials have also acknowledged that human beings need to leave their isolated apartments and to access open space for exercise and interaction with other human and non-human beings.", [["human", "ORGANISM", 159, 164], ["human", "ORGANISM", 277, 282], ["non-human", "ORGANISM", 287, 296], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 277, 282]]], ["That the use of open space is essential for health and social reasons, was already the realization of urban planners at the end of the nineteenth century when for example the New Parks movement (Mullaly 1882) in New York led to the introduction of Central Park, a 843 acres large area carved out of the street grid in the center of Manhattan island.", [["open space", "TREATMENT", 16, 26], ["Manhattan island", "OBSERVATION", 332, 348]]]]}